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ABSTRACT 
 
The work in my thesis focuses on developing highly sensitive tests, using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) for the measurement of 
antiretroviral drugs within plasma, cells, and cerebral spinal fluid from clinical 
studies evaluating compartmentalised antiretroviral therapy (ART) pharmacokinetics 
and forgiveness for missed or late dosing.  
Firstly I developed and validated a LC-MS/MS assay to quantify the antiretroviral 
(ARV) drugs, lopinavir, darunavir, ritonavir and raltegravir in peripheral blood 
mononuclear cells (PBMCs). This intracellular assay included optimising 
methodology for cell separation to minimise loss of drug (Chapter 4). All drugs 
eluted within an 8 minute run time. Matrix effects were minimal (-2.9%). Calibration 
curves were validated over a concentration range of 0.4-150ng/mL. Intra and inter 
assay variation ranged between 0.01-2.29% for precision and 96.76-102.32% for 
accuracy. 
Secondly I developed and validated a LC-MS/MS assay to simultaneously detect and 
quantify 10 ARVs; maraviroc (MVC), nevirapine (NVP), rilpivirine (RPV), 
raltegravir (RAL), atazanavir (ATV), darunavir (DRV), amprenavir (APV), ritonavir 
(RTV), lopinavir (LPV) and etravirine (ETV) in cerebral spinal fluid (CSF). All 
drugs eluted within a 10 minute run time. Calibration curves were validated over the 
following concentration ranges; LPV, MVC, RTV = 0.78-100 ng/mL, RAL, APV, 
ATV, RPV, ETV, DRV = 1.95-250 ng/mL and NVP = 19.5-2500 ng/mL (r
2 
values 
>0.99; quadratic 1/x). Intra and inter assay variation ranged between 1.59-15% for 
precision and -10.5-6.4% for accuracy. Carryover was <20% of the lower limit of 
4 
 
quantification for all drugs. The recovery was >70% and the co-efficient of variation 
(CV%) at low, medium and high concentrations was less than 20% for all drugs. 
Thirdly I developed and validated a LC-MS/MS assay to quantify intracellular 
tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) within 
PBMCs. This work was very technically challenging and something that was not 
being done by any other laboratory within the United Kingdom. Analytes eluted 
within 12 minutes run-time with adequate separation. Calibration curves were 
validated over the following range TFV-DP=0.35-10.91 ng/mL, FTC-TP=0.38-
103.17 ng/mL (r
2 
values >0.99; linear 1/x). The lower limit of quantification was <20 
%, signal to noise was >5% and carryover <0.1%. The precision was; TFV-DP=6.3-
11% and FTC-TP=6-18.6%, and accuracy was TFV-DP=97.5-100.8%, FTC-TP=98-
100.3%. 
Finally, all assays developed and validated were successfully applied to collaborative 
clinical trials (see Communications; Published Research Papers). 
Benefits are expected to accrue from this work in the design of more forgiving 
therapy regimens for HIV patients, and better drug selection to specifically target 
HIV replicating within sanctuary sites. 
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PREFACE 
Chapter 1 
Presents an introduction and overview of the pathogenesis of HIV and provides an 
outline of the current ARV therapies. This chapter also provides an introduction to 
the instrumentation and use of liquid chromatography tandem mass spectrometry 
(LC-MS/MS) for the development of ARV drug assays described in this thesis.  
 
Chapter 2 
Describes the development and validation of a LC-MS/MS assay to detect and 
quantify the protease inhibitors lopinavir, darunavir, ritonavir and the integrase 
inhibitor raltegravir within a peripheral blood mononuclear cell (PBMC) matrix. 
 
Chapter 3 
Presents clinical trial data investigating the pharmacokinetics of plasma and 
intracellular levels of ritonavir boosted darunavir and raltegravir (at once and twice 
daily dosing) when co-administered to HIV-infected subjects.  
 
Chapter 4 
Investigates the number of wash steps used in the isolation of PBMC by comparison 
of methodologies currently used for intracellular ARV pharmacokinetic clinical 
studies. 
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Chapter 5 
Describes the development and validation of a LC-MS/MS for the simultaneous 
quantification of 10 ARV drugs within cerebral spinal fluid (CSF), to greater 
understand their concentrations within this sanctuary site. 
 
Chapter 6 
This chapter describes the development, validation and technical challenges of a LC-
MS/MS assay to detect and measure the intracellular phosphorylated anabolites of 
tenofovir (TDF) and emtricitabine (FTC). 
 
Chapter 7 
Presents data from a clinical trial to assess the ‘pharmacokinetic forgiveness’ of 
intracellular tenofovir- diphosphate (TFV-DP), emtricitabine- triphosphate (FTC-
TP), and plasma efavirenz (EFV), over a period of 9.5 days after drug intake 
cessation to provide information on how best to advise HIV-infected patients on 
non-adherence (delayed and missed doses). 
 
Chapter 8 
Concludes the work carried out in this thesis, highlighting the important findings in 
LC-MS/MS ARV assay development and the clinical trial pharmacological findings 
for which they were applied. Areas which could be further investigated are also 
outlined.
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ABBREVIATIONS 
 
%    Percentage 
>    Greater than 
<    Less than 
o
C    Degree centigrade 
3TC    Lamivudine 
ABC    Abacavir 
ACN    Acetonitrile 
aCSF    Artificial cerebral spinal fluid 
AIDS    Acquired immune deficiency syndrome 
ALB    Albumin 
APV    Amprenavir (Fosamprenavir) 
ARV    Antiretroviral 
ATP    Adenosine triphosphate 
ATV    Atazanavir 
AUC    Area under the curve 
AUC0-24   Area under the curve from 0 to 24 hours 
AUC0-last Area under the curve from 0 hour to last measurable 
time point 
AZT    Zidovudine 
BSA    Bovine serum albumin 
BHIVA   British human immunodeficiency virus association 
cART    Combination antiretroviral therapy 
CoHr    Concentration at 0 hour 
C12Hr    Concentration at 12 hours 
C24Hr    Concentration at 24 hours 
C36Hr    Concentration at 36 hours 
C48Hr    Concentration at 48 hours 
C60Hr    Concentration at 60 hours 
C84Hr    Concentration at 84 hours 
C108Hr    Concentration at 108 hours 
C132Hr    Concentration at 132 hours 
C156Hr    Concentration at 156 hours  
C180Hr    Concentration at 180 hours 
C204Hr    Concentration at 204 hours 
C228Hr    Concentration at 228 hours  
CCR5    Chemokine receptor 5 
CD4+    Helper T lymphocyte antigen marker 
CE    Collision energy 
CSF    Cerebral spinal fluid 
CI    Confidence interval 
CI-ATP   2-chloroadenosine 5′-triphosphate 
Clast    Concentration at last time point 
Cmax    Maximum concentration 
Cmin    Concentration at minimum concentration  
CNS    Central nervous system 
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Conc    Concentration 
CPT    Cell preparation tube 
Ctrough    Trough concentration 
CV    Coefficient of variation 
CXCR4   CX chemokine receptor 4 
C&W    Chelsea and Westminster Hospital 
D4t    Stavudine 
DDI    Drug-drug interaction 
ddI    Didanosine 
ddC    Zalcitabine (dideoxycytidine) 
DLV    Delavirdine 
DMHA   Dimethylhexylamine 
DNA    Deoxyribose nucleic acid 
dNTP    Deoxynucleotide triphosphate 
DRV    Darunavir 
DRV/r    Ritonavir boosted darunavir 
DTG    Dolutegravir 
EDTA    Ethylenediaminetetraacetic acid 
EFV    Efavirenz 
ESI    Electrospray ionisation 
ETV    Etravirine 
EVG    Elvitegravir 
Exp    Experiment 
FBS    Foetal bovine serum 
FDA    Food and drug administration 
FI    Fusion inhibitors 
Fig    Figure 
fL    Femtolitre 
f/mol    Femtomole 
FTC    Emtricitabine 
FTC-DP   Emtricitabine-diphosphate 
FTC-MP   Emtricitabine-monophosphate 
FTC-TP   Emtricitabine-triphosphate 
g    Gram 
g/L    Grams per litre 
GCLP    Good clinical laboratory practice 
GCP    Good clinical practice 
GM    Geometric mean 
GMR    Geometric mean ratio 
HAART   Highly active antiretroviral therapy 
HAND    HIV associated neurological disorders 
HBSS    Hanks balanced salt solution 
H-ESI    Heated electrospray ionisation 
HILIC    Hydrophilic interaction chromatography 
HIV    Human immunodeficiency virus 
HIV-1    Human immunodeficiency virus type 1 
HPLC    High performance liquid chromatography  
HQC    High quality control 
Hr    Hour 
IC    Intracellular 
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IC90    Concentration of a drug required to inhibit 90% of 
    viral replication 
IC50    Concentration of a drug required to inhibit 50% of 
    viral replication 
ID    Identification 
IDV    Indinavir 
IS    Internal standard 
ITT    Internal transfer tube 
ITC    Internal transfer capillary 
L    Litre 
LC    Liquid chromatography 
LC-MS   Liquid chromatography mass spectrometry 
LC-MS/MS   Liquid chromatography tandem mass spectrometry 
LLoD    Lower limit of detection 
LLQ    Lower limit of quantification 
Log    Logarithmic  
LPV    Lopinavir 
LPV/r    Ritonavir boosted lopinavir 
LQC    Low quality control 
MΩ    Mega-ohm 
MEC     Minimum effective concentration 
MeOH    Methanol 
mg    Milligram 
mg/h/L
-1
   Milligrams per hour per litre 
mg/L
-1 
   Milligrams per litre 
µg    Microgram 
µL    Microlitre 
µm    Micromililitre 
µM    Micromolar 
Mins    Minutes 
mL    Millilitre 
mm    Millimetre 
Mm    Millimolar 
Mol    Molar 
MQC    Medium quality control 
MRM    Multiple reaction monitoring 
MS    Mass spectrometry 
mTorr    Millitorr 
MVC    Maraviroc 
m/z    Mass to charge ratio 
n    Number of observations 
NaCl    Sodium Chloride 
NDP    Nucleo-diphosphate 
NFV    Nelfinavir 
ng    Nanogram 
ng/mL    Nanogram per millilitre 
nL    Nanolitre 
NMP    Nucleo-monophosphate 
NNRTIs   Non-nucleoside reverse transcriptase inhibitors 
NRTIs    Nucleoside reverse transcriptase inhibitors 
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NTP    Nucleo-triphosphate 
NtRTIs   Nucleotide reverse transcriptase inhibitors 
NVP    Nevirapine 
PBMC    Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PD    Pre-dose 
PGC    Porous graphitic chromatography 
pH    Minus Log(base 10) of Hydrogen ion concentration 
PIs    Protease inhibitors 
PK    Pharmacokinetics 
PKa    Dissociation constant 
pL    Picolitres 
p/mL    Picomole 
PrEP    Pre-exposure prophylaxis 
Q1    First quadrupole 
Q2    Second quadrupole 
Q3    Third quadrupole 
QC    Quality control 
r
2
    Correlation coefficient 
QX    6,7-dimethyl-2,3-di(2pyridyl)-quinoxaline 
RAL    Raltegravir 
rcf    Relative centrifugal force 
Recon    Reconstituted 
RLUH    Royal Liverpool University Hospital 
RNA    Ribonucleic acid 
rpm    Revolutions per minute 
RPV    Rilpivirine 
RT    Retention time 
RTIs    Reverse transcriptase inhibitors 
RTV    Ritonavir 
s.d    Standard deviation 
SPE    Solid phase extraction 
SRM    Selective reaction monitoring 
SQV    Saquinavir 
T1/2    Drug half life 
TEt ½    Terminal elimination half life 
T20    Enfuvirtide 
TDF    Tenofovir disoproxilfumarate 
TFV    Tenofovir 
TFV-DP   Tenofovir-diphosphate 
TFV-MP   Tenofovir-monophosphate 
TDM    Therapeutic drug monitoring 
TIC    Total ion count 
Tmax    Time taken to reach maximum drug concentration 
TP    Triphosphate 
TPV    Tipranavir 
UGT 1A1   UDP glucuronosyltransferase 1 family, polypeptide A1 
UK    United Kingdom 
ULQ    Upper limit of quantification 
USA    United States of America 
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V    Voltage 
v/v    Volume per volume 
WAX    Weak anion exchange 
WHO    World health organisation 
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1.1 Human Immunodeficiency Virus 
1.1 Aetiology of HIV 
Human immunodeficiency virus (HIV), the causative agent of acquired 
immunodeficiency syndrome (AIDS), is a lentivirus, which belongs to the 
retroviridae family. The primary target of HIV is the immune system, which it 
destroys, allowing opportunistic infections and cancers to thrive. HIV is transferred 
by exposure of infected bodily fluids (blood, semen, vaginal fluid, breast milk, pre-
ejaculate) and although these routes of infection are well established allowing 
preventive measures to be implemented (screening of blood for donation, use of 
condoms etc.), a staggering 6,300 people world-wide contract the virus everyday 
(nearly 262 new infections every hour) [1]. UNAIDS estimated that in 2012 there 
were 2.3 million new HIV diagnoses (260,000 under 15 years of age), giving a total 
of 35.3 million people living with HIV/AIDS world-wide (3.3 million under 15 years 
of age) [1]. HIV infection is however declining with a 50% reduction in new cases 
between 2001 and 2012, in adults and children (under the age of 15) [1]. This can be 
attributed to greater education of preventative measures and the on-going advances 
and accessibility of combination antiretroviral therapy (cART), which has 
dramatically reduced HIV morbidity and mortality. The introduction and use of 
cART, has enabled durable suppression of the virus’ ability to replicate and has 
therefore changed HIV from a fatal disease to a chronic manageable disease [2], if 
diagnosed and treated in the early stages of infection. In 2010, the United Kingdom 
HIV statistics showed the one year mortality rate in late diagnoses was 40 per 1,000 
cases, which is 8 times greater than that of earlier diagnoses (5 per thousand). It was 
also found that 1 in 10 late diagnoses in the over 50 age group, died within a year 
[3].  
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1.2 Antiretroviral therapy 
Since the advent of the first HIV antiretroviral (ARV) drug, zidovudine (AZT) in 
1987 [4], there are now 27 drugs approved by the Anti-Infective Advisory 
Committee to United States Food and Drug Administration (FDA). Table 1 shows all 
of the ARVs and their class. Table 2 shows the co-formulations of ARVs.  
ARV drugs work by interruption of the HIV life cycle within the immune cell. ARVs 
fall into 5 main pharmacological classes according to their mechanism of action. 
Each class targets HIV at a different point within its life cycle and ultimately 
prevents the virus from replicating.  
 
1.2.1 Reverse Transcriptase Inhibitors  
The first class of ARV agents to be developed was the nucleoside/ nucleotide reverse 
transcription inhibitors (NRTIs/ NtRTIs). NRTIs are analogues of the naturally 
occurring intracellular deoxyribonucleic acid (DNA) building blocks, the purine 
nucleosides guanine and adenosine and the pyrimidine nucleosides cytidine and 
thymidine. Once inside the immune cell, NRTI undergo phosphorylation. The 
addition of these phosphate groups (three phosphate groups are added to NRTI and 
two phosphates to NtRTI) to their deoxyribose moiety by intracellular kinase 
enzymes, changes the NRTI in to its active phosphorylated metabolite. This is then 
able to inhibit the viral enzyme reverse transcriptase which is responsible for the 
synthesis of viral ribonucleic acid (RNA) into viral DNA. The main mechanism of 
action of NRTI is that their phosphorylated analogues do not possess the 3'-hydroxyl 
group, thus preventing the formation of the next 5'-3' phosphodiester bond which is 
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essential in viral DNA elongation. Therefore viral DNA chain termination occurs 
and the production of viral DNA is inhibited preventing further viral replication [5]. 
NRTIs act quickly within the cell, and due to the long duration of their action, a 
single once daily dose is administered.  
 
1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)  
The second pharmacological class of ARV therapy are the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). Like the NRTI, NNRTIs primary mechanism of 
action is to prevent viral RNA being transcribed into viral DNA. However, the 
molecular structure of NNRTI are not analogues of the naturally occurring cellular 
nucleosides and therefore do not competitively compete for incorporation into the 
viral DNA. Instead NNRTI, target the viral reverse transcriptase enzyme which they 
bind to non-competitively. Once bound, the reverse transcriptase enzyme undergoes 
a conformational change in its 3-dimensional shape. This shape change, a hyper 
extension of the p66 thumb domain, reduces the catalytic activity of the enzyme by 
inhibition of the reverse transcriptase’s active site, thus preventing the viral RNA 
being transcribed to viral DNA [6].  
 
1.2.3 Protease Inhibitors (PIs) 
The third pharmacological class of ARV are the protease inhibitors (PIs). HIV 
protease is an essential enzyme in the life cycle of HIV. It is responsible for the 
cleavage of viral precursor proteins required for the assembly of mature viral 
proteins to form new infectious virus particles [7]. PIs mode of action is to bind to 
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the active site of the protease enzyme, thus disabling its action. This leads to the 
production of immature HIV virus proteins which are non-infectious.  
 
1.2.4 Integrase Stand Transfer Inhibitors (ISTIs) 
The integrase stand transfer inhibitors (ISTI) are the fourth class of ARV drugs. 
ISTIs are the newest pharmacological class of therapeutic HIV drugs, with 
raltegravir being approved in 2007 and dolutegravir and elvitegravir in 2013 by the 
FDA [8]. HIV integrase is an essential viral enzyme which encodes the viral DNA 
into the host genome (integration) [9]. ISTIs mechanism of action is direct 
competition with viral DNA to bind to the active site of the integrase enzyme. In 
doing so, ISTIs block the viral DNA being integrated in the cell nucleus and 
ultimately prevents viral replication [10]. 
 
1.2.5 Entry/ Fusion Inhibitors (FIs) 
The fifth and final ARV pharmacological class are the entry/fusion inhibitors (FIs). 
This class of ARVs differs from the other four classes as the mechanism of action of 
these drugs is extracellular. FIs prevent the initial attachment of the virus to the cell 
surface receptors. There are two currently approved entry inhibitors, the first 
enfuvirtide, is a synthetic biomimetic peptide which is administered subcutaneously 
due to its lack of bioavailability when given orally. It works by binding to the HIV 
viral transmembrane protein gp41, preventing the virus from creating an entry pore 
in the CD4+ cell membrane thus keeping the capsid of the HIV virus out of the cell 
[7]. The second FI, maraviroc is a CCR5 inhibitor. Its mechanism of action is to 
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prevent HIV from binding to the cell membrane by blocking the CCR5 chemokine 
receptor, thus preventing HIV (which has to be tropic to either the beta- chemokine 
receptor CCR5 or the alpha-chemokine receptor CXCR4) gaining access to the cell 
[7]. 
The mechanisms of action for each of the five classes are shown in Figure 1.
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Table 1. List of HIV antiretroviral drugs approved by the FDA. 
Generic name Brand name Abbreviation FDA approval Class 
Abacavir Ziagen ABC 1998 NRTI 
Didanosine Videx & Videx 
EC 
DDI 1994 NRTI 
Emtricitabine Emtriva FTC 2003 NRTI 
Lamivudine Epivir 3TC 1994 NRTI 
Stavudine Zerit D4t 1996 NRTI 
Zidovudine Retrovir AZT 1987 NRTI 
Zalcitabine 
[dideoxycytidine] 
(no longer 
marketed) 
Hivid ddC 1992-2006 NRTI 
Tenofovir 
disoproxil 
fumarate 
Viread TDF 2002 NtRTI 
Delavirdine Rescriptor DLV 1997 NNRTI 
Efavirenz Sustiva EFV 2002 NNRTI 
Etravirine Intellence ETV 2008 NNRTI 
Nevirapine Viramune NVP 1996 NNRTI 
Rilpivirine Edurant RPV 2011 NNRTI 
Amprenavir, APV 
(no longer 
marketed) 
Agenerase APV 1999-2004 PI 
Atazanavir Reyataz ATZ 2004 PI 
Darunavir Prezista DRV 2007 PI 
Fosamprenavir 
(Prodrug of APV) 
Telzir APV 2003 PI 
Indinavir Crixivan IND 1996 PI 
Lopinavir/ritonavir Kaletra LPV/r 2000 PI 
Nelfinavir Viracept NFV 1996 PI 
Ritonavir Norvir RTV 1996 PI 
(booster) 
Saquinavir Invirase SQV 2006 PI 
Tipranavir Aptivus TPV 2005 PI 
Enfuvirtide Fuzeon T20 2003 FI 
Maraviroc Celsentri MVC 2007 FI 
Elvitegravir GS-9137 EVG 2013 ISTI 
Raltegravir Isentress RAL 2007 ISTI 
Dolutegravir Tivicay DTG 2013 ISTI 
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Table 2. List of antiretroviral co-formulations approved by the FDA. 
Fixed dose 
combinations 
Generic Name Brand 
Name 
FDA 
approval 
Multi-drug 
class 
combinations 
efavirenz, emtricitabine and 
tenofovir disoproxil fumarate 
Atripla 2006 
 emtricitabine, rilpivirine, and 
tenofovir disoproxil fumarate 
Complera 2011 
 elvitegravir, cobicistat, emtricitabine, 
tenofovir disoproxil fumarate 
Stribild 2012 
NRTI co-
formulations 
lamivudine and zidovudine Combivir 1997 
 abacavir and lamivudine Epzicom 2004 
 abacavir, zidovudine, and lamivudine Trizivir 2000 
 tenofovir disoproxil fumarate and 
emtricitabine 
Truvada 2004 
 
31 
 
                   
Figure 1. Schematic of HIV replication life cycle and sites of drug action. Modified from Merck Isentress leaflet. 
FUSION/ ENTRY
INHIBITORS
REVERSE TRANSCRIPTASE 
INHIBITORS
INTEGRASE
INHIBITORS
PROTEASE INHIBITORS
HIV viron
CD 4 Receptor
CCR5 or CXCR4
Co-receptor
Viral RNA Un-integrated double 
stranded Viral DNA
Integrated
viral DNA
Gag-pol 
polyprotein
Protease
Capsid proteins 
and viral  RNA
Immature non-
infectious virus particle
New HIV particle
Nucleus
Cellular 
DNA
Viral 
mRNA
ATTACHMENT UNCOATING
REVERSE 
TRANSCRIPTION
INTEGRATION
TRANSCRIPTION
TRANSLATION ASSEMBLY AND 
RELEASE
REVERSE
TRANSCRIPTASE INTEGRASE
32 
 
1.2.6 Current Therapy Guidelines  
The combination of antiretroviral drugs currently recommended by the British HIV 
Association (BHIVA) [11] for treatment naïve patients is a ritonavir boosted PI or an 
NNTRI or a ISTI plus two NRTI drugs, the choice of which are dependent on 
number of factors including the balance of benefit/risk, age, presence or absence of 
any drug resistance and co-infection [7]. The BHIVA summary is outlined in Table 
3. For treatment experienced patients, the combination is dependent upon their viral 
genotype and includes three active ARV’s from at least two different ARV 
pharmacological classes [7]. 
Table 3. BHIVA summary of cART  
 Preferred Alternative 
NRTI backbone TDF and FTC ABC and 3TC*
╪
 
Third ARV ATZ/r LPV/r 
 DRV/r APV/r 
 EFZ NVP
┼
 
 RAL RPV
╪
 
*ABC is contraindicated in HLA-B*57:01 positive patients. 
┼ 
NVP is 
contraindicated if baseline CD4 cell count is greater than 250/400 cells/µL in 
women/men. 
╪
The use is only recommended if the base line viral load is <100 000 
copies/ mL: RPV as a third ARV, ABC and 3TC as NTRI backbone [11]. 
 
BHIVA recommend initiation of ARV treatment in patients with a CD4 count less 
than 350 cells/ µL, and should not be delayed in patients approaching this threshold. 
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1.2.7 Adherence 
It is vital to the success of cART that patients adhere to their given ARV regimen to 
avoid therapy failure. It is well documented that viral rebound, drug resistance, HIV 
progression to AIDs and mortality are associated with poor ARV adherence [12-14]. 
BHIVA break down non-adherence into two categories, firstly intentional and 
secondly unintentional [11]. Intentional non-adherence to ARV therapy is described 
as a conscious decision which is influenced by beliefs, emotions and patient 
preferences. Unintentional non-adherence is described as a reduction in the ability to 
adhere to the intended treatment due to factors limiting the capacity or resources of 
the ARVs. [11]. In order to avoid non-adherence BHIVA recommends assessment, 
discussion and support addressing both intentional and non-intentional non-
adherence limitations, with patients about their therapy whenever ARVs are 
prescribed.  
 
1.2.8 Drug- drug interactions (DDIs) 
As with any infection requiring therapeutic treatment, drug interactions can cause 
major clinical problems especially in HIV therapy. Drug interactions can be 
classified as follows: (i) a physical or chemical interaction between two or more 
drugs prior to them being absorbed into the body, (ii) pharmacokinetic, in which case 
one drug will increase or decrease the concentration of the other, (iii) 
pharmacodynamic, the combination of two or more drugs given together will change 
the effect of the drug if given alone.  
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Many studies have looked at various ARVs given in combination with one another 
and also with a wide range of other pharmaceutical agents, and as a result many 
online drug interaction web sites have been established, which highlight 
contraindicated effects of poly-pharmacy in order to circumvent drug-drug 
interactions. 
As well as pharmaco-vigilance, another method of ensuring that a therapy regime is 
at an optimum for a patient is via therapeutic drug monitoring (TDM). This involves 
pharmacokinetic (PK) sampling at different time points post drug intake, to ensure 
that the drug is within its correct concentration range (sub optimal concentrations 
will cause viral rebound and resistance and too much drug can result in toxicity). 
Although BHIVA recommend against the use of unselected use of TDM, it plays a 
key part in the clinical management of some patients (dose adjustments in children, 
and pregnant women) and also highlights patients who are not fully adherent to their 
therapy, and in identifying these patients’, methods and support can be given to 
increase their drug intake regime [11, 15].  
 
1.3 Sanctuary sites and viral reservoirs 
Despite cART (when adhered to) being highly effective and life-prolonging in HIV-
infected individuals, it is only successful in the suppression of HIV viral replication, 
thus ARVs do not cure HIV infection. It is clear that the virus is not completely 
eradicated from the body and HIV-1 RNA has the ability to persist in anatomical and 
cellular compartments, which may or may not be reached by drug in high enough 
concentrations. 
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The definition of a viral reservoir is described by Blankson et al. as “a cell type or 
anatomical site in association with which a replication-competent form of the virus 
accumulates and persists with more stable kinetic properties than in the main pool of 
actively replicating virus.” Blankson et al. also cite that “a viral reservoir must have 
a biologically plausible mechanism that allows the virus to escape from biological 
decay processes or, in the case of a cellular reservoir, from immune effector 
mechanisms” [16, 17]. Put simply, a viral reservoir is a compartment where HIV is 
present but is in a latent state (versus productive infection).  
A HIV anatomical sanctuary site is a compartment where HIV is present but ARV 
drugs are not/ or at least not in a high enough concentration to prevent viral 
replication. This is due to prevention of sufficient drug penetration into the sanctuary 
which is influenced by physical barriers, physiochemical characteristics, drug 
transporters and sequestration. Possible HIV sanctuary sites include the central 
nervous system (CNS), genital tract, lymphoid tissue, CD4
+
 T cells (resting/ memory 
and naïve), CD8
+
 T cells, monocytes, B cells and dendritic cells [16-20]. 
The eradication of virus from the possible sanctuary sites is not currently feasible 
with current cART but a greater understanding of the pharmacokinetics of ARVs in 
these anatomical compartments may allow us to implement better strategies and 
identify optimal cART drugs that will enable the greatest viral suppression at each of 
the sites.  
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1.4 Liquid Chromatography-Tandem Mass Spectrometry 
The assays designed in this thesis to accurately quantify the level of ARVs in various 
matrices (plasma, CSF and PBMCs), utilise high performance liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The combination of 
liquid chromatography coupled with tandem mass spectrometry provides an 
excellent analytical method for separation, detection and quantification of ARVs.  
The first step in the LC-MS/MS system is physical separation of the analytes by 
means of liquid chromatography (LC). This is achieved by the transfer of the sample 
through two immiscible phases; a mobile phase solution such as acetonitrile with a 
selected flow rate through the stationary phase within a selected column. 
Chromatographic separation occurs during binding and release (sorption/ desorption) 
due to the differences in distribution coefficients of the analytes during their transfer 
through the stationary phase of the column. The selection of the mobile phases and 
the column are dependent up on the physical characteristics and molecular structure 
of the analytes to be separated. Once selected, optimal conditions are assessed for 
parameters such as, temperature (of column), flow rate (of mobile phases), pH, and 
mobile phase gradient (isocratic, or step-wise).  
The LC system is interfaced to a triple quadrupole tandem mass spectrometer 
(MS/MS). The mass spectrometer can be divided into three basic parts, (i) the 
ionisation source, (ii) the analyser and (iii) the detector. For all assays developed and 
used in this thesis the ionisation source selected was heated electrospray ionisation 
(H-ESI), and the analyser used was a triple quadrupole. During H-ESI the eluted 
sample from the LC system is pumped through a heated narrow capillary probe at a 
set flow rate. The tip of the capillary which is situated in the MS ionisation source 
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housing, then has a high voltage applied to the exit tip. As a result of this strong 
electric field, sample entering the source housing unit is dispensed as highly charged 
aerosol droplets. This process is helped by the introduction of nitrogen used as a 
nebulising gas, which flows around the outside of the heated capillary. The nitrogen 
gas directs the aerosol droplets towards the entrance of the MS system. As the 
droplets travel towards the MS, the warm nitrogen evaporates the solvent eluent, 
resulting in charged sample ions entering the ion transfer tube (ITT) and being taken 
into the MS which is held under a high vacuum.  
Once the charged precursor parent ions enter the MS they are selected according to 
their mass-to-charge ratio (m/z) [molecular related ions (M+H)
+
 or (M-H)
- 
depending 
on ionisation mode selected i.e. positive or negative] within the first mass analyser 
(quadrupole 1), these selected ions then travel into a collision cell (quadrupole 2) 
where they are bombarded with gas molecules (argon) which results in the formation 
of charged fragment (daughter) ions. Finally, the fragment ions are focused into a 
second mass analyser (quadrupole 3) and the intensity of each fragment ion is 
measured resulting in a chromatographic peak. The intensity of the fragment ions 
produced is proportional to the concentration of the sample analyte. The sample 
concentration can then be determined by comparison to the relevant calibrator of 
known concentration. The internal travel path of the analytes through the MS/MS 
system can be seen in figure 2. 
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Figure 2. Internal view of the triple quadrupole tandem mass spectrometer modified 
from a TSQ Thermo Scientific programme screen shot.  
 
1.5 Bioanalytical method validation 
In the development of a new bioanalytical methodology for the detection and 
quantification of HIV antiretroviral drugs and their metabolites, it is essential that the 
methods used are selective and sensitive and fully validated according to the Food 
and Drug Administration, Guidance for Industry; Bioanalytical Method Validation 
guidelines [21]. These guidelines ensure that any quantitative method (in any matrix 
i.e. plasma, PBMC, CSF etc.) shows reproducibility, reliability and robustness for its 
intended use. These guidelines were adhered to and followed where appropriate with 
some modifications. The six main factors in any assay validation procedure are as 
follows: selectivity and sensitivity, precision, accuracy, reproducibility and stability.  
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In the context of LC-MS/MS assays developed in this thesis, assays have undergone 
full validation and in some circumstances partial validation (in that sample matrix 
has been limited or direct measurement without prior sample preparation has been 
utilised). When addressing the selectivity of the assays, the ability to differentiate 
and quantify the ARV in the presence of endogenous and potentially exogenous 
interferences contained in the sample matrix were investigated and assessed 
appropriately. Tests were also run of blank (in the absence of any ARV analytes), 
sample matrix (plasma, PBMC and CSF) from numerous sources or batch numbers 
in the case of artificial CSF (due to limitation of large CSF blank sample 
availability), to investigate selectivity. Assessment included the investigation of 
possible interference at the lower limit of quantification (LLQ) for each individual 
ARV drug, and also the possibility of carryover, which can occur when a sample of 
high concentration within the upper limit of quantification of the assay is followed 
by a sample of a low concentration of the analyte, which could result in the over 
estimation of the proceeding sample as a response of residual predeceasing sample 
contamination. 
Precision of the analytical methodology described, was also investigated. Precision 
describes the closeness of individual measurements of the HIV ARV analytes when 
the methodology was applied repeatedly to multiple individual samples within the 
matrix. Accuracy was conducted also, and this describes the closeness of the mean 
analytical test result (actual concentration of the analysed sample) to the nominal 
value (concentration at which the calibration sample [known sample concentration] 
of the analyte) concentration. Inter and intra-day variability was assessed also by 
analysis of 10 or more assays in duplicate carried out on separate days; two of which 
were carried out on the same day (intra-day). The reproducibility of the assays also 
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was addressed, but with regards to the de-novo nature of the assays described, 
standard guidelines and ‘gold standard’ methodology are not currently in place and 
therefore methodology in this area opens an area which can be enhanced upon.  
Stability experiments were conducted to replicate the conditions likely to be faced 
during sample transfer, handling and analysis. Within this thesis, clinical samples 
from HIV-infected patients were heat inactivated (58˚C, 40 minutes), stored at -40˚C 
or -70˚C for preservation of the ARVs and then thawed prior to analysis when 
appropriate. Therefore, in these circumstances heat and freeze thaw, short term and 
long term stability was investigated where applicable against quality control 
samples.  
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1.6 Hypothesis of this thesis research 
Pharmacological characterisation of ARV exposure within plasma, cells and 
anatomical sanctuary compartments, yields important insight into the effectiveness 
of HIV therapy, potential eradication of drug from sanctuary sites and forgiveness 
(the amount of times a drug therapy can be not taken before detecting viral rebound) 
for missed or late doses. 
 
Aims of this thesis 
 
 To develop and validate sensitive and robust assays for the detection of the 
ARV drugs; LPV, DRV, RTV and RAL in peripheral blood mononuclear 
cells (PMBC), MVC, NVP, RPV, RAL, ATV, ETV, LPV, RTV, APV and 
DRV in cerebral spinal fluid, and the ARV intracellular metabolites TDF-DP 
and FTC-TP in cells. 
 
 Quantification of ARV and their intracellular metabolites within plasma, cells 
and cerebral spinal fluid. 
 
 Estimation of the terminal elimination half–life of the ARVs in order to 
characterise forgiveness for missed/ late dosing.  
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Chapter 2 
 
Development and validation of a LC MS/MS assay to detect 
and quantify the antiretroviral drugs, lopinavir, darunavir, 
ritonavir and raltegravir in peripheral blood mononuclear cells. 
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2.1 Introduction 
 
Since 1987, when the first anti-retroviral (ARV) drug zidovudine (AZT) was 
approved by the Food and Drug Administration (FDA), a further 24 ARV’s have 
been licenced and used for the management of HIV infection, which infects an 
estimated 34 million people worldwide (WHO estimate 2011,[22]). There are five 
classes of HIV ARVs, each targeting a different stage in the HIV life cycle. The 
classes comprise of, the nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse 
transcriptase inhibitors (NtRTIs) and the protease inhibitors (PIs), the entry/fusion 
inhibitors and the newest class, the strand transfer integrase inhibitors. Highly active 
ARV therapy (HAART) is a combination of drugs from these different classes. The 
British Human Immunodeficiency Virus Association (BHIVA) guidelines 
recommend a standard first line treatment regimen of at least three ARV’s. However, 
it is reported that within the first two years of initiating HAART, there is a 10% 
failure rate [23]. The failure of HAART is a complex matter of various factors 
previously discussed in chapter one, which include drug resistance due to viral 
genome mutations [24], poor adherence [25], pharmacological uptake into sanctuary 
sites, protein binding factors and sub-therapeutic levels due to pharmacokinetic (PK) 
drug variability between patients. Therapeutic drug monitoring (TDM) is a helpful 
tool in the optimisation and improvement of an individual patient response to 
HAART. The majority of TDM tests rely on measurements of ARVs within the 
plasma fraction of the blood, giving an individual indication of the drug efficacy. It 
plays a crucial role in the reduction of toxicity and ensures optimal viral suppression 
[26]. However, the measurement of the ARVs within the plasma fraction maybe of 
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limited clinical significance because the major site of action of the ARVs is within 
the infected cell itself, and only the percentage of drug reaching this intracellular 
compartment, actually has any impact on preventing the replication of HIV [27]. An 
effective ARV should therefore be able to penetrate the primary target cells of HIV 
infection. It is the lymphocytes, CD4+ cells and macrophages of the immune system, 
which are the target cells for HIV and these cells are collectively known as 
peripheral blood mononuclear cells (PBMCs). To date there is little data on the 
intracellular analysis of ARVs compared to the thousands of published research 
papers on plasma drug levels. This is mainly due to the complexity of intracellular 
(IC) sampling and analysis. To be able to isolate PBMC from whole blood and take a 
direct measurement of the IC ARV concentrations enables a greater understanding of 
the true penetration of HAART into HIV target cells, leading to a greater 
understanding as to why some patients develop treatment failure despite having 
optimal ARV plasma concentrations and a fully sensitive virus [28]. It was therefore 
the primary aim of this chapter to develop a quantitative IC ARV LC-MS/MS assay 
which was robust and highly sensitive in the accurate measurement of four ARV 
drugs, to enable a greater insight to the mechanisms underlining HIV drug therapy 
failure.         
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
Lopinavir (LPV) and ritonavir (RTV) were provided by Abbott Laboratories (Abbott 
Park, Chicago, IL, USA). Darunavir (darunavir ethanolate, DRV) was provided by 
Tibotec (Mechelen, Belgium), and raltegravir (RAL) was obtained from Merck 
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Sharp & Dohme (Haarlem, The Netherlands). Quinoxaline (6,7-dimethyl-2,3-
di(2pyridyl)-quinoxaline, QX) was used as the internal standard (IS) and this was 
purchased from Sigma Aldrich (UK). LCMS grade acetonitrile (ACN) was 
purchased from Fisher Scientific (Loughborough, UK). HPLC grade methanol 
(MeOH) was purchased from VWR Laboratory supplies, UK. Formic acid and 
Hanks balanced salt solution (HBSS) were purchased from Sigma-Aldrich, UK. 
Deionised water was obtained from an Elga Option-S water purification unit (Elga 
LabWater, High Wycombe, UK) and then further purified to 18.2 MΩ with a Purelab 
Ultra unit (Elga LabWater, High Wycombe, UK). Ficoll was purchased from G.E 
Healthcare (Bucks, UK). Human peripheral blood mononuclear cells (PBMCs) were 
purchased from the National Blood Service (Liverpool, UK).  
 
2.2.2 Equipment 
The high performance liquid chromatography (HPLC) system consisted of a variable 
loop Accela autosampler (set to a temperature of 15
o
C) and an Accela LC pump 
(Thermo Fisher Scientific, Hemel Hempstead, UK). A reverse phase Ascentis™ C18 
column (3μm: 100 mm×2.1 mm) set at an oven temperature of 30 oC (Supelco, 
Dorset, UK), fitted with a 2μm C18 Quest column saver, (Thermo Fisher Scientific, 
Hemel Hempstead, UK) was used to separate all analytes and internal standard. The 
HPLC system was interfaced with a Thermo Fisher Scientific TSQ Quantum Ultra 
triple stage quadrupole mass spectrometer, fitted with a heated-elecrospray ionisation 
(H-ESI) probe, housed in an ion max source. Two E2M30 rotary vacuum pumps 
(Edwards High Vacuum International, West Sussex, UK), a NM30LA nitrogen 
generator (Peak Scientific Instruments, Renfrew, UK), and research grade (99% 
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pure) argon gas (10L size V, BOC, Manchester, UK) were used. Analyte tuning and 
optimisation parameters were gained with the use of TSQ Tune software (Thermo 
Fisher Scientific, Hemel Hempstead, UK). LC Quan 
TM
 software (Version 2.7, 
Thermo Fisher Scientific, Hemel Hempstead, UK) was used to acquire and process 
the data.  
 
2.2.3 Chromatographic system 
The injection mode was set at full loop (10l loop), therefore only requiring a 
sample volume of 10µL. The autosampler tray temperature was set at 15
o
C and the 
column oven control at which chromatographic separation took place was set at 
30
o
C. Separation of the antiretrovirals and IS was facilitated by a gradient elution 
(Table 1). Mobile phase A consisted of 0.2% formic acid, and mobile phase B 
consisted of 100% ACN. The flow rate was constant at 400 L/min. At 6.1 minutes 
the mobile phase ratio was returned back to the starting conditions to allow 
equilibration of the column. The total run time for the assay was therefore 8 minutes. 
A wash solution containing ACN: water, 80:20, v/v, was used to clean the injection 
syringe (2 mL) between each sample injection. Both the mobile phase and the wash 
solution were de-gassed and mixed by sonication for 20 minutes prior to use. All 
analytes were scanned for using selective reaction monitoring (SRM) by the TSQ 
Quantum Ultra operated in positive ionisation mode. 
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Table 1. Mobile phase gradient. 
Time (min) Mobile Phase A % Mobile Phase B % 
Flow rate 
(µL/min) 
0 95 5 400 
2 95 5 400 
3.5 20 80 400 
6 20 80 400 
6.1 95 5 400 
8 95 5 400 
 
 
2.2.4 Mass spectrometric system 
Each of the antiretroviral drugs and the IS were prepared in methanol at a 
concentration of 1µg/mL. This combined solution was then directly injected in to the 
mass spectrometer using a syringe pump (10 µL/min). The molecular mass (parent 
mass), for each of the analytes were scanned for in the first quadrupole (Q1). Once 
detected the tube lens was then optimised for each of the drugs (Fig 1). The parent 
ions then travelled to the second quadrupole (Q2) which contains inert gas molecules 
that fragment the ions into their product ions. Collision energy was applied at a range 
of voltages (v) (Fig. 2) and the product ions for each of the parent masses were 
scanned for in the selected reaction monitoring (SRM) mode in the third quadrupole 
(Q3). Two product ions for each of the parent ions were selected. These were the 
ions which gave the greatest mass to charge ratio (m/z) for their parent ion, with the 
least amount of background noise. The optimised mass spectrometric parameters are 
shown in table 2. 
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Figure. 1. Optimisation of the tube lens in the first quadrupole. The previous setting show those optimised for an ARV plasma assay. Each ARV 
is shown in a different colour with its corresponding parent mass. RTV = 721.4 m/z, LPV = 629.3 m/z, DRV = 548.2 m/z, RAL = 445.1 m/z and 
QX (internal standard) = 313.1 m/z.  
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Figure. 2. Optimisation of collision energy in the second quadrupole for each of the analyte parent ions, to fragment into the daughter ions. Each 
ARV daughter ion is shown in a different colour, outlined in the figure key. Table 2 outlines the ARV parent ions m/z and the fragment ions post 
collision energy.  
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Table 2. Optimised conditions for the mass spectrometric detection of each of the analytes in positive ionisation mode. 
Drug 
Name 
Retention 
Time (mins) 
Parent 
ion (m/z) 
Product 
ion (m/z) 
Spray 
voltage 
Vap 
temp 
Sheath gas 
pressure 
Aux gas 
pressure 
Capillary 
temp 
tube 
lens 
offset 
Coll 
pressure 
(mTorr) 
Collision 
energy (v) 
LPV 4.78 629.3 154.99 5000 350 60 40 300 77 1.5 37 
  
  
429.13 5000 350 60 40 300 77 1.5 21 
RTV 4.68 721.3 269.01 5000 350 60 40 300 95 1.5 27 
  
  
296.01 5000 350 60 40 300 95 1.5 18 
DRV 4.35 548.2 155.87 5000 350 60 40 300 95 1.5 33 
  
  
392.73 5000 350 60 40 300 95 1.5 14 
RAL 4.19 445.1 108.97 5000 350 60 40 300 83 1.5 33 
  
  
361.01 5000 350 60 40 300 83 1.5 17 
QX 4.3 313.1 246.04 5000 350 60 40 300 109 1.5 42 
      284.03 5000 350 60 40 300 109 1.5 45 
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2.2.5 Source and chromatography maintenance 
Concentrated constituents of the intracellular lysate may build up in the column 
guard, column and LC tubing. In order to circumvent this, the column and column 
guard were reverse flushed at a flow rate of 400 µL / minute, with 95% ACN and 5% 
water for 30 minutes after each analytical run. The Ultra source housing unit was 
removed and cleaned with 50% MeOH after each analytical run. The source cone 
and ion transfer tube were also removed and cleaned between each assay by 
immersion in 50% MeOH and sonicated for 20 minutes at room temperature. 
 
2.2.6 Column re-equilibration 
Prior to a new assay, the Ascentis™ C18 column was re-equilibrated. This was 
achieved by manually controlling the LC pump conditions to the chromatography 
starting conditions for the assay (95% mobile phase A and 5% mobile phase B), with 
a flow rate of 400 µL / minute, for a period of at least 15 minutes. This was also 
sufficient to raise the source temperature to optimal conditions prior to the samples 
been run.  
 
2.3 Sample preparation  
2.3.1 Isolation and preparation of ARV drug free peripheral blood mononuclear cells 
(PBMCs). 
This method is adapted from that published by Colombo el al. [29]. Blood samples 
were collected in lithium heparin coated tubes and kept at a temperature of 4
o
C until 
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the isolation was carried out. This was done to prevent lysis of the cells. Whole 
blood (10 mL) was carefully layered over 5ml of ficoll paque™ in a clean sterile 
universal tube. This was centrifuged at 2000 rpm for 30 minutes at 4
o
C without 
break applied. The isolation of the PBMC fraction (containing the lymphocytes and 
monocytes) was thus achieved on a buoyancy gradient basis as the PBMC’s are of a 
lower buoyancy density than the ficoll paque™. After centrifugation the central band 
containing the PBMCs was carefully removed using a sterile fine tipped Pasteur 
pipette and transferred into a clean sterile universal container. The volume was 
adjusted to 25 mL with ice cold Hanks balanced salt solution (HBSS) and 
centrifuged (2000 rpm, 5 minutes, at 4
o
C). This sample wash/spin step was repeated 
X3. On the final re-suspension only 10 mL (exactly) of HBSS was added and a 50 
µL sample of this was transferred into a clean microtube to which 50 µL of each 
solution A and solution B was added (solutions supplied and used as per 
manufacture guidelines for Chemometec Nucleocounter cell counting cassettes). 
From this, 50 µL was drawn into a nucleocounter cassette for a cell count 
(Nucleocounter NC-100). Once the cell count was known, the cell suspension was 
centrifuged as before and all the HBSS carefully removed. Methanol (70%) was then 
added to the cell pellet at a volume calculated to obtain a final PBMC lysed cell 
density of 4 X 10
6
 cells/ mL. This cell lysate was then sonicated for 10 minutes and 
followed by centrifugation (5500 rpm, 5 minutes, 4
o
C, without brake). The sample 
was then stored overnight at -80
o
C. The supernatant /cell lysate was then carefully 
transferred into a new tube and the pellet discarded. 
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2.3.2 Investigation of PBMC Lysis 
It was important to decide the concentration of methanol versus water to use, and 
also what role the use of sonication of cells played in influencing the greatest lysis 
yield of ARV from within the cellular compartment. Therefore PBMC were isolated 
with the use of ficoll paque™ as described above. The PBMC were counted and the 
cell density corrected to 1 X 10
7
 cells/ mL. Cell suspension (500 µL) was aliquoted 
into labelled 1.5 mL microtubes. Radiolabelled ARV (x 2 activity) was made up in 
RPMI 1640 media (Sigma, UK) + 15% foetal bovine sera (FBS). 500 µL of this 
compound was added to the cells and then incubated at 37
o
C for 30 minutes. The 
samples were then centrifuged (9000 rpm/ 1 min) and a 100 µL aliquot was removed 
and placed into a scintillation vial. The remaining media in the sample was removed 
and the cell pellet was resuspended in 1 mL of ice cold HBSS and then centrifuged 
(9000 rpm / 1 minute). The supernatant was removed and the wash step repeated (X 
2). The cell lysis was then investigated by re-suspending the cell pellets in 100 µL of 
corresponding lysis solution;  
Sonicated Non-sonicated 
100 % Methanol 100 % Methanol 
70 % Methanol 70 % Methanol 
60 % Methanol 60 % Methanol 
Distilled water Distilled water 
 
Samples were then centrifuged (9000 rpm/ 1 minute) and the supernatant removed to 
a scintillation vial. Scintillation fluid (4 mL) was added to each vial and then capped 
before placing into the liquid scintillation counter. The counter was run using the 
appropriate departmental standard operating procedure for the radioactive ARV 
isotope being investigated. Results are shown in Table 3. 
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Table 3. Investigation results of PBMC lysis experiment. 
  
Buffy coat 1 
Cellular 
count (dpm) 
Extracellular 
count (dpm) 
Cellular 
Accumulation ratio 
(CAR) 
Sonicated  
Intracellular 100% MeOH 256.01 59863.2 0.21 
Intracellular 70% MeOH 215.72 59084.3 0.18 
Intracellular 60% MeOH 231.73 59396.8 0.2 
Intracellular Distilled water 93.7 61213.6 0.08 
Non 
Sonicated 
Intracellular 100% MeOH 298.58 61541.9 0.24 
Intracellular 70% MeOH 207.23 62110.6 0.17 
Intracellular 60% MeOH 264.72 61425.7 0.22 
Intracellular Distilled water 57.47 61069.6 0.05 
  
Buffy coat 2 
Cellular 
count (dpm) 
Extracellular 
count (dpm) 
Cellular 
Accumulation ratio 
(CAR) 
Sonicated  
Intracellular 100% MeOH 289.18 59542.8 0.24 
Intracellular 70% MeOH 254.35 60487.8 0.2 
Intracellular 60% MeOH 181.84 60682.5 0.15 
Intracellular Distilled water 96.85 60319.6 0.08 
Non 
Sonicated 
Intracellular 100% MeOH 200.76 61571.3 0.16 
Intracellular 70% MeOH 293.49 61442.2 0.24 
Intracellular 60% MeOH 312.6 60848.2 0.26 
Intracellular Distilled water 88.34 59180.5 0.07 
  
Buffy coat 3 
Cellular 
count (dpm) 
Extracellular 
count (dpm) 
Cellular 
Accumulation ratio 
(CAR) 
Sonicated  
Intracellular 100% MeOH 330.97 69282.3 0.24 
Intracellular 70% MeOH 355.71 68730.5 0.26 
Intracellular 60% MeOH 352.72 66158.3 0.27 
Intracellular Distilled water 313.13 74362.7 0.21 
Non 
Sonicated 
Intracellular 100% MeOH 421.57 66237.6 0.32 
Intracellular 70% MeOH 410.12 68500.3 0.3 
Intracellular 60% MeOH 250.45 72211.5 0.17 
Intracellular Distilled water 143.07 81191.4 0.09 
 
We found that the method we had adopted and had been using throughout all 
intracellular analysis was indeed the method of choice, 70% MeOH with a ten 
minute sonication. 
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2.3.3 Preparation of standards and quality controls  
Blank PBMC lysate at a cell density of 4 x 10
6
 / mL was spiked with LPV, DRV, 
RTV and RAL at concentrations of 0.5, 5, 10, 20, 50, 100 and 150 ng/ mL, to yield 
an eight point (including the blank) standard curve. The volume of methanol was 
adjusted at each concentration to keep the cell density the same throughout. Quality 
controls (QCs) were generated similarly at concentrations of 5, 50 and 150 ng/ mL 
(low, medium and high). All standards and QCs were validated in accordance with 
the Food and Drug Association Guidelines for Industry (FDA 2001[21]). Once the 
standards and QC were prepared they were stored in the fridge at 4
o
C, ensuring that 
the screw capped bottles were firmly closed to prevent evaporation. 
 
2.3.4 Preparation of internal standard 
Quinoxaline (6,7-dimethyl-2,3-di(2pyridyl)-quinoxaline), (QX), was used as the 
internal standard. A stock solution was prepared at 1 mg/mL in 100% methanol. This 
was then diluted 1:10 (v/v) with methanol to give a concentration of 100 µg / mL. A 
working internal standard solution was then prepared. 100 µL of the 100 µg/ mL was 
added to 4.95 mL of methanol and 4.95 mL of deionised water to give a 1 µg/ mL 
solution. This was then further diluted to a 100 ng/ mL (1 mL of 100 µL/ mL 
solution to 4.5 mL of methanol and 4.5 mL of water), to give the final working 
concentration of internal standard. This was prepared fresh on a daily basis.  
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2.3.5 Calibration standards and QC sample pre-treatment 
Calibration standards and QC samples were removed from the fridge and 100 µL 
from each was aliquoted into appropriate labelled autosampler vials. To each sample 
20 µL of working internal standard QX (100 ng/mL) was added. The vials were then 
crimp sealed and then vortexed. Aliquots were then centrifuged for 4 minutes at 
2500 rpm at room temperature. Sample vials were then loaded into the Accela 
autosampler ready for analysis. 
 
2.3.6 Preparation of clinical samples 
Clinical samples were treated as described earlier (2.3.1 Isolation and preparation of 
ARV drug free peripheral blood mononuclear cells (PBMCs). They were then stored 
at -80
o
C. Prior to testing, the methanol was evaporated to dryness and 500 µL of 
70% methanol was added. The sample was then spiked with working internal 
standard (QX 10µL, 100 ng/ mL in water / methanol [50:50]). 
 
2.3.7 Analyte extraction 
No further extraction procedures were carried out. Once the PBMCs had been 
isolated as described, 100 µL of sample was aliquoted into labelled autosampler vials 
and analysed by HPLC-MS/MS.   
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2.3.8 Calculation of the cell-associated concentration of the ARVs 
There are two ways in which the  results from patient samples could be reported. The 
first is to express the result in ng/ mL per 10
6
 cells (taking in to account the original 
cell count for the sample) and the second to report the cell associated drug 
concentration (ng/ mL) assuming that the average volume of a cell is 0.4 pl [30]. 
 
2.4 Validation of the LC-MS/MS system  
This assay within a lysate matrix using the LC MS/MS system was validated for the 
drugs LPV, DRV, RTV, RAL and the internal standard QX.  
 
2.4.1 Standard curves 
A total of 20 calibration curves (with each level sampled in duplicate) were run and 
assessed to validate the assay. Each standard curve consisted of seven concentration 
levels with the addition of a blank lysate sample (level zero), giving 8 levels in total. 
Level Concentration of ARV (ng/mL) 
0 0 
1 0.5 
2 5 
3 10 
4 20 
5 50 
6 100 
7 150 
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The assays were also assessed for their linearity, the calibration data was analysed 
using a quadratic least-square regression of the peak area ratio (drug peak area / IS 
peak area), versus the nominal concentration of the sample with a weighting factor of 
1 / concentration (1/x), which achieved co-efficient of correlation (r
2
) values greater 
than 0.98 for all validation assays. Once the calibration values were validated the 
quality control (QC) samples at low (5 ng/mL), medium (50 ng/mL) and high (150 
ng/mL) concentrations were prepared. QC samples at each of the levels were run in 
duplicate (n = 10) against the standard curves to ensure that all the values (both QC 
and calibrators) achieved a co-efficient of variation from the target value within +/- 2 
standard deviations of the mean target value.  
 
2.4.2 Accuracy and Precision  
A inter and intra-day precision and accuracy was determined following the FDA 
guidelines. Six replicate lysate spiked QC samples containing each of the analytes 
and the IS at three concentrations (low, medium and high, 5, 50 and 150 ng/mL 
respectfully) were analysed. Accuracy was determined as the absolute percentage 
deviation from the theoretically determined concentration (% difference), and the 
precision of the assay was expressed as the relative standard deviation of the mean as 
a percentage (% CV) for each of the three concentrations. 
 
2.4.3 Lower limit of quantification 
The lower limit of quantification (LLQ) was determined as the lowest concentration 
which was measured accurately and precisely with the detection not being affected 
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by interfering influences, i.e. matrix effects or residual analyte carryover. The LLQ 
concentrations had to be reliable and robust with a co-efficient of variability (CV) % 
of < 20% for each of the analytes. 
 
2.4.4 Specificity and selectivity 
Spectrometric chromatographs for each of the parent ions were assessed and 
examined to ensure no interference from endogenous compounds was present. The 
precursor ion chromatographs were examined and then the product ion 
chromatographs were assessed to ensure the respective ions correlated to their parent 
masses. 
 
2.5.5 Lysate matrix effects 
Lysate matrix effects were assessed by post column infusion of the analytes into the 
HPLC-MS/MS detector during simultaneous chromatographic analysis of the matrix 
(PBMC) extract. A standard solution of each of the ARV drugs was infused using a 
T connection mixer, at the same time as the blank matrix and the mobile phase. 
Unexpected suppression / enhancement, retention time drift or shift of the analytes 
chromatographic responses due to any co-eluting intracellular endogenous 
constituents, were examined to ensure there was no interference at the retention time 
of each of the ARVs. The ‘absolute matrix effect’ was also investigated. This was to 
expose any difference in response between the solvent standard (mobile phase) and 
the sample PBMC lysate matrix [31].  
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2.5 Results 
A successful method has been developed for the detection and quantification of 
LPV, DRV, RTV and RAL in PBMC lysate by HPLC-MS/MS. 
 
2.5.1 Precursor and product selection for validation 
Each of the following chromatographs (Figures 3-12) are the original raw data whilst 
tuning the mass spectrometer for each of the analytes and the internal standard, at a 
concentration of 1 µg/ mL by direct injection, with a flow rate of 400 µL/ min. The 
first chromatographic figures for each drug shows the parent ion (precursor 
spectrum) from the Q1 cell without any collision energy being applied, followed by 
the second chromatographs which highlight the daughter ions (product spectrum) in 
the third quadrupole (Q3) with collision energy applied (see Table 2 for optimised 
values).  
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Figure 3. LPV precursor ion spectrum in Q1 LPV + H (629.27) 
Figure 4. LPV SRM fragment ions (154.93 and 429.08) used for quantification post 
collision energy application 
090522_090522101514 #1 RT: 0.01 AV: 1 NL: 1.15E7
T: + p ESI Q1MS [450.070-700.000]
460 480 500 520 540 560 580 600 620 640 660 680 700
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
629.27
651.32
667.21 687.09648.66
593.43 611.14508.94482.48462.04 525.04 691.36549.12 581.60
matrix_090519_VW_026 #4954 RT: 4.79 NL: 3.11E4
F: + c ESI SRM ms2 629.390@cid37.00 [154.921-154.931, 429.070-429.080]
100 150 200 250 300 350 400
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 I
n
te
n
s
it
y
154.93
429.08
64 
 
Figure 5. DRV precursor ion spectrum in Q1. DRV + H (548.01) 
Figure 6. DRV SRM fragment ions used for the quantification (155.86 and 392.04) 
post collision energy application 
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Figure 7. RTV precursor ion spectrum in Q1. RTV + H (721.10)  
Figure 8. RTV SRM fragment ions used for the quantification (269.0, 296.0) post 
collision energy application. 
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Figure 9. RAL precursor ion spectrum in Q1. RAL + H (445.04). 
Figure 10. RAL SRM fragment ions used for the quantification (108.93, 360.99) post 
collision energy application. 
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Figure 11. QX precursor ion spectrum in Q1. QX + H (313.05). 
Figure 12. QX SRM fragment ions used in the quantification (246.04, 284.03) post 
collision energy application. 
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2.5.2 Optimisation of the chromatographic peaks 
Each of the ARVs were tuned and optimised on the HPLC-MS/MS system 
described. Figures 13-17 show the chromatographic peak and retention time for each 
of the ARVs and internal standard. Mass spectrometric parameters were controlled 
through the LC Quan software to provide the optimal conditions which gave way to 
the greatest resolution (sharpest peaks). Each chromatographic peak used at least 16 
individual scanning event points. Confirmation for specificity was achieved using 
the same software, and on highlighting the chromatographic peak product ions, 
showing their mass to charge ratio (m/z), this was observed and checked. The 
chromatographs show that the method allows simultaneous determination and 
quantification of the five analytes (Figure 18). 
 
Figure 13. Optimised validation chromatographic peak for LPV (150 ng/mL). 
Retention time (RT) 4.77 mins. 
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Figure 14. Optimised validation chromatographic peak for DRV (150 ng/mL). 
Retention time (RT) 4.34 mins. 
Figure 15. Optimised validation chromatographic peak for RTV (150 ng/mL). 
Retention time (RT) 4.69 mins. 
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Figure 16. Optimised validation chromatographic peak for RAL (150 ng/mL). 
Retention time (RT) 4.18 mins. 
Figure 17. Optimised validation chromatographic peak for internal standard QX (100 
ng/mL). Retention time (RT) 4.31 mins. 
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Figure 18.Chromatograph of a calibration standard (150 ng/mL), showing the peak 
resolution and retention time for each ARV, internal standard QX and the total ion 
count (TIC). 
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2.5.3 Accuracy and precision  
The precision of this methodology describes the closeness of each individual analyte 
measured when it is repeatedly applied to multiple samples. The accuracy of this 
methodology is described by the closeness of the mean test result for each of the 
individual analytes when compared to the ARV stock concentration prepared. The 
assay was linear over the concentration range 0.5-150 ng/ mL in PBMC lysate. The 
inter and intra-assay performance data are presented in Table 3. Accuracy was 
defined in terms of percentage bias and precision was defined as CV % relative to 
the standard deviation of the mean. All calculations were derived from the three 
levels of quality control samples with n = 10. Assays were also assessed for their 
linearity, the calibration data was analysed using the quadratic least-square 
regression of the peak area ratio (drug peak area / IS peak area), versus the nominal 
concentration of the sample with a weighting factor of 1 / concentration (1/x) which 
achieved a co-efficient of correlation (r
2
) values greater than 0.98 for ARV 
validation assays.  
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Drug 
Nominal concentration (ng/ 
mL)
Inter-assay (n = 6) Intra-assay (n= 6)
Mean (ng/ mL) Precision (%CV)
Accuracy (% 
bias)
S.D Mean (ng/ mL) Precision (%CV)
Accuracy (% 
bias)
S.D
DRV
7.92 7.88 0.36 99.49 0.0. 7.90 0.18 99.75 0.01
52.67 52.98 0.41 100.59 0.22 53.88 1.59 102.25 0.86
130.60 133.25 1.41 101.99 1.87 133.70 1.64 102.32 2.19
Precision CV % = 0.36-1.41 Precision CV % = 0.36-1.41
Accuracy % = 99.49-101.99 Accuracy % = 99.49-101.99
LPV
10.09 10.25 1.10 101.56 0.11 10.13 0.28 100.39 0.00
52.36 52.48 0.16 100.23 0.08 52.45 0.12 100.17 0.10
126.16 128.38 1.22 101.73 1.57 128.10 1.07 101.51 1.40
Precision CV % = 0.0.16-1.22 Precision CV % = 0.12-1.07
Accuracy % = 100.23-101.73 Accuracy % =100.17-101.51
RAL 0.15
10.0.1 10.03 0.14 100.20 0.01 9.80 1.52 97.86 0.07
50.88 51.26 0.52 100.74 0.27 50.78 0.14 99.80 0.59
128.86 129.00 0.08 100.11 0.10 129.70 0.46 100.65
Precision CV % = 0.08-0.52 Precision CV % = 0.14-1.52
Accuracy % = 100.11-100.74 Accuracy % =97.86-100.65
RTV
9.56 9.7 1.02 101.44 0.10 9.6 0.29 100.42 0.03
49.14 49.85 1.01 101.42 0.50 47.6 2.29 96.76 1.09
125.62 123.9 0.98 98.61 1.22 125.6 0.01 99.98 0.01
Precision CV % = 0.98-1.02 Precision CV % = 0.01-2.29
Accuracy % = 98.61-101.44 Accuracy % = 96.76-100.42
Table.3. Inter and intra-assay performance data for each of the ARVs 
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2.5.4 Matrix effects 
The lysate matrix effect was -2.9%, this was calculated using the matrix factor, 
which is expressed as (peak area response of the cell lysate [n = 20]) divided by the 
(peak area response of the mobile phase [n = 20]) multiplied by 100. The result 
being a negative percentage, suggests that there is a slight enhancement of the signal 
response in the lysate matrix. Therefore, the effect of this for each individual ARV 
was analysed by post column infusion, which is a more precise method of 
investigation. Figure 19 shows the typical overlay of the observed signals for a post 
column infusion injection. Coloured peaks indicate the specific drug of interest, the 
black line indicates the lysate matrix injection and the grey line indicates the mobile 
phase injection. A decrease in the relative abundance is known as ion suppression 
and an increase is ion enhancement. The coloured peaks of the ARVs should 
therefore ideally not be in either of these areas, which are a result of the co-elution of 
endogenous cellular components, hence causing the matrix effect.
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Figure 19. Post column infusion chromatograph overlays of the observed signals of the following injections, (150 ng/ mL of each of the 
analytes). Coloured peaks indicate the drug of interest, black line indicates the lysate matrix, and the grey line indicates the mobile phase. Eight 
minute assay run time. 
Time (min)
0
50
100
0
50
100
0
50
100
0
50
100
Re
la
tiv
e A
bu
nd
an
ce
0
50
100
0
50
100
313.200@cid42.00 
[246.034-246.044, 
284.020-284.030]  MS 
445.170@cid33.00 
[108.926-108.936, 
360.983-360.993]  MS 
548.300@cid33.00 
[155.855-155.865, 
392.031-392.041]  MS 
629.390@cid37.00 
[154.921-154.931, 
429.070-429.080]  MS 
721.430@cid27.00 
[267.899-267.909, 
295.887-295.897]  MS 
QX
RAL
DRV
LPV
RTV
Total Ion Count
76 
 
2.5.5 Signal to noise ratio 
The signal to noise ratio was investigated to determine the lower limit of 
quantification (LLQ) for each of the ARVs. The analyte response at the LLQ should 
be a least five times greater than that of a blank response. The LLQ represents the 
lowest point on the standard calibration curve and therefore must be measured with 
accuracy and precision (co-efficient of variation should not exceed +/- 20 %). This 
was achieved by DRV (mean 6), RAL (mean 31), and RTV (mean 6) at level one 
(<1 ng/ mL), however, LPV failed to achieve this at the level one standard and 
therefore level two was LLQ of LPV (mean 12). 
 
2.5.6 Carry over 
Carry over is described as a residual drug concentration which is detected in a 
sample as a result of the preceding injected sample. This can occur when a sample of 
a high concentration is followed by a sample of very low concentration and therefore 
the result given is falsely enhanced. To assess the level of carryover for each of the 
ARV’s the highest calibration standard was analysed, followed by five blank 
samples and comparing the mean signal response value for the high concentration 
sample to the response given for each set of blank samples. The signal response was 
extrapolated into a concentration value and carry over was as follows; DRV = 0.04 
ng/mL, LPV = 0 ng/mL, RAL = 0.11 ng/mL and RTV = 0.0 ng/mL. Therefore, it 
was confirmed that during an analytical run, over calculation of an analyte due to a 
high concentration sample preceding a low concentration sample, carryover did not 
have significant impact on LLQ results. 
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2.6 Conclusions 
Described here, is the development, optimisation and validation of an LC-MS/MS 
assay to simultaneously quantify the ARVs, DRV, LPV and RTV which are protease 
inhibitors and also RAL which is a strand transfer integrase inhibitor, in PBMC 
lysate. This assay performance was monitored with the use of known concentration 
quality controls at low, medium and high levels appropriate to the calibration range 
of the analytes. All ARVs showed good inter assay accuracy, expressed as the % bias 
(DRV range 99.49-101.99%, LPV range 100.23-101.73%, RAL range 100.11-
100.74% and RTV range 98.61-101.44%), and good intra assay accuracy (DRV 
range 99.49-101.99%, LPV range 100.17-101.51%, RAL range 97.86-100.65% and 
RTV range 96.76-100.42%). All ARVs also showed good inter assay precision, 
expressed as the % coefficient of variation (DRV range 0.36-1.41%, LPV range 
0.02-1.22%, RAL range 0.08-0.52% and RTV range 0.98-1.02%), and good intra 
assay precision (DRV range 0.49-101.99%, LPV range 0.12-1.07%, RAL range 
0.14-1.52% and RTV range 0.01-2.29%). All analyte calibration data curves 
illustrated excellent linearity with correlation coefficients (r
2
) greater than 0.99, 
using a quadratic least-square regression equation with a weighting factor of 1/x.  
The assay run time is only 8 minutes for each sample. This rapid time efficiently 
allows for a high through put of sample analysis which is especially advantageous 
when sampling large numbers of samples from clinical pharmacokinetic trials, and 
also for the use in therapeutic drug monitoring (TDM). 
The selection of which ARVs to include in this assay was based solely on two 
clinical trials which needed to quantify intracellular DRV, LPV, RAL and RTV, and 
as an intracellular/ plasma ratio would be calculated the internal standard QX was 
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chosen for this method as it is matched in the established departmental multi ARV 
plasma assay. At the time of development it was not fully established in the 
published literature, what concentration ranges would be required for clinical 
samples. Therefore, the ARV concentration ranges selected were mainly for the 
purpose of a robust assay development, which could later be altered if needed be. 
The dynamic range was validated at 0.5-150 ng/mL for DRV, RAL and RTV and 5-
150 ng/mL for LPV as this ARV did not show consistency at the LLQ of 0.5 ng/mL. 
In the initial stages of ARV LC-MS/MS optimisation, up to 6 mass transitions for 
each analyte were scanned for. From these quantification was carefully selected for 
by selection of the two best (4 scanned for) fragment ions for each ARV. Fragment 
ion selection was based on their relative mass intensity. In doing this, all four 
fragment ions were scanned for and signal intensity monitored.  Each combination of 
the fragment ions was investigated and the duo which gave the greatest signal with 
the least background noise interference were selected. It is important to have the 
least background noise possible to enable the greatest assay sensitivity.  
One major point of this assay development is that the ARVs are directly spiked in to 
PBMC lysate. In doing so, the calibration standard levels were constant and were not 
affected by PBMC batch cell transporters or other cell accumulation factors. This 
was the only way to regulate and quality control the assay. Therefore, when 
comparison with clinical samples there are no wash steps involved. The amount of 
drug spiked into the lysate could therefore not be reduced/ changed depending on 
various washing procedures. The effects of differences in the clinical sample 
washing procedures are investigated in chapter 4. 
In conclusion, the results of this bio-analytical validation, demonstrate that this LC-
MS/MS IC methodology is reliable and reproducible. It is robust, accurate, precise 
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and sensitive for the simultaneous quantification of DRV, LPV, RAL and RTV in 
PBMC lysate, enabling a greater insight into the level of ARV which reaches the IC 
compartment target. To be able to directly quantify IC ARV concentration enables a 
greater understanding of the true efficacy of HAART and assists in the elucidation of 
why some patients develop treatment failure despite having optimal ARV plasma 
concentrations.  
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Chapter 3 
 
A study investigating plasma and intracellular 
pharmacokinetics of once daily darunavir / ritonavir and once 
and twice daily raltegravir in HIV infected individuals. 
81 
 
CHAPTER 3  
 
A STUDY INVESTIGATING PLASMA AND 
INTRACELLULAR PHARMACOKINETICS OF ONCE 
DAILY DARUNAVIR/r AND ONCE AND TWICE DAILY 
RALTEGRAVIR IN HIV INFECTED INDIVIDUALS  
 
3.1 Introduction 
 
3.2 Materials and Methods  
3.2.1 Subjects 
3.2.2 Study design 
3.2.3 Peripheral blood mononuclear cell (PBMC) isolation 
3.2.4 Analytical methods 
3.2.5 Plasma extraction and analysis 
3.2.6 Drug quantification in peripheral blood mononuclear cells (PBMC) 
3.2.7 Pharmacokinetics and statistical analysis 
 
3.3 Results 
3.3.1 Demographic and clinical characteristics 
3.3.2 Raltegravir pharmacokinetics and statistical analysis 
3.3.3 Darunavir pharmacokinetics and statistical analysis 
3.3.4 Ritonavir pharmacokinetics and statistical analysis 
 
3.4 Discussion and Conclusion 
82 
 
This clinical trial was published in J. Acquir Immune Defic Syndr. 2011 December 
15; 58(5): 450-457. 
3.1. Introduction  
The primary target for antiretroviral (ARVs) drugs is within the cells infected with 
HIV, therefore the success of a therapy regime can be directly correlated to the 
amount of drug which penetrates the infected cell. Previous studies have shown links 
between the activity of ARVs and IC concentrations for protease inhibitors (PIs) and 
nucleoside reverse transcriptase inhibitors (NRTIs) [26], however the methods used 
in the measurement of intracellular ARV concentrations is extremely difficult, with 
each class of ARV measurement having their own challenges, i.e. mass 
spectrometric ionisation of highly polar drugs in the case of tenofovir. There are 
currently no ‘gold standard’ methodologies for the IC measurement of ARVs and as 
a result present literature shows extensive inconsistency in the reported data, which 
will be discussed further in this chapter. 
There are many different pharmacological considerations which may influence the 
concentration of IC ARVs, these include but are not limited to, drug oral 
bioavailability, the percentage of plasma protein binding, drug physiochemical 
characteristics, and the involvement of multi-drug transport proteins responsible for 
cellular influx and efflux[26]. Therefore depending on the class of ARV drug, the IC 
concentration and accumulation can vary greatly. 
While PI cellular accumulation has been studied by several research groups 
previously[26, 29, 32-34], drug interactions involving ARV agents are more 
commonly studied in formal pharmacokinetic clinical trials investigating drug 
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concentrations in plasma, again this is mainly due to the more complex nature of IC 
drug measurement.  
Darunavir (DRV) is an antiretroviral used in the combination treatment regime of 
HIV. It belongs to the class of protease inhibitors and was licenced for use in 
treatment-naïve patients by the Food and Drug Administration (FDA) at a once daily 
dose of 800 mg co-administered with 100 mg of ritonavir (RTV) in 2008, and at a 
twice daily dose of 600 mg/ 100 mg for treatment experienced patients in 2006 [35]. 
Current data on DRV IC concentrations is constrained to a few heavily pre-treated 
HIV-infected patients on the 600/100 mg regime taken in combination with RTV, 
raltegravir (RAL) and etravirine (ETV). Ter Heine reported the DRV IC to plasma 
ratio to be 1.32 [36]. However, in the same study, Ter Heine also reported that RAL 
IC concentrations were not detected [36]. This is in contrast to other groups who 
have investigated IC RAL concentrations and have reported IC to plasma ratios of 
0.039, 0.07, and 0.24 [37-39].  
The potent ARV raltegravir is the first HIV-1 integrase strand-transfer inhibitor. It 
was licenced by the FDA for use in the United States of America (USA) in 2007 and 
then in Europe in 2008 for use in HIV combination therapy, for treatment-
experienced patients at a dose of 400 mg twice daily as a result of clinical findings 
from the BENCHMRK 1 and 2 [40] studies. In 2009, clinical data from the 
STARTMRK trial, showed that RAL (in combination with Truvada) given as a first 
line therapy, obtained a level of viral suppression the same as that achieved with an 
efavirenz based regime, and was therefore given approval for initial therapy also 
[41]. 
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RAL primary clearance mechanism is UGT1A1- mediated glucoronidation, and as it 
is not a substrate of cytochrome P450 or an inducer of CYP3A4 it is therefore 
characterized as having a low drug-drug interaction potential [42]. 
A once a day dose of RAL (800 mg) has also been investigated by Eron et al, and 
they concluded that the once daily dose did not show the same level of virological 
response as the twice daily dosing, especially in patients with a high viral load at 
base line [43]. 
The primary objective of this clinical trial was to investigate the plasma and IC PK 
of DRV/r and RAL (at once and twice daily dosing) when co-administered to HIV-
infected subjects.  
 
3.2 Materials and Methods 
3.2.1 Subjects 
Twenty four adult male HIV-1 antibody positive subjects were recruited. All subjects 
had a CD4 count greater than 100 cells per cubic millimetre and a viral load less than 
400 copies/mL, with no history of virological failure. Subjects were on a stable dual 
class regimen containing two NRTI’s and an NNRTI or a boosted protease inhibitor 
or an integrase inhibitor. All recruited subjects were aged between 18 and 65 years.  
Subjects were excluded based on the following criteria; (1) presence of any currently 
active clinical disease or AIDS-defining illness, (2) a body mass index greater than 
35, (3) clinically relevant drug or alcohol abuse, or (4) the use of any disallowed 
concomitant therapies. 
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Approval for the study was granted by the Riverside Research Ethics Committee, 
UK. All subjects gave written informed consent before any study procedures were 
undertaken. 
 
3.2.2 Study Design 
This trial was a 50 day (excluding screening and follow-up), open label, three phase, 
pharmacokinetic study, conducted at a single trial site (The Clinical Trial Unit of the 
St. Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK), and was 
carried out in accordance with Good Clinical Practice (GCP), the declaration of 
Helsinki, and relevant regulatory requirements (EudraCT, 2008-008321-30). 
Following successful screening, subjects were randomised 1:1 to Group 1 or Group 2 
for phase 2 of the study.  
The study treatment regimen was as follows (Figure 1); 
Phase I; All subjects (n= 24) received one raltegravir (Insentress) 400 mg film coated 
tablet twice daily for 21 days. On day 2, subjects underwent an intensive 12 hour 
pharmacokinetic sampling analysis, with a witnessed morning and evening drug 
intake.  
Phase II; On day 22, all subjects commenced darunavir/ritonavir 800/100 mg once 
daily. Subjects in Group 1 (n=13) commenced darunavir 800 mg tablets plus one 
ritonavir (Norvir) 100 mg capsule once daily plus one raltegravir 400 mg tablet twice 
daily. Subjects in Group 2 (n=11) received darunavir 800 mg tablet plus one 
ritonavir 100 mg capsule once daily plus two raltegravir 400 mg tablets once daily 
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for 14 days. On day 35, all subjects underwent an intensive pharmacokinetic 
sampling analysis.  
Phase III; On day 36, all subjects cessed raltegravir intake and continued to take 
darunavir 800 mg tablet and one ritonavir 100 mg capsule once daily plus their 
background regime for the following 14 days. A 24 hour concentration sample was 
collected on day 36 from each subject.  
On day 49, all subjects underwent a final intensive pharmacokinetic sampling 
analysis, and on day 50 a final 24 hour concentration sample was also collected for 
analysis.  
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Figure 1. Flow diagram to show the study treatment regimen. *Plasma and intracellular intensive PK profile analysis at 0 (pre dose within 10 
minutes before dosing), 1, 2, 4, 6, 8, and 12 hours post dose (and darunavir [DRV] concentrations at 24 hours on days 35 and 49).
Phase I  
Day 1 to 21 
Phase II  
Day 22 to 35  
Phase III 
Day 36 to 49 
 
 
  
 
 
  
27 Screened; 2 not 
eligible, one 
withdrew prior to 
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  24 Eligible subjects; 
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Switch to 2 
NRTI + (RAL 
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DAILY)   
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GROUP 2 (n=11) 
2 NRTI 
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DAILY 
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End of study; resumed 
previous antiretroviral 
therapy regimen 
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DAY 1 DAY 21, 12 hr PK*           DAY 35, 24 hr PK* DAY 49, 24 hr PK* 
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3.2.3 Peripheral Blood Mononuclear Cell (PBMC) Isolation  
Two 8mL cell preparation tubes (CPT) (Becton-Dickinson Vacutainer; Oxford, 
United Kingdom) were collected for each time point. The anticoagulant was mixed 
thoroughly by gently inverting the tubes 8-10 times. CPT were then immediately 
centrifuged (horizontal rotor) for 20 minutes (1600 relative centrifugal force [rcf]) at 
room temperature (20°C). Peripheral blood mononuclear cells (PBMCs) were then 
suspended in the plasma by carefully inverting the CPT. The mixed plasma/cells 
suspension from both cell preparation tubes were then combined into a single 
graduated 50 mL conical tube to which isotonic saline (0.9%) was added to bring the 
total volume to exactly 30 mL. The cell/plasma sample was then gently mixed by 
inversion, and a 40 μL aliquot was taken for initial cell counting (Digital Bio Adam 
Microchip Automatic Cell Counter; NanoEnTek, Inc, Seoul, Korea). The cell count 
was normalised by multiplying by 30 to calculate the actual total cell count in 30 mL 
and recorded. As there were problems with the cell counter a confirmatory cell count 
was obtained using a DNA-based method developed by Benech et al[44]. The 
plasma/cell suspension was then centrifuged for 15 minutes, at 400 relative rcf to 
pellet the cells. The supernatant was carefully removed to avoid disruption of the cell 
pellet. In total this cell isolation method used a single cell wash step to remove the 
supernatant; this contrasts with methods used in other studies, each having a 
different number of cell washes in the isolation process [36-38]. Ice-cold methanol 
(precisely 1 mL, 70%) was added to the pellet to lyse the cells and ultimately release 
the intracellular drugs. The cell lysate was vortexed (3–5 minutes) and stored at 
−80°C. 
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3.2.4 Analytical Methods 
The concentrations of the antiretroviral drugs RAL, DRV and RTV were determined 
in a total of 552 plasma samples, paired with a further 552 intracellular samples, 
collected during the clinical pharmacology study. Concentrations of each 
antiretroviral was determined by reversed phase high performance liquid 
chromatography (HPLC) interfaced with a triple quadrupole mass spectrometer. 
 
3.2.5 Plasma Extraction and Analysis 
Plasma samples for the analysis of RAL, DRV and RTV were extracted alongside 
standard calibrators and quality controls (QC) at low, medium and high 
concentrations. Each sample was extracted in duplicate (100 µL per sample). The 
internal standard quinoxaline (6,7-dimethyl-2,3-di(2pyridyl)-quinoxaline) [QX] (20 
µL of a 1 µg/mL) was added to each sample followed by acetonitrile (500 µL). 
Samples were then mixed with the use of a hand vortex covered and left to stand, at 
room temperature for 15 minutes to precipitate the proteins. This was followed by 
vortexing the samples once again and then centrifuging for 10 minutes at 4000 
revolutions per minute (rpm).  The resulting supernatant was then carefully 
transferred into clean glass labelled 5 mL tubes. To each sample 0.05% formic acid 
(200 µL) was then added and the samples vortexed once again. Samples were then 
pipetted into glass autosampler vials ready for injection (10 µL) onto the HPLC 
column. This method described is a modified validated version of that published by 
Else et al[45] to incorporate the detection and quantification of the RAL.  
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RAL, DRV and RTV plasma concentrations were extrapolated from validated spiked 
plasma matrix calibration curves. The range of each calibration curve was as 
follows; RAL 4.7- 2011 ng/mL, DRV 76-14803 ng/mL, and RTV 13-4993 ng/mL. 
Calibration curves were obtained using 1/concentration weighted quadratic 
regression of peak area ratio versus nominal concentration. The lower limit of 
quantification (LLQ) for each of the ARV’s were determined to be; RAL = 4.7, 
DRV = 76, and RTV = 13ng/mL. LLQ was defined as the lowest concentration for 
which the percentage deviation from the nominal standard concentration was less 
than 20 % and signal to noise was greater than 5%. 
The precision, expressed as a coefficient of variation [CV%] ((Standard deviation / 
mean) X 100), of the assays, as determined from the analysis of low, medium and 
high quality control samples, was as follows; RAL = 6.9-9.3%, DRV = 7.8-10.6%, 
RTV = 6.7-8.2%. 
The accuracy, expressed by percentage bias ((measured value – target value) / 
measured value) X 100) of the assays, as determined from the analysis of 6 replicates 
of each quality control samples in relation to the actual target quality control sample 
concentration for plasma samples, was as follows; RAL = 89.3-100.3%, DRV = 
97.5-102.6, RTV = 102.9-105.7%. 
 
3.2.6 Drug Quantification in Peripheral Blood Mononuclear Cells (PBMC) 
The methodology for the determination of the intracellular concentration of 
raltegravir, darunavir and ritonavir is described in chapter 2 of this thesis. Briefly, 
subject intracellular lysate samples in 1 mL of 70% methanol (MeOH) were removed 
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from the -80
o
C freezer. Samples were centrifuged and the cell lysate was transferred 
into a clean tube. The methanol was evaporated off the lysate samples and they were 
then reconstituted in 400µL of 70% MeOH, ready for direct analysis by reverse 
phase HPLC interfaced with a triple quadrupole mass spectrometer.   
Calculations to normalize the reading from the LC-MS/MS for intracellular samples 
were as follows: 
A = Raw mass spectrometer result 
B = Cell count (cells per 1 mL)  
1000 = Normalization to 1 mL 
400 = Reconstituted (MeOH) volume for extraction 
2.5 x 10
9
= (PBMC volume 0.4 pL transformed and normalized from ng/pL to 
ng/mL) 
Equation 
(
 
    
)    
 
         
Example = Raw raltegravir mass spectrometer value for a patient sample was 3.64 
ng/mL. However, the number of cells, the volume of liquid which the cells are in and 
the average volume of a PBMC in that sample must be taken in to account: 
 
3.64 X 400 
1000   X 2.5x10
9
 
 
12755075 
= 285 ng/mL 
92 
 
RAL, DRV and RTV intracellular concentrations were extrapolated from validated 
spiked cell lysate matrix calibration curves. The range of each calibration curve was 
as follows; RAL = 0.45-146.08 ng/mL, DRV = 0.45-1483 ng/mL, and RTV = 0.48-
153.23 ng/mL. Calibration curves were obtained using 1/concentration weighted 
linear regression of peak area ratio versus nominal concentration. The lower limit of 
quantification (LLQ) for each of the ARV’s were determined to be; RAL = 0.45, 
DRV = 0.45 and RTV = 0.48 ng/mL. LLQ was defined as the lowest concentration 
for which the percentage deviation from the nominal standard concentration was less 
than 20 % and signal to noise was greater than 5%. 
The precision, expressed as a coefficient of variation [CV%] (Standard deviation / 
mean] X 100), of the assays, as determined from the analysis of low, medium and 
high quality control samples, was as follows; RAL =7.0-9.3%, DRV = 5.1-10.0%, 
RTV = 7.2-9.5%. 
The accuracy, expressed by percentage bias ((measured value – target value) / 
measured value) X 100) of the assays, as determined from the analysis of 6 replicates 
of each quality control samples in relation to the target actual target quality control 
sample concentration for plasma samples, was as follows; RAL = 98.5-104.2 %, 
DRV = 98.9-100.4 %, RTV = 97.6-100 %. 
 
3.2.7 Pharmacokinetics and Statistical Analysis 
The pharmacokinetic parameters calculated for plasma and intracellular RAL, DRV 
and RTV were Ctrough, defined as the plasma concentration at hour 12 and 24 after 
observed drug intake. The maximum concentrations (Cmax), elimination half-life 
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(t1/2), time point at Cmax (Tmax), and total drug exposure, expressed as area under the 
plasma/ intracellular concentration time curve (AUC) from 0-12 (for RAL in both 
groups in phase I and in Group 1 in phase II) and 0-24 hours (Group 2 in phase II) 
after drug intake.  
Pharmacokinetics were calculated using WinNonLin version 5.2 (Mountain View, 
CA, USA), by non-compartmental linear-linear trapezoidal analysis. Inter-individual 
variability in concentration of RAL, DRV and RTV was assessed by calculating the 
percentage coefficient of variation (%CV = standard deviation/mean × 100). 
Intracellular accumulation was expressed as the ratio of intracellular drug to plasma 
drug concentration for each of the pharmacokinetic parameters. Calculation of 
geometric means (GM), ratios (GMR), and 90% confidence intervals (CIs), were 
used to assess within-subject changes of drug concentrations (drug alone versus drug 
combination). Any changes in pharmacokinetic parameters were only considered 
significant when the 90% CI did not cross the value of 1. 
 
3.3. Results 
3.3.1 Demographic and Clinical Characteristics 
Twenty seven HIV positive patients were screened for the study, two participants 
were not eligible (one screened positive for drugs of abuse, and the second because 
of problems gaining venous access). A third participant withdrew for personal 
reasons, leaving 24 eligible participants (Group 1; n = 13, Group 2; n = 11). 
Assuming a wide inter individual variability (approximately 60%) in the study drug 
pharmacokinetics, 24 subjects provided a 90% power to show any effect of an 
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interaction of the drugs studied to be statistically significant at a 5% level. The 
median age range of the 24 participants was 37 (range = 21-62) years, body mass 
index was 26 (range = 19-32) kg/m
2
, and CD4 count was 466 (range = 249-849) 
cells per cubic millimetre. All participants were male (17 white, 4 Asian and 3 
black), on a stable antiretroviral therapy (concomitant ARV medications taken 
during the study included tenofovir [n = 21], emtricitabine [n= 21], abacavir [n = 3] 
and lamivudine [n = 3] ), with viral loads less than 50 copies per millimetre. No 
grade 3 or 4 adverse effects were reported during the clinical trial and all study drugs 
were well tolerated. 
 
3.3.2 Raltegravir Pharmacokinetics and Statistical Analysis 
Plasma and IC patient pharmacokinetic profiles and parameters for Group 1 and 2 in 
phase I; RAL in the absence of DRV and phase II; RAL in the presence of DRV are 
shown in Figures 2, 3, 4 and 5. The plasma and IC pharmacokinetic parameter ratios 
for Group 1 and Group 2 are shown in Tables 1 and 2 respectively.  
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Group 1 plasma and IC RAL PK profiles for Phase I (day 21) 
 
 
Figure 2. Group 1 plasma and IC RAL, 400 mg twice daily in the absence of DRV 
(phase I day 21) PK patient profiles. The mean concentrations are highlighted by the 
black line. The geometric mean, lower and upper 90% confidence intervals, 
minimum and maximum concentrations and the coefficient of variation for each of 
the PK parameters are shown below each PK profile set.      
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Time (h) 
          IC RAL Phase I Group 1 
t1/2 (h)
Tmax         
(h)
Cmax 
(ng/ml)
Ctrough 
(ng/ml)
AUC0-12 
(ng.h/ml)
Pre-dose 
(ng/ml)
CL/F (L/h)
Geomean 2.29 3.93 533 23 1944 114 206
low 90% 2.03 2.00 441 9 1686 122 180
up 90% 2.66 5.69 857 62 2623 312 276
Min 1.68 0.00 169 10 942 2 91
Max 3.21 12.00 1774 195 4414 651 425
CV 24 105 70 150 47 95 46
Group 1 Plasma PK parameters RAL 400 mg BID 
Day 21 (-DRV)
t1/2 (h)
Tmax         
(h)
Cmax 
(ng/ml)
Ctrough 
(ng/ml)
AUC0-12 
(ng.h/ml)
Pre-dose 
(ng/ml) CL/F (L/h)
Geomean 2.83 3.67 2306 101 9010 609 44
low 90% 2.11 2.70 1892 24 7852 624 37
up 90% 4.72 6.90 3636 403 13519 1339 70
Min 1.38 2.00 1008 35 2820 36 19
Max 8.26 12.00 7453 1766 21588 2825 142
CV 70 84 69 179 58 80 66
Day 21 (- DRV)
Group 1 IC PK parameters RAL 400 mg BID 
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Group 2 plasma and IC RAL PK profiles for Phase I (day 21) 
 
 
Figure 3. Group 2 plasma and IC RAL, 400 mg twice daily in the absence of DRV 
(phase I day 21) PK patient profiles. The mean concentrations are highlighted by the 
black line. The geometric mean, lower and upper 90% confidence intervals, 
minimum and maximum concentrations and the coefficient of variation for each of 
the PK parameters are shown below each PK profile set. 
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Tmax         
(h)
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(ng/ml)
Ctrough 
(ng/ml)
AUC0-12 
(ng.h/ml)
Pre-dose 
(ng/ml)
CL/F (L/h)
Geomean 3.46 3.63 361 28 1635 101 245
low 90% 2.50 2.31 269 20 1311 88 208
up 90% 5.59 5.32 609 66 2663 188 372
Min 2.21 0.00 152 7 638 18 94
Max 11.92 12.00 1239 131 4252 304 627
CV 73 79 74 103 68 73 57
Day 21 ( - DRV)
Group 2 Plasma PK parameters RAL 400 mg BID 
t1/2 (h)
Tmax         
(h)
Cmax 
(ng/ml)
Ctrough 
(ng/ml)
AUC0-24 
(ng.h/ml)
Pre-dose 
(ng/ml)
CL/F (L/h)
Geomean 2.6 3.4 1871 115 8780 511 46
low 90% 2.2 2.4 1276 80 7286 424 38
up 90% 3.3 5.6 4185 345 16400 918 84
Min 1.6 2.00 574 21 2728 164 15
Max 5.3 12.00 9416 723 27218 1529 147
CV 38 75 102 119 77 74 76
Day 21 (-DRV)
Group 2 IC PK parameters RAL 400 mg BID 
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Group 1 plasma and IC RAL PK profiles for Phase II (day 35) 
 
Figure 4. Group 1 plasma and IC RAL, 400 mg twice daily in the presence of DRV 
800 mg RTV 100 mg once daily (phase II day 35) PK patient profiles. The mean 
concentrations are highlighted by the black line. The geometric mean, lower and 
upper 90% confidence intervals, minimum and maximum concentrations and the 
coefficient of variation for each of the PK parameters are shown below each PK 
profile set. 
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(ng/ml)
AUC0-12 
(ng.h/ml)
Pre-dose 
(ng/ml)
CL/F (L/h)
Geomean 3.26 2.72 438 20 1759 146 227
low 90% 2.64 1.25 337 17 1459 144 202
up 90% 4.97 2.75 999 25 2937 362 344
Min 1.87 0.00 174 12 660 20 70
Max 8.74 4.00 2552 34 5676 788 606
CV 62 82 108 34 73 95 57
Group 1 Plasma PK parameters RAL 400 mg BID
Day 35 (+ DRV)
t1/2 (h)
Tmax         
(h)
Cmax 
(ng/ml)
Ctrough 
(ng/ml)
AUC0-12 
(ng.h/ml)
Pre-dose 
(ng/ml) CL/F (L/h)
Geomean 2.41 3.81 2173 105 9223 605 43
low 90% 2.09 3.09 1846 51 7416 464 39
up 90% 2.90 5.91 4299 295 15694 1791 65
Min 1.65 2.00 754 38 3672 116 11
Max 3.99 12.00 8896 958 35452 5314 109
CV 29 66 87 148 78 129 55
Day 35 (+ DRV)
Group 1 IC PK parameters RAL 400 mg BID (steady-state) 
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Group 2 plasma and IC RAL PK profiles for Phase II (day 35) 
 
 
Figure 5. Group 2 plasma and IC RAL, 800 mg once daily in the presence of DRV 
800 mg RTV 100 mg once daily (phase II day 35) PK patient profiles. The mean 
concentrations are highlighted by the black line. The geometric mean, lower and 
upper 90% confidence intervals, minimum and maximum concentrations and the 
coefficient of variation for each of the PK parameters are shown below each PK 
profile set.    
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IC RAL Phase II Group 2 
t1/2 (h)
Tmax         
(h)
Cmax 
(ng/ml)
Ctrough 
(ng/ml)
AUC0-24 
(ng.h/ml)
Pre-dose 
(ng/ml)
CL/F (L/h)
Geomean 9.08 2.27 556 11 1979 16 404
low 90% 7.25 1.94 273 9 1079 13 365
up 90% 13.63 3.15 1298 20 4318 27 574
Min 3.99 1.00 268 5 1023 8 65
Max 24.79 4.00 3862 35 12373 46 782
CV 58 48 131 75 121 71 45
Group 2 Plasma PK parameters RAL 800 mg OD  
Day 35/36 ( + DRV)
t1/2 (h)
Tmax         
(h)
Cmax 
(ng/ml)
Ctrough 
(ng/ml)
AUC0-24 
(ng.h/ml)
Pre-dose 
(ng/ml)
CL/F (L/h)
Geomean 7.2 2.4 2817 22 11183 54 72
low 90% 3.4 2.1 2289 16 7201 36 59
up 90% 18.8 3.2 4153 59 23547 156 121
Min 2.99 1.00 991 4 3345 8 13
Max 57.06 4.00 7260 146 62495 422 239
CV 139 42 55 114 107 125 69
Day 35/36 (+DRV)
Group 2 IC PK parameters RAL 800 mg OD (steady-state) 
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Table 1. Geometric mean ratio, lower and upper 90 % confidence intervals and % co efficient of variance for Group 1 and 2 plasma RAL phase I 
(day 21 without DRV/r) versus phase II (day 35 with DRV/r). 
 
-DRV +DRV ratio log ratio -DRV +DRV ratio log ratio -DRV +DRV ratio log ratio -DRV +DRV ratio log ratio -DRV +DRV ratio log ratio
Geomean 2.3 3.3 1.11 3.9 2.7 0.77 532.7 438.2 0.82 22.9 19.9 0.76 1943.8 1759.1 0.90
low 90% CI 2.0 2.6 1.00 -0.20 3.0 2.3 0.65 -0.23 441.4 337.3 0.62 -0.24 9.0 17.5 0.69 -0.30 1686.4 1459.0 0.73 -0.20
high 90% CI 2.7 5.0 1.95 0.29 7.0 3.5 1.01 0.01 857.1 999.0 1.67 0.10 62.1 24.5 1.12 0.00 2622.6 2937.1 1.44 0.10
anti-log low 90% CI 0.64 0.58 0.57 0.50 0.69
anti-log high 90% CI 1.93 1.03 1.18 1.10 1.19
min 1.7 1.9 0.10 2.0 2.0 0.33 169.0 174.0 0.39 10.0 12.0 0.10 942.0 660.0 0.43
max 3.2 8.7 2.81 12.0 4.0 1.00 1774.0 2552.0 3.99 195.0 34.0 1.40 4413.5 5675.5 3.24
cv% 24.3 61.7 58.87 78.3 36.5 34.64 70.0 108.2 99.82 150.1 33.7 45.80 47.5 73.5 71.60
-DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio
Geomean 3.5 9.1 3.10 3.6 2.3 0.59 360.6 555.7 1.27 27.5 11.4 0.42 1634.7 1979.0 1.21
low 90% CI 2.5 7.3 2.61 0.34 2.7 1.9 0.46 -0.39 269.2 273.0 1.09 0.00 19.9 9.3 0.35 -0.50 1310.8 1079.4 1.03 0.00
high 90% CI 5.6 13.6 4.57 0.64 5.7 3.1 1.02 -0.10 608.8 1297.9 1.82 0.21 65.9 20.4 0.59 -0.30 2662.6 4317.8 1.77 0.20
anti-log low 90% CI 2.17 0.40 0.92 0.30 0.90
anti-log high 90% CI 4.41 0.86 1.64 0.53 1.60
min 2.2 4.0 0.77 2.0 1.0 0.17 152.0 268.0 0.38 7.0 5.0 0.02 637.5 1022.5 0.47
max 11.9 24.8 6.65 12.0 4.0 2.00 1239.0 3862.0 2.87 131.0 35.0 0.88 4252.0 12373.0 2.90
cv% 73.2 58.5 49.48 69.0 47.7 72.32 74.1 131.2 48.50 102.8 75.3 49.40 68.4 120.6 53.10
GROUP 1 Plasma RAL : DAY 21 (RAL 400 mg BID) vs. DAY 35 (RAL 400 mg BID PLUS DRV/r 800/100 mg OD). 
GROUP 2 Plasma RAL : DAY 21 (RAL 400 mg OD) vs. DAY 35 (RAL 800 mg OD PLUS DRV/r 800/100 mg OD). 
SIG Difference SIG Difference NON sig Difference SIG Difference NON sig Difference
increase by 210% decrease by 41% increase by 27% decrease by 58% increase by 21%
Plasma half-life (h) Plasma Tmax (h) Plasma Cmax (ng/ml) Plasma Ctrough(ng/ml) Plasma AUC0-24 (ng.h/ml)
NON sig Difference NON sig Difference
Plasma Cmax (ng/ml) Plasma Ctrough(ng/ml) Plasma AUC (ng.h/ml)
increase by 11% decrease by 23% decrease by 18% decrease by 24% decrease by 10%
NON sig Difference NON sig Difference
Plasma half-life (h) Plasma Tmax (h)
NON sig Difference
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Table 2. Geometric mean ratio, lower and upper 90% confidence intervals and  % co efficient of variance for Group 1 and 2 IC RAL phase I 
(day 21 without DRV/r) versus phase II (day 35 with DRV/r). 
 
-DRV +DRV ratio log ratio -DRV +DRV ratio log ratio -DRV +DRV ratio log ratio -DRV +DRV ratio log ratio -DRV +DRV ratio log ratio
Geomean 2.8 2.4 0.82 3.7 3.8 0.91 2306.5 2172.6 0.94 101.2 104.7 0.70 9009.8 9222.8 1.02
low 90% CI 2.1 2.1 0.47 -0.34 2.7 3.1 0.75 -0.2 1891.5 1846.4 0.68 -0.15 23.7 51.5 0.57 -0.48 7851.6 7415.8 0.81 -0.14
high 90% CI 4.7 2.9 1.75 0.17 6.9 5.9 1.40 0.1 3636.5 4299.1 1.66 0.10 403.2 295.0 2.06 0.26 13519.3 15693.9 1.67 0.10
anti-log low 90% CI 0.45 0.64 0.71 0.34 0.78
anti-log high 90% CI 1.48 1.30 1.25 1.43 1.35
min 1.4 1.7 0.22 2.0 2.0 0.33 1008.0 754.0 0.39 35.0 38.0 0.04 2819.5 3672.0 0.42
max 8.3 4.0 2.89 12.0 12.0 2.00 7453.0 8896.0 4.55 1333.0 958.0 47.85 21587.5 35452.0 3.99
cv% 69.6 29.4 85.99 83.8 66.0 55.47 69.0 87.2 91.22 178.7 147.6 108.70 58.0 78.3 76.00
-DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio -DRV/r +DRV/r ratio log ratio
Geomean 2.6 7.2 2.72 3.4 2.4 0.68 1870.8 2816.7 1.51 114.6 21.7 0.19 8780.0 11183.3 1.27
low 90% CI 2.2 3.4 1.42 0.24 2.4 2.1 0.55 -0.32 1275.8 2289.4 1.18 0.02 80.5 16.2 0.12 -0.95 7285.9 7201.5 1.07 -0.03
high 90% CI 3.3 18.8 6.80 0.63 5.6 3.2 1.08 -0.01 4185.2 4152.6 2.59 0.34 344.7 59.1 0.50 -0.48 16400.2 23547.2 1.94 0.24
anti-log low 90% CI 1.74 0.48 1.04 0.11 0.93
anti-log high 90% CI 4.27 0.97 2.19 0.33 1.74
min 1.6 3.0 0.89 2.0 1.0 0.17 574.0 991.0 0.46 21.0 4.0 0.01 2727.5 3345.0 0.57
max 5.3 57.1 18.30 12.0 4.0 2.00 9416.0 7260.0 4.84 723.0 146.0 1.28 27217.5 62494.5 2.76
cv% 37.9 139.4 125.38 74.5 42.5 62.68 102.1 5.4 71.70 119.1 114.5 116.70 77.3 106.9 58.94
SIG Difference SIG Difference SIG Difference SIG Difference NON sig Difference
increase by 172% decrease by 32% increase by 51% decrease by 81% increase by 27%
GROUP 2 IC RAL : DAY 21 (RAL 400 mg OD) vs. DAY 35 (RAL 800 mg OD PLUS DRV/r 800/100 mg OD). 
IC half-life (h) IC Tmax (h) IC Cmax (ng/ml) IC Ctrough(ng/ml) IC AUC0-24 (ng.h/ml)
NON sig Difference NON Sig Difference NON sig DifferenceNON sig Difference NON sig Difference
GROUP 1 IC RAL : DAY 21 (RAL 400 mg BID) vs. DAY 35 (RAL 400 mg BID PLUS DRV/r 800/100 mg OD). 
decrease by 2%decrease by 30%decrease by 6%decrease by 9%decrease by 18%
IC half-life (h) IC Tmax (h) IC Cmax (ng/ml) IC Ctrough(ng/ml) IC AUC0-12 (ng.h/ml)
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Correlation between IC and plasma PK parameters for RAL in the absence (phase I day 21) and presence of DRV (phase II day 35), for Group 1 
and Group 2 are shown in Figures 6 and 7. 
 
Figure 6. Correlation between IC and plasma pharmacokinetic parameters (AUC 0-12hr, Cmax, and Ctrough) for Group 1 and 2, phase I (day 21) RAL 
400 mg twice daily in the absence of DRV/r.  
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Figure 7. Correlation between IC and plasma pharmacokinetic parameters (AUC 0-12hr, Cmax, and Ctrough) for Group 1 and 2, phase II (day 35) 
RAL 400 mg twice daily (Group 1) RAL 800 g once daily (Group 2) in the presence of DRV/r 800/100 mg once daily.  
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RAL comparisons of individual patient geometic mean IC to plasma ratio for AUC, Cmax and Ctrough are displayed side by side for Groups 1 and 2 
during phase I and II (RAL without and with DRV/r).  
 
Figure 8. RAL PK parameters comparison of geometric mean IC to plasma ratios for Groups 1 and 2 during phase I and II. For each set of group 
data the mean ratio is highlighted by a solid horizontal bar. RAL PK parameters showed a high level of inter-individual variability in the plasma 
(53-220%) and also within the cells (69-202%).
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3.3.3 Darunavir Pharmacokinetics and Statistical Analysis 
Plasma and IC patient pharmacokinetic profiles and parameters for Group 1 and 2 in 
phase II; DRV/r in the presence of RAL and phase III; DRV/r in the absence of RAL 
are shown in Figures 9, 10, 11 and 12. The pharmacokinetic parameter ratios for 
plasma and IC for Group 1 and Group 2 are shown in Tables 3 and 4 respectively. 
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Group 1 plasma and IC DRV/r PK profiles for Phase II (day 35) 
 
 
Figure 9. Group 1 plasma and IC DRV/r, 800/100 mg once daily in the presence of RAL 400 mg twice daily (phase II day 35) PK patient 
profiles. The mean concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence intervals, minimum 
and maximum concentrations and the coefficient of variation for each of the PK parameters are shown below each PK profile set. 
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Group 2 plasma and IC DRV/r PK profiles for Phase II (day 35) 
 
 
Figure 10. Group 2 plasma and IC DRV/r, 800/100 mg once daily in the presence of RAL 800 mg once daily (phase II day 35) PK patient 
profiles. The mean concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence intervals, minimum 
and maximum concentrations and the coefficient of variation for each of the PK parameters are shown below each PK profile set. 
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Group 1 plasma and IC DRV/r PK profiles for Phase III (day 49) 
 
 
Figure 11. Group 1 plasma and IC DRV/r, 800/100 mg once daily in the absence of RAL (phase III day 49) PK patient profiles. The mean 
concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence intervals, minimum and maximum 
concentrations and the coefficient of variation for each of the PK parameters are shown below each PK profile set. 
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Group 2 plasma and IC DRV/r PK profiles for Phase III (day 49) 
 
 
Figure 12. Group 2 plasma and IC DRV/r, 800/100 mg once daily in the absence of RAL (phase III day 49) PK patient profiles. The mean 
concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence intervals, minimum and maximum 
concentrations and the coefficient of variation for each of the PK parameters are shown below each PK profile set. 
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Table 3. Group 1 and 2 pharmacokinetic parameter ratios for plasma DRV/r 800/100 mg once daily in the presence of RAL 400 mg twice daily 
(Group 1) and RAL 800 mg once daily (Group 2), (phase II day 35) versus DRV 800 mg once daily in the absence of RAL (phase III day 49). 
Note: N= 2 AUC results 0-12 Hr only. 
 
ID + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio
Geomean 12.7 16.8 1.27 3.1 3.3 1.09 4235.1 4106.4 0.97 697.0 1150.6 1.62 40064.3 49870.5 1.24
low 90% CI 10.6 14.2 1.05 -0.03 2.6 3.0 0.95 -0.05 3787.9 3534.0 0.88 -0.06 615.8 1005.5 1.32 0.10 36905.3 44378.8 1.13 0.00
high 90% CI 18.0 23.8 1.95 0.24 4.2 4.1 1.43 0.13 5101.5 5338.6 1.11 0.03 877.1 1505.0 2.33 0.30 44708.9 60884.5 1.45 0.20
anti-log low 90% CI 0.92 0.88 0.87 1.26 1.10
anti-log high 90% CI 1.74 1.34 1.08 2.10 1.40
min 6.9 7.8 0.31 2.0 2.0 0.50 2244.0 1937.0 0.72 347.0 537.0 0.80 29082.5 27280.5 0.90
max 28.1 40.5 3.30 8.0 6.0 2.00 7665.0 9843.0 1.43 1077.0 2261.0 4.35 63499.0 93519.0 1.90
cv% 52.0 55.3 60.22 50.5 33.9 43.78 32.3 44.4 24.22 35.2 43.5 55.70 20.9 34.3 27.80
ID + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio
Geomean 17.4 14.5 0.80 2.3 2.4 1.07 5092.2 5271.6 1.04 1106.0 1134.7 1.03 50040.2 57054.9 1.14
low 90% CI 13.7 12.5 0.67 -0.18 1.9 2.1 0.91 -0.05 4443.1 4755.3 0.93 0.00 979.2 1016.9 0.89 0.00 43432.5 51386.3 1.07 0.00
high 90% CI 24.4 18.6 1.06 0.00 3.0 3.2 1.36 0.11 6265.6 6108.7 1.20 0.07 1313.4 1339.2 1.24 0.07 61160.7 65625.9 1.24 0.09
anti-log low 90% CI 0.65 0.88 0.92 0.90 1.06
anti-log high 90% CI 0.99 1.28 1.17 1.17 1.23
min 9.8 8.9 0.47 1.0 1.0 0.50 3328.0 3061.0 0.66 775.0 636.0 0.80 36895.5 41255.0 0.88
max 47.0 27.0 1.71 4.0 4.0 2.00 8822.0 7977.0 1.63 1859.0 1634.0 1.96 94896.0 88921.0 1.46
cv% 54.0 39.2 42.87 42.2 42.5 39.80 34.2 25.0 25.20 29.3 27.5 32.19 34.1 24.5 15.20
SIG Difference NON sig Difference NON sig Difference NON sig Difference SIG Difference
decrease by 20% increase by 7% increase by 4% increase by 3% increase by 14%
Plasma half-life (h) Plasma Tmax (h) Plasma Cmax (ng/ml) Plasma Ctrough(ng/ml) Plasma AUC0-24 (ng.h/ml)
GROUP 2 Plasma DRV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 800 mg OD) vs. DAY 49/50 (DRV/r 800/100 mg OD)
NON sig Difference NON sig Difference NON sig DifferenceNON sig Difference SIG Difference
increase by 24%increase by 62%decrease by 3%increase by 9%increase by 27%
Plasma half-life (h) Plasma Tmax (h) Plasma Cmax (ng/ml) Plasma Ctrough(ng/ml) Plasma AUC0-24 (ng.h/ml)
GROUP 1 Plasma DRV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 400 mg BID) vs. DAY 49/50 (DRV/r 800/100 mg OD)
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Table 4. Group 1 and 2 pharmacokinetic parameter ratios for IC DRV/r 800/100 mg once daily in the presence of RAL 400 mg twice daily 
(group 1) and RAL 800 mg once daily (group 2), (phase II day 35) versus DRV 800 mg once daily in the absence of RAL (phase III day 49). 
 
+ RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio
Geomean 13.5 15.0 1.02 4.3 3.1 0.72 20209.5 25433.3 1.11 3431.2 4984.4 1.45 202865.4 251471.3 1.24
low 90% CI 10.2 11.2 0.85 -0.12 3.8 2.8 0.64 -0.28 18167.7 22050.2 0.95 -0.12 3078.4 4112.4 1.22 0.02 181237.1 217731.5 1.07 -0.01
high 90% CI 24.7 24.3 1.55 0.14 5.4 4.3 1.09 -0.01 24323.8 35538.0 1.94 0.21 4788.3 8525.5 2.41 0.30 243108.7 338134.8 1.73 0.20
anti-log low 90% CI 0.76 0.53 0.76 1.06 0.98
anti-log high 90% CI 1.38 0.99 1.61 2.00 1.57
min 5.7 9.0 0.35 2.0 1.0 0.17 9259.0 9899.0 0.17 1262.0 1765.0 0.53 136019.5 91576.0 0.55
max 51.2 62.6 2.57 8.0 6.0 2.00 31882.0 64976.0 4.32 6940.0 16912.0 4.63 348096.0 609933.0 2.95
cv% 83.8 80.4 58.79 37.0 45.6 57.72 30.0 51.2 74.27 47.5 76.3 71.43 32.0 47.3 51.72
+RAL -RAL ratio log ratio +RAL -RAL ratio log ratio +RAL -RAL ratio log ratio +RAL -RAL ratio log ratio +RAL -RAL ratio log ratio
Geomean 13.5 13.1 0.97 2.7 2.3 0.83 29293.0 24082.1 0.82 4555.1 4909.9 1.08 263148.1 270193.5 1.03
low 90% CI 11.3 10.3 0.63 -0.16 2.4 1.9 0.69 -0.18 25964.6 22445.7 0.73 -0.14 3914.1 4258.7 0.86 -0.06 229990.8 239620.4 0.94 -0.04
high 90% CI 18.2 19.1 1.95 0.14 3.4 3.1 1.13 0.01 35803.6 26371.0 0.96 -0.03 5901.2 6253.8 1.53 0.13 325739.3 323007.4 1.16 0.06
anti-log low 90% CI 0.69 0.66 0.72 0.87 0.92
anti-log high 90% CI 1.37 1.03 0.94 1.34 1.15
min 7.5 7.1 0.52 2.0 1.0 0.50 15353.0 16025.0 0.50 2729.0 2510.0 0.64 157620.0 159065.0 0.69
max 30.4 38.8 5.06 4.0 4.0 2.00 47146.0 29222.0 1.38 8014.0 8464.0 3.06 422727.5 433263.5 1.29
cv% 47.0 60.0 103.49 35.9 47.7 48.06 32.0 16.2 27.14 40.7 38.1 57.01 34.6 29.8 20.82
NON Sig Difference NON Sig Difference SIG Difference NON sig Difference NON sig Difference
decrease by 3% decrease by 17% decrease by 18% increase by 8% increase by 3%
GROUP 2 IC DRV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 800 mg OD) vs. DAY 49/50 (DRV/r 800/100 mg OD)
IC half-life (h) IC Tmax (h) IC Cmax (ng/ml) IC Ctrough(ng/ml) IC AUC0-24 (ng.h/ml)
NON Sig Difference SIG Difference NON sig DifferenceNON sig Difference SIG Difference
GROUP 1 IC DRV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 400 mg BID) vs. DAY 49/50 (DRV/r 800/100 mg OD)
increase by 24%increase by 45%increase by 11%decrease by 28%increase by 2%
IC half-life (h) IC Tmax (h) IC Cmax (ng/ml) IC Ctrough(ng/ml) IC AUC0-24 (ng.h/ml)
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Correlation between IC and plasma PK parameters for DRV in the presence (Phase II day 35) and absence of RAL (Phase III day 49), for Group 
1 and Group 2 are shown in Figures 13and 14. 
 
Figure 13. Correlation between IC and plasma pharmacokinetic parameters (AUC 0-12hr, Cmax, and Ctrough) for Group 1 and 2, phase II (day 35) 
DRV/r 800/100 mg once daily in the presence of RAL 400 mg twice daily(Group 1) and RAL 800 mg once daily (Group 2). 
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Figure 14. Correlation between IC and plasma pharmacokinetic parameters (AUC 0-12hr, Cmax, and Ctrough) for Group 1 and 2, phase III (day 49) 
DRV/r 800/100 mg once daily in the absence of RAL. 
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DRV/r comparisons of individual patient geometic mean IC to plasma ratio for AUC, Cmax and Ctrough are displayed side by side for Groups 1 and 
2 during phase II and III (DRV/r with and without RAL).  
 
Figure 15. DRV PK parameters comparison of geometric mean IC to plasma ratios for Groups 1 and 2 during phase II and III. For each set of 
group data the mean ratio is highlighted by a solid horizontal bar.
GM IC to Plasma Ratio DRV Phase II (Day 35 with RAL) DRV Phase III (Day 49 without RAL) 
Group 1 Group 2 Group 1 Group 2
GM AUC, ng.h-1.mL-1 5.3 5.6 5.3 4.9
GM Cmax, ng/mL 6.8 6.3 6.8 4.8
GM Ctrough, ng/mL 4.4 4.3 4.8 4.4
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DRV PK parameters showed a high level of inter-individual variability in the plasma 
(32-87%) and also within the cells (32-86%). During phase III (PK day 49) in the 
absence of RAL, the plasma AUC was marginally increased in both Group 1 and 2 
(24 % and 14 % respectively). Group 1 also showed a 37 % increase in the plasma 
Ctrough concentration in the absence of RAL whereas no change was seen in Group 2. 
An increase of 45 % in Ctrough was observed in the IC concentrations of DRV for 
Group 1, in the absence and presence of RAL and for Group 2 a decrease of 18 % in 
Cmax was shown (Table 4). 
 
3.3.4 Ritonavir Pharmacokinetics and Statistical Analysis 
Plasma and IC patient pharmacokinetic profiles and parameters for Group 1 and 2 in 
phase II; RTV in the presence of DRV (800 mg) and RAL (800 mg) and phase III; 
RTV in the presence of DRV (800 mg) and the absence of RAL are shown in Figures 
16, 17, 18 and 19 respectively. The pharmacokinetic parameter ratios for plasma and 
IC for Group 1 and Group 2 are shown in Tables 5 and 6 respectively.
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Group 1 plasma and IC RTV PK profiles for Phase II (day 35) 
 
 
Figure 16. Group 1 plasma and IC RTV 100 mg once daily in the presence of DRV 800 mg once daily plus RAL 400 mg twice daily (phase II 
day 35) PK patient profiles. The mean concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence 
intervals, minimum and maximum concentrations and the coefficient of variation for each of the PK parameters are shown below each PK 
profile set. 
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Group 2 plasma and IC RTV PK profiles for Phase II (day 35) 
 
 
Figure 17. Group 2 plasma and IC RTV 100 mg once daily in the presence of DRV 800 mg once daily plus RAL 800 mg once daily (phase II 
day 35) PK patient profiles. The mean concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence 
intervals, minimum and maximum concentrations and the coefficient of variation for each of the PK parameters are shown below each PK 
profile set. 
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Group 1 plasma and IC RTV PK profiles for Phase III (day 49) 
 
 
Figure 18. Group 1 plasma and IC RTV 100 mg once daily in the presence of DRV 800 mg once daily and the absence of RAL (phase III day 
49) PK patient profiles. The mean concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence 
intervals, minimum and maximum concentrations and the coefficient of variation for each of the PK parameters are shown below each PK 
profile set. 
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Group 2 plasma and IC RTV PK profiles for Phase III (day 49) 
 
 
Figure 19. Group 2 plasma and IC RTV 100 mg once daily in the presence of DRV 800 mg once daily and the absence of RAL (phase III day 
49) PK patient profiles. The mean concentrations are highlighted by the black line. The geometric mean, lower and upper 90% confidence 
intervals, minimum and maximum concentrations and the coefficient of variation for each of the PK parameters are shown below each PK 
profile set. 
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Table 5. Group 1 and 2 pharmacokinetic parameter ratios for plasma RTV 100 mg once daily plus DRV 800 mg once daily in the presence of 
RAL 400 mg twice daily (group 1) and RAL 800 mg once daily (group 2), (phase II day 35) versus RTV 100 mg and DRV 800 mg once daily in 
the absence of RAL (phase III day 49). Note: N= 2 AUC results 0-12 Hr only. 
 
ID + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio
Geomean 5.5 5.8 0.95 5.3 4.5 1.18 482.8 528.0 0.91 48.2 44.0 1.09 4299.1 4568.3 0.94
low 90% CI 5.1 5.4 0.90 0.00 3.8 4.0 0.80 0.00 439.4 468.4 0.82 -0.10 5.3 37.7 -0.03 -0.10 3823.1 4069.6 0.83 -0.10
high 90% CI 6.0 6.3 1.00 0.00 8.8 5.2 2.10 0.20 564.1 677.8 1.11 0.00 195.4 59.6 4.63 0.20 5175.6 5426.7 1.16 0.00
anti-log low 90% CI 0.89 0.93 0.78 0.73 0.81
anti-log high 90% CI 1.01 1.51 1.07 1.65 1.09
min 4.4 4.8 0.70 4.0 4.0 0.70 220.0 208.0 0.50 16.0 20.0 0.50 2747.0 3087.0 0.60
max 7.4 7.7 1.10 24.0 8.0 6.00 788.0 1022.0 1.40 788.0 110.0 19.20 8016.5 8366.5 1.90
cv% 15.7 15.5 11.90 86.7 27.3 96.70 27.2 39.9 32.50 207.1 49.3 221.40 32.8 31.2 36.30
ID + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio
Geomean 5.6 5.5 1.01 3.9 4.2 0.93 616.6 527.4 1.17 34.4 36.3 0.95 4359.0 4516.1 0.97
low 90% CI 5.1 5.0 1.00 0.00 3.6 3.8 0.80 -0.10 534.8 441.8 1.05 0.00 30.0 31.0 0.86 -0.10 3881.2 3885.2 0.88 -0.10
high 90% CI 6.2 6.1 1.10 0.00 4.4 4.9 1.20 0.00 819.9 790.3 1.56 0.20 48.2 52.8 1.09 0.00 5377.4 5898.8 1.13 0.00
anti-log low 90% CI 0.95 0.79 0.91 0.85 0.84
anti-log high 90% CI 1.08 1.09 1.50 1.06 1.11
min 4.3 4.2 0.80 2.0 2.0 0.50 341.0 225.0 0.40 11.0 13.0 0.60 2569.5 2274.5 0.60
max 7.8 8.1 1.30 6.0 6.0 2.00 1153.0 1563.0 2.10 75.0 94.0 1.40 7255.0 10475.0 1.40
cv% 20.0 21.4 13.70 22.4 27.6 38.90 46.0 61.8 42.20 50.7 57.0 25.10 35.3 45.0 28.00
SIG Difference SIG Difference SIG Difference SIG Difference SIG Difference
increase by 1% decrease by 7% increase by 17% decrease by 5% decrease by 3%
Plasma half-life (h) Plasma Tmax (h) Plasma Cmax (ng/ml) Plasma Ctrough(ng/ml) Plasma AUC0-24 (ng.h/ml)
GROUP 2 Plasma RTV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 800 mg OD) vs. DAY 49/50 (DRV/r 800/100 mg OD)
Plasma half-life (h) Plasma Tmax (h) Plasma Cmax (ng/ml) Plasma Ctrough(ng/ml) Plasma AUC0-24 (ng.h/ml)
GROUP 1 Plasma RTV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 400 mg BID) vs. DAY 49/50 (DRV/r 800/100 mg OD)
SIG Difference SIG Difference SIG Difference SIG Difference SIG Difference
decrease by 5% increase by 18% decrease by 9% increase by 9% decrease by 6%
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Table 6. Group 1 and 2 pharmacokinetic parameter ratios for IC RTV 100 mg once daily plus DRV 800 mg once daily in the presence of RAL 
400 mg twice daily (group 1) and RAL 800 mg once daily (group 2), (phase II day 35) versus RTV 100 mg and DRV 800 mg once daily in the 
absence of RAL (phase III day 49). 
 
+ RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio + RAL - RAL ratio log ratio
Geomean 7.9 7.8 1.02 4.9 4.4 1.12 3883.4 4041.2 0.96 457.6 478.3 0.96 33788.9 36768.9 0.92
low 90% CI 7.2 7.2 0.90 0.00 4.5 4.1 1.00 0.00 2391.7 2858.5 0.56 -0.20 387.8 399.0 0.82 -0.10 27362.2 29157.3 0.82 -0.10
high 90% CI 8.8 8.7 1.20 0.10 5.7 4.9 1.40 0.10 9163.3 7074.9 2.15 0.10 675.8 718.4 1.32 0.10 53254.8 53037.2 1.11 0.00
anti-log low 90% CI 0.90 0.97 0.69 0.77 0.78
anti-log high 90% CI 1.15 1.30 1.34 1.19 1.08
min 5.9 4.9 0.70 4.0 4.0 0.70 1518.0 1688.0 0.40 174.0 129.0 0.50 14787.5 21775.5 0.50
max 11.8 10.7 1.90 8.0 6.0 2.00 28767.0 19836.0 7.00 1312.0 1565.0 2.20 115160.0 123456.5 1.50
cv% 20.3 21.0 28.90 26.0 19.7 32.90 128.1 92.8 127.80 59.2 62.5 51.00 70.2 63.5 32.60
+RAL -RAL ratio log ratio +RAL -RAL ratio log ratio +RAL -RAL ratio log ratio +RAL -RAL ratio log ratio +RAL -RAL ratio log ratio
Geomean 7.8 7.2 0.91 3.9 3.9 0.99 2606.7 3288.9 1.26 368.7 328.6 0.89 27652.0 28682.7 1.04
low 90% CI 7.0 6.5 0.80 -0.10 3.5 3.4 0.80 -0.10 1936.5 2718.9 1.08 0.00 263.0 269.5 0.78 -0.10 21621.4 23317.7 0.94 0.00
high 90% CI 9.2 8.2 1.00 0.00 4.9 5.0 1.30 0.10 4239.5 5614.9 1.67 0.20 645.3 488.7 1.10 0.00 42997.0 43701.8 1.18 0.10
anti-log low 90% CI 0.80 0.78 1.01 0.75 0.93
anti-log high 90% CI 1.03 1.25 1.57 1.06 1.16
min 5.5 5.0 0.60 2.0 2.0 0.50 1203.0 1079.0 0.60 136.0 123.0 0.50 14018.5 10786.0 0.80
max 11.4 9.5 1.30 6.0 8.0 2.00 9589.0 10018.0 2.50 1552.0 885.0 1.60 88347.0 78422.0 1.50
cv% 27.3 23.1 23.90 33.5 39.8 47.00 75.0 69.9 43.10 84.6 58.1 35.60 66.5 61.1 22.10
NON Sig Difference NON Sig Difference NON Sig Difference NON sig Difference NON sig Difference
decrease by 9% decrease by 1% increase by 26% decrease by 11% increase by 4%
GROUP 2 IC RTV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 800 mg OD) vs. DAY 49/50 (DRV/r 800/100 mg OD)
IC half-life (h) IC Tmax (h) IC Cmax (ng/ml) IC Ctrough(ng/ml) IC AUC0-24 (ng.h/ml)
GROUP 1 IC RTV: DAY 35/36 (DRV/r 800/100 mg OD PLUS RAL 400 mg BID) vs. DAY 49/50 (DRV/r 800/100 mg OD)
IC half-life (h) IC Tmax (h) IC Cmax (ng/ml) IC Ctrough(ng/ml) IC AUC0-24 (ng.h/ml)
SIG Difference SIG Difference SIG Difference SIG Difference SIG Difference
increase by 2% increase by 12% decrease by 4% decrease by 4% decrease by 8%
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Figure 20. Correlation between IC and plasma pharmacokinetic parameters (AUC 0-12hr, Cmax, and Ctrough) for Group 1 and 2, phase II (day 35) 
RTV 100 mg plus DRV 800 once daily in the presence of RAL 400 mg twice daily(Group 1) and RAL 800 mg once daily (Group 2). 
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Figure 21. Correlation between IC and plasma pharmacokinetic parameters (AUC 0-12hr, Cmax, and Ctrough) for Group 1 and 2, phase III (day 49) 
RTV 100 mg plus DRV 800 once daily in the absence of RAL. 
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Figure 22. RTV PK parameters comparison of geometric mean IC to plasma ratios for Groups 1 and 2 during phase II and III. For each set of 
group data the mean ratio is highlighted by a solid horizontal bar. The plasma and IC RTV PK parameters were equivalent in both phases I and 
II when administered with and without RAL.
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3.4. Discussion and Conclusion 
This clinical trial reports the pharmacokinetics of the co-administration of the ARV 
drugs DRV/r and RAL during steady-state within plasma and the IC compartment of 
HIV infected subjects. DRV/r was studied at the recommended dose of 800/100 mg 
once daily in the presence and absence of RAL, whereas RAL was examined at two 
different doses; the currently recommended dose of 400 mg twice daily, and also 800 
mg once daily. Both doses were studied in the presence and absence of DRV/r. 
During the study all patients were monitored and all drugs were well tolerated. No 
major adverse effects were reported.  
Data investigating any drug interaction with the use of DRV/r co-administered with 
RAL once daily and RAL IC concentrations do not exist, therefore this study was the 
first to investigate the two ARVs from different classes in plasma and within the 
intracellular compartment. 
The DRV AUC concentrations in the absence of RAL for both group 1 and 2 was 
higher than the concentrations seen in the presence of RAL (geometric means; group 
1 minus RAL = 49871 ng.h/mL, plus RAL = 40064 ng.h/mL, and group 2 minus 
RAL = 57055 ng.h/mL, plus RAL 50040 ng.h/mL). In light of the intracellular AUC 
concentrations, we seen again no significant changes, therefore, we do not believe 
that the DRV plasma decrease in the presence of RAL to be of any clinical 
significance. The group 1 plasma Ctrough concentration in the absence of RAL (1151 
ng/mL) was 62% higher than that seen in the presence of RAL (697 ng/mL) but in 
group 2 there was only an increase of 3% in the absence of RAL, therefore although 
it may appear statistically significant we do not believe that this to have any clinical 
significance on the efficacy of DRV, but instead a result of the high level of inter 
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individual patient variability in the plasma and IC concentrations found. The 
confirmation of a drug-drug interaction, leading to a reduced DRV concentration 
when co-administrated with RTV and RAL, remains uncertain. Given that DRV and 
RAL use two different metabolic pathways the potential for a drug-drug interaction 
was characterised as low. Further studies may need to be conducted with larger 
populations to determine if there is indeed a drug-drug interaction of any clinical 
significance. A study published by Taiwo et al, describes 112 treatment naïve, HIV 
infected subjects who received DRV/r 800/100 mg once daily plus RAL 400 mg 
twice daily. They concluded that the co-administration of DRV/r and RAL were well 
tolerated in most subjects however they reported sub-optimal efficacy, viral failure 
and integrase resistance was found to be common especially in subjects with a viral 
load greater than 100,000 copies per mL at base line analysis [46].Fabbiani et al [47] 
discuss the question of a drug interaction further and highlight other clinical trials 
which have also shown a reduction in DRV concentrations when co-administered 
with RAL [48-50], However, Fabbiani et al also point out that DRV plasma Ctrough 
concentration levels far exceed the IC50 (0.550 µg/mL) for PI resistant virus [35], 
therefore the modest reduction in DRV concentration when co-administered with 
RAL is probably negligible and of no clinical significance in the majority of patients 
taking combined ARV therapy. Further studies are important to address this. One 
possibility for the reduction could be transporter competition in the uptake of the 
drugs in the gastrointestinal tract and a future clinical trial investigating this 
mechanism of reduction at the transporter level may do this. 
The RAL PK profiles for group 1 and 2, showed a marked level of inter individual 
patient variability in both the plasma and the IC results. However, those patients who 
showed higher plasma Cmax concentrations mirrored this with higher IC Cmax levels. 
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In Figure 2, one patient concentration increases significantly at the 12 hour PK 
analysis, this is probably due to the sample being taken post the second dose of RAL 
and not pre-dose as it should have been. 
Group 1 plasma RAL AUC (geometric mean) in the absence of DRV/r (1944 
ng.h/mL) and in the presence of DRV/r (1759 ng.h/mL), showed no significant 
difference. Group 2 RAL AUC (geometric mean) in the absence of DRV/r (1635 
ng.h.mL) and in the presence of DRV/r (1979 ng.h/mL) also showed no significant 
difference.  
However, in a previous study by Fayet Mello et al, involving 10 HIV-infected 
patients, a reduction in plasma AUC by 33% and a 29% decrease in Cmax were 
observed. Six of the ten study patients were also taking DRV/r twice daily as part of 
their combination therapy [37]. 
The methodology used for the measurement of intracellular drugs is extremely 
complex. There is currently no ‘Gold Standard’ for PBMC isolation and this as a 
result means that different research groups are using different approaches, i.e. ficol, 
CPT or magnetic bead isolation, and then further to this, the number of washes each 
group conducts varies greatly[29, 36, 44]. This lack of standardization is perhaps the 
cause of the variation in plasma to IC drug concentrations. Our group and others 
have previously published data on the IC measurements of PIs and their 
accumulation [32, 34, 51, 52]. Here we report a DRV geometric IC to plasma ratio of 
5.3 to 5.6 in the presence of RAL and 4.9 to 5.3 in the absence of RAL, this ratio is 
greater than that previously reported by Ter Heine et al [36] but consistent with other 
PI concentrations. The RTV IC concentrations reported here are also slightly higher 
compared to those reported by Ter Heine, RTV geometric IC to plasma ratio of 6.9 
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to 10.0 in the presence of RAL and 6.5 to 9.5 in the absence, compared to 7.72 [36]. 
However, overall the IC to plasma ratios reported here for PI measurements are 
effected very minimally by the reduced cell washing. This however is not the case 
when we compare the integrase inhibitor concentrations for IC RAL. The results 
presented and found here are much higher than those reported from four other 
research groups. Ter Heine et al reported that IC levels of RAL were undetectable 
and therefore were unable to give a ratio [36], Molto et al [38] reported a plasma to 
IC ratio of 0.07 (range 0.05-0.10), Fayet Mello et al reported 0.039 (range 0.007-
0.177) [37] and Wang et al reported 0.24 (range 0.06-0.58) [39]. 
These differences reported are most certainly due to the techniques used in the 
PBMC isolation procedures. IC measurements are always going to vary when 
different isolation methodologies are applied and I will discuss this further in chapter 
4. Due to the rapid efflux of RAL from cells (demonstrated in a parallel study 
involving isolation of PBMC with varying number of washes [53]), our methodology 
here used only one cell washing step. This clearly reduced the amount of RAL 
effluxing from the cells during the isolation procedure and ultimately gave us the 
higher plasma to IC RAL concentration compared to other group findings who used 
more washing steps.  
This study has shown a wide inter-individual variation in all the studied drugs for 
both IC and plasma concentrations especially for RAL. The reasoning for this could 
be due to a number of factors previously discussed in addition to drug intake with 
food (increased RAL concentrations with the intake of food [54]), genetic variability 
of drug efflux/influx transporters responsible for drug metabolism, and differences in 
PBMC isolation methodologies. However, Arab-Alameddine at al reported in their 
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population PK analysis of RAL, that a large majority of RAL pharmacokinetic 
variability remains unexplained [55]. 
To conclude, reported here are the findings of a clinical trial investigating the co-
administration of DRV/r and RAL plasma and IC concentrations given to HIV–
infected subjects. This was also the first time that a dose of RAL 800 mg once daily 
has been studied and measured within the cellular compartment. The results found 
here increase our knowledge of IC drug measurements and highlight the importance 
in the need for consistency between groups by means of a gold standard method for 
the isolation of PBMC for each class of ARV drugs. 
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Chapter 4 
 
Investigation of variability of reported intracellular raltegravir 
concentrations: Contribution of peripheral blood mononuclear 
cell (PBMC) isolation methodology. 
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This work was presented at the 12
th
 International Workshop on Clinical 
Pharmacology of HIV Therapy. 13-15
th
 April 2011, Miami, Florida, USA. 
4.1 Introduction 
The primary site of action for highly active antiretroviral drug therapy (HAART) in 
the treatment of HIV is within the infected immune cell. Previously therapeutic drug 
monitoring (TDM) to study the pharmacokinetics (PK) of HAART has focused on 
measurement within the plasma fraction of the blood but with advances in analytical 
instrumentation, namely LC-MS/MS it is now possible to achieve much greater 
levels of sensitivity, thus in turn leading to more intracellular PK clinical trials being 
conducted. This knowledge of cellular penetration and intracellular (IC) 
pharmacokinetics should aid understanding of virological response and toxicity.  
In order to accurately measure IC drug concentrations the peripheral blood 
mononuclear cells (PBMC) have to be isolated from the patient whole blood. To do 
this there are currently two main methodological approaches used by TDM research 
groups. The first method uses self-contained Vacutainer® cell preparation tubes™ 
(CPT). Cells are isolated by buoyancy gradient centrifugation (total 20 minutes) at 
room temperature (18-25
o
C), with zero to four washing steps. The second most 
commonly used method is the use of Ficoll Paque, which again works on the 
principle of buoyancy gradient centrifugation but is carried out at a much lower 
temperature (4
o
C), with a longer centrifugation time (30 minutes), with one to four 
washing steps. The number of washes in both methodologies varies in different 
research groups. 
Recently Bazzoli et al [7] summarised findings from PK studies on IC 
concentrations of antiretrovirals and highlighted clear limitations, e.g. small 
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numbers, poor design and methodological aproaches. The determination of IC drug 
quantification is indeed challenging. Here I address methodological issues 
particularly cell collection and washing procedures. The impetus was the observation 
of marked differences in raltegravir (RAL) IC disposition in 5 publications [36, 38, 
56-58], ranging from undetectable to IC/plasma ratios of 0.07, 0.05, 0.24 and 5.11 
respectively (i.e. a difference of > 100-fold). Since I was involved in the analysis of 
two of the studies (Barcelona [38] and London [58]) generating different data it 
seemed prudent to investigate the underlying causes of the disparity. As the LC-
MS/MS assay used was the same in both studies, I decided to investigate the pre-
analysis isolation step by direct comparison of CPT tubes versus Ficoll paque 
separation to try to pin-point why such variation was occurring. My primary 
hypothesis was that in this initial cell isolation procedure step, the number of washes, 
temperature and length of time to final PBMC isolation had an integral influence on 
the quantification of the RAL IC drug concentration. 
 
4.2. Methods  
4.2.1 Comparisons of PBMC isolation methods: 
Initial investigation was to look at the PBMC isolation methodology used by 
different research groups.  
4.2.2 Ficoll gradient cell preparation method (Liverpool) 
The method routinely used at the Liverpool Bioanalytical Facility 
5 mL of Ficoll paque solution is measured into a sterilin. Using a pipette, 8 mL of 
whole blood is very carefully trickled down the side of the plastic container so that it 
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rested on top of the Ficoll paque solution. This is then spun in a pre-cooled 
centrifuge (4
o
C) for 30 min at 2000 rpm. The top plasma layer is then carefully 
removed using a Pasture pipette and discarded. The interface layer containing the 
cells is then transferred into a fresh 20 mL sterilin. Ice cold Hanks balanced salt 
solution is then added to bring the total volume to exactly 20 mL. This is then gently 
inverted to mix the cells/ Hanks evenly. A 50 µL sample is taken for counting. The 
cell count is recorded. The sterilin is then centrifuged at 2000 rpm for 5 min at 4
o
C. 
The supernatant is carefully removed. 1 mL of ice cold Hanks is added to the cell 
pellet, mixed well and a further 9 mL of Hanks is added to bring the cell pellet back 
into solution. This is then further centrifuged at 2000 rpm for 5 min. The supernatant 
is carefully removed taking care not to disrupt the cell pellet. 1 mL of ice cold 70% 
methanol is then added to the cell pellet to re-suspend the cells. The cells are then 
vortexed and placed in to the freezer (-40
o
C) for 24 hours to allow complete lysis of 
the cells.  
4.2.3 Vacutainer cell preparation tube (CPT) method (London) 
The method supplied by C&W hospital London was used as follows [58];  
8 mL of whole blood was measured into a CPT. The tube was then gently inverted 8-
10 times to mix the anticoagulant thoroughly. The CPT was then immediately 
centrifuged (horizontal rotor) at room temperature (20
o
C) for 20 minutes at a speed 
of 1600 RCF (relative centrifugal force). After centrifugation the CPT was gently 
inverted to suspend the PBMCs in the plasma. The plasma/cells were then 
transferred into a sterilin using a disposable Pasture pipette. Ice cold Hanks balanced 
salt solution was then added to bring the total volume to exactly 15 mL. This was 
inverted gently to mix the plasma/cells/ Hanks evenly. A 50 µL sample was taken for 
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counting. The cell count was recorded. The sterilin was then centrifuged for 15 
minutes at 400 RCF to pellet the cells. The supernatant was carefully removed taking 
care not to disrupt the cell pellet. 1 mL of ice cold 70% methanol was then added to 
the pellet to re-suspend the cells. The cells were then vortexed and placed in the 
freezer (-40
o
C) for 24 hours to allow complete lysis of the cells. 
4.2.4 Ficoll gradient cell preparation method (Spain) 
The method supplied by Barcelona hospital Spain was used as follows [38];  
Blood samples for the PK measurements of RAL concentrations were collected into 
potassium and EDTA 10 mL tubes, and were processed within 1 hour after 
collection, at 4
o
C. Samples were first centrifuged at 390 g for 10 minutes. The 
supernatant was then transferred to 10 mL tubes and centrifuged at 1090 g for 10 
minutes, and the isolated plasma was stored at -80
o
C until analysis. The remaining 
cellular fraction was diluted with 0.9 % sodium chloride (NaCl) at 4
o
C up to a total 
volume of 10 mL. Subsequently, it was transferred to a 50 mL conical tube 
containing 5 mL of Ficoll paque at 4
o
C, and centrifuged at 720 g for 30 minutes. 
Thereafter, the PBMC layer was washed twice using 0.9% NaCl solution at 4
o
C, and 
the final cell pellet was stored at -80
o
C for further cell analysis.  
Note a cell count was not taken at the time of isolation and therefore a DNA 
detection procedure substantially based on the method described by Benech et al [44] 
was used.  
The above methods are the pre-analysis methods used for the two studies (Barcelona 
[38] and London [58]) generating very different RAL data (IC / plasma ratio; 0.07 
versus 5.11 respectively) on the same LC-MS/MS at the Liverpool Biomedical 
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Research Centre. Table 1, summarises these methods alongside three other IC RAL 
PK studies.  
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Table 1. Comparison of IC RAL PK studies. 
Reference Ter Heine R et al [36] 
Fayet-Mello A et al 
[56] 
Molto J et al [38] Wang L et al [57] Jackson A et al [58] 
Amount of whole blood 8 mL 8 mL Not given Not given 8 mL 
CPT/ Ficoll paque 
CPT for patients, Ficoll 
used for standard 
curves 
CPT for patients, Ficoll 
used for standard 
curves 
Ficoll (post removal of 
plasma) diluted in 0.9% 
NaCl. Ficoll used for 
standard curves 
Not given 
CPT for patients, Ficol 
used for standard 
curves 
Number of washes 
X 2 in PBS with 0.1% 
ice cold BSA  
X 3 in PBS with 2% ice 
cold FBS  
X 2 in 0.9% NaCl at 
4
o
C 
Not given No wash  
Cell count method 
Cell-Dyn 4000 
differential counter 
Cell-Dyn 3500 coulter 
counter 
DNA detection method 
[44] 
Not given 
Digital Bio Adam 
Microchip Automatic 
cell counter 
Cell counts for standard 
curves 
5 x 10^6 cells 4-10 x 10^6 cells 4 x 10^6 cells Not given 4 x 10^6 cells 
Extraction solution 50% Methanol 50% Methanol 70% Methanol Not given 70% Methanol 
Lysis method 
Sonicated for 10 
minutes 
3 Hr on shaker and 
sonicated for 5 minutes 
Vortexed and overnight  Not given Vortexed and overnight 
IC/ Plasma ratio Not detected 0.05 0.07 0.24 5.11 
PBS = Phosphate buffered saline. BSA= Bovine serum albumin. FBS= Foetal bovine serum. 
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4.3 Investigation of methodology and results 
Due to this disparity in IC /plasma ratios the following RAL drug quantification 
experiments comparing the use of CPT tubes versus Ficoll paque, and the number of 
wash steps was compared.  
This was carried out in two ways; The first experiment was conducted with a known 
concentration of RAL (1000 ng/mL) being spiked in to whole blood, which was 
subsequently tumbled for 1 hour at room temperature (ex vivo). This was carried out 
to allow the uptake of RAL into the PMBCs. 8 mL of spiked blood was then placed 
into CPT tubes or layered over Ficoll paque. The number of wash steps varied from 
zero to four and both cell lysate and wash supernatant were analysed. Figure 1, 
shows a diagrammatic representation of the experiment.  
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Drug quantification experiment comparing the two methods 
 
          CPT TUBES         FICOLL GRADIENT  
1. No wash       1.  No wash 
2. 1 washes                    2.  1 wash 
3. 2 washes                   3.  2 washes 
4. 3 washes                   4.  3 washes 
5. CONTROL tube                   5.  CONTROL tube 
CPT and Ficoll Tubes 
TUBE 1 NO wash    
TUBE 2 ONE wash   cells  +  wash  
TUBE 3 TWO washes   cells  +  wash 1 + wash 2 
TUBE 4 THREE washes   cells  +  wash 1 +  wash 2 + wash 3 
TUBE 5 CONTROL tube   cells remove sample for NO wash   
                 remove sample after one wash                 
               remove sample after two washes   
            remove sample after three washes           
Figure 1. RAL drug quantification experiment comparing methodology.  
100 ml of whole blood spiked with RAL 
1000 ng/mL and tumbled for 1 hour  
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All 1 mL cell lysate samples were removed from the freezer and spun at 13,000 g for 
5 minutes to remove the cell debris. The samples were then transferred in to clean 
glass tubes and dried in a rotary evaporator. 400 µL of 70% methanol was added to 
each tube and vortexed thoroughly. 150 µL of each sample was pipetted into an 
autosampler vial and 20 µL of 100 ng/mL internal standard was added. The aliquots 
were then capped, mixed carefully and then analysed by LC-MS/MS for RAL 
quantification. Results are shown in Table 2. 
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Table 2. Colour scale: The darker blue is equal to more wash steps. Red type 
indicates quantification below the validated limit of quantification for the assay 
(<0.47 ng/mL). Time between each CPT wash = 20 minutes. Time between each 
Ficoll wash = 5 minutes. CPT room temp/ Ficoll 4
o
C. Note. The first wash 
supernatants were not analysed as they were too ‘dirty’ to put through the LC-
MS/MS system without the use of a validated extraction method. 
Calculated raw 
Conc (ng/mL) Sample ID 
Final RAL 
ng/mL (EXP 1) 
Final RAL 
ng/mL (EXP 2) 
 752.710 Cell CPT 1 NO WASH 78530.0 15364.0 
 7.339 Cell CPT 2 ONE  WASH 691.1 995.9 
 2.166 Cell CPT 3 TWO WASH 204.0 122.9 
 1.138 Cell CPT 4 THREE WASH 150.6 303.3 
 0.621 Cell CPT 5 FOUR WASH 73.8 95.5 
 19.916 Cell Ficoll Tube 1 NO WASH 1899.5 7868.3 
 1.053 Cell Ficoll Tube 2 ONE WASH 109.4 342.8 
 0.639 Cell Ficoll Tube 3 TWO WASH 91.1 129.2 
 0.469 Cell Ficoll Tube 4 THREE WASH 64.4 135.0 
 0.338 Cell Ficoll Tube 5 FOUR WASH 112.2 112.6 
 13.423 CPT tube 2, wash 2 201.34   
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9.275 CPT tube 3, wash 2 139.12 338.9 
0.648 CPT tube 3, wash 3 9.72 4.6 
12.401 CPT tube 4, wash 2 186.01 200.3 
0.496 CPT tube 4, wash 3 7.44 4.6 
0.324 CPT tube 4, wash 4 4.86   
12.814 CPT tube 5, wash 2 192.21 224.2 
0.808 CPT tube 5, wash 3 12.12 3.9 
0.269 CPT tube 5, wash 4 4.04   
0.259 CPT tube 5, wash 5 3.89   
1.336 Ficoll tube  2, wash 2 20.05 47.7 
1.648 Ficoll tube  3, wash 2 24.72 41.4 
0.291 Ficoll tube  3, wash 3 4.36   
1.362 Ficoll tube  4, wash 2 20.43 24.3 
0.257 Ficoll tube  4, wash 3 3.86   
0.254 Ficoll tube  4, wash 4 3.81   
1.929 Ficoll tube  5, wash 2 28.94 40.2 
0.308 Ficoll tube  5, wash 3 4.62   
0.250 Ficoll tube  5, wash 4 3.75   
0.251 Ficoll tube  5, wash 5 3.77   
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These results shows an (n) of 2 (EXP 1 and EXP 2) which were carried out on 
separate days. The results show the lysate sample results and also a sample taken 
from each of the wash supernatants (which usually gets discarded). The results show 
a much higher drug level in the CPT cell sample tubes with no wash. After the first 
wash there is a much greater loss of the drug into the supernatant, this is suggestive 
that drug is efluxed out of the cell over the greater centrifugal time (20 minutes) at 
room temperature.  
The second approach in this investigation was to use HIV infected patients blood 
who were receiving a RAL-containing regime (n = 4; four time points collected, in 
vivo). Figure 2 shows a diagrammatic representation of the experimental procedure.  
Calculation of the cell count for each method was taken at the initial step of addition 
of Hanks balanced salt solution in each instance. A 1 mL sample from the CPT or 
Ficoll tube was also removed, centrifuged at 4000 rpm for 5 minutes and the 
supernatant removed carefully as not to disrupt the pellet. The cell pellets were then 
re-suspended in 70% methanol, vortexed and then stored overnight at – 40oC to 
allow cell lysis. 
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Figure 2. Flow diagram of the methodology used with patient samples to investigate number of washes in CPT versus Ficoll. 
CPT Cell isolation FicollCell isolation
8mL of patient whole blood into CPT 
Gently invert 10 to 15 times
Centrifuge [2000 rpm, 20 mins, 20oC]
Carefully invert to mix cells with plasma
Aspirate into clean sterlin
Add ice cold Hanks to 15 mL 
Count Cells
8mL of patient whole blood carefully 
layered over 5mL of ficoll
Centrifuge [2000 rpm, 30 mins, 4oC] C]
Carefully remove top plasma layer- discard
Aspirate the interface layer containing the
cells into a clean sterlin
Add ice cold Hanks to 25 mL 
Count cells
Remove 1 mL aliquot (0 WASH SAMPLE))
Centrifuge [2000rpm for 5 mins] ]
Supernatant removed 
1 mL of ice cold 70% methanol added to lyse 
cells, vortexed, stored -40oC -40 oC
Split remaining 14mL into 
two separate universals
Split remaining 24mL into 
two separate universals  
Tube 1 (7mL) (1 WASH))
Add ice cold Hanks to 
15 mL and gently mix
Count cells
Centrifuge [15 mins
400 g]
Remove supernatant 
Re-suspend pellet in 1mL
ice cold 70% methanol
-
methanol
Tube 2 (7mL) (2 WASH))
Add ice cold Hanks to 
15 mL and gently mix
Centrifuge [15 mins
400 g]
Remove supernatant 
Re-suspend pellet in 
15 mL ice cold Hanks
-
Count cells
Centrifuge [15 mins
400 g]
Remove supernatant 
Re-suspend pellet in 1mL
ice cold 70% methanol
-
methanol
Tube 1 (12mL) (1 WASH)
Add ice cold Hanks to 
20 mL and gently mix
Count cells
Centrifuge [5 mins, 
2000 rpm
Remove supernatant 
Re-suspend pellet in 1 mL
ice cold 70% methanol
-
Tube 2 (12mL) (2 WASH))
Add ice cold Hanks to 
20 mL and gently mix
Centrifuge [5 mins,
2000 rpm
Remove supernatant 
Re-suspend pellet in 20 mL
ice cold Hanks 
Count cells
Centrifuge [5 mins,
2000 rpm
Remove supernatant 
Re-suspend pellet in 1mL
ice cold 70% methanol
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Figure 3. Representive HIV + patient graphs to show the IC RAL concentration after 0, 1 or 2 washes in CPT versus Ficoll separation. 
 
Table 3. IC RAL % loss post 1 and 2 washes in CPT and Ficoll cell isolation methodology.
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0 WASH
1 WASH
2 WASH
CPT WASH RAL ng/mL % loss FICOLL WASH RAL ng/mL % loss
0 HOUR 0 WASH 5239 0 HOUR 0 WASH 4014
1 WASH 114 97.8 1 WASH 145 96.4
2 WASH 50 99.0 2 WASH 50 98.8
2 HOUR 0 WASH 9453 2 HOUR 0 WASH 9170
1 WASH 200 97.9 1 WASH 304 96.7
2 WASH 61 99.4 2 WASH 58 99.4
3 HOUR 0 WASH 7507 3 HOUR 0 WASH 5528
1 WASH 107 98.6 1 WASH 149 97.3
2 WASH 22 99.7 2 WASH 94 98.3
5 HOUR 0 WASH 1816 5 HOUR 0 WASH 2141
1 WASH 42 97.7 1 WASH 59 97.2
2 WASH 37 97.9 2 WASH 74 96.5
CPT Ficoll 
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4.4 Discussion and Concluding comments  
Cell counts following the CPT and Ficoll methodologies of cell separation were 
comparable. However, the number of washes markedly impacted the final 
intracellular RAL concentration. Results from both the ex-vivo and in-vivo samples 
show a decrease in the intracellular concentration of RAL as the number of washes 
increases (Table. 3). The greatest difference was seen between no wash and the first 
wash (e.g. ex-vivo in CPT tubes had a RAL loss of approximately 95% and in Ficoll 
the RAL loss was approximately 95% also). In the in-vivo collection there was a 
greater reduction in intracellular RAL concentration after the first wash with samples 
layered over Ficoll (>95% reduction) than with CPT (approximately 70% loss). Cells 
for the CPT collection showed a greater loss after the second wash in comparison 
with the cells from the Ficoll collection method. 
Bazzoli et al. [7] have previously discussed some of the methodological issues in 
relation to intracellular measurements of ARVs. Differences between studies can be 
attributed to, i) cell isolation by either conventional Ficoll paque gradient 
centrifugation or Vacutainer cell preparation tubes (CPT), ii) the timing between 
blood sampling and cell isolation, iii) the number of cell isolation washing steps, and 
iv) temperature at which isolation is undertaken. 
In conclusion, the number of cell isolation washes has a marked impact on the 
quantification of intracellular RAL concentration. The most notable effect was that 
the washing reduced the intracellular concentration by > 96% (in a single wash) and 
more thereafter in both methods investigated. The marked difference between the 
data from Jackson et al. [58] (IC/ plasma ratio of 5.11) and other studies (which 
show no drug- to IC/ plasma ratio of 0.24) is directed related to the number of 
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washes used in the PBMC isolation. The absence of a washing step (as shown in the 
London clinical trial [58], potentially over-estimates the true intracellular RAL 
concentration by inclusion of residual plasma drug contamination and drug bound to 
cell membrane. RAL has also shown that it is rapidly effluxed out of the cellular 
compartment during isolation washing.  
Currently the ‘optimal’ numbers of washes for intracellular determination of RAL is 
unclear. It is important to have consensus if studies from different research groups 
are to be compared and a ‘gold standard’ of cell isolation methodology should be 
internationally decided up on and implemented under governed regulations for the 
isolation of intracellular RAL. Further analysis is required to investigate the impact 
of cell isolation washing steps for other ARVs.  
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Chapter 5 
 
Development and validation of a LC-MS/MS assay to quantify 
10 antiretroviral (ARV) drugs in cerebral spinal fluid (CSF).
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This work was presented as a poster at the 13
th
 International Workshop on Clinical 
Pharmacology of HIV Therapy. 16-18
th
 April 2012, Barcelona, Spain. 
5.1. Introduction 
The use of combination antiretroviral therapy (cART) has resulted in a dramatic 
decline in HIV morbidity and mortality [59]. However, in an ageing HIV-infected 
population, HIV-associated neurocognitive disorders (HAND) remain a concern 
[60]. HIV may reside outside of the systemic circulation in anatomical sanctuary 
sites, including the central nervous system (CNS). There is some evidence that 
antiretrovirals (ARV) exhibiting high CNS penetration effectiveness (CPE) score, 
suppress compartmentalised viral replication and improve neurocognitive 
functioning [61, 62], however the 2014 BHIV treatment guidelines debate the 
clinical relevance of the CPE score in relation to clinical outcome [23]. Ineffective 
penetration of ARVs into the CNS can result in sub-therapeutic concentrations and 
the possibility of viral resistance, whereas excessive levels can potentially lead to 
neurotoxicity. A greater understanding of ARV pharmacokinetics (PK) in the CNS 
may influence the timing of cART initiation, in order to preserve neurocognitive 
functioning. In order to gain better understanding of ARV penetration into 
anatomical sanctuary sites we need sensitive and specific analytical methods. Here I 
describe the validation of a LC-MS/MS method for the quantification of 10 ARV 
agents in cerebral spinal fluid (CSF). 
 
5.2 Materials and Methods  
5.2.1 Chemicals 
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LPV and RTV were kindly donated by Abbott Laboratories Ltd (Chicago, IL, USA), 
APV by GlaxoSmithKline (Middlesex, UK), ATV (atazanavir sulphate) by Bristol-
Myers Squibb (Hounslow, UK), DRV (darunavir ethanolate), RPV (rilpivirine 
hydrochloride) and ETV by Janssen-Cilag Ltd (Mechelen, Belgium). NVP was 
kindly contributed by Boehringer Ingelheim Pharmaceuticals Inc (Berkshire, UK), 
RAL by Merck (New Jersey, USA) and MVC by Pfizer (Sandwich, Kent, UK). The 
internal standards, [
13
C6]-Rilpivirine was obtained from Alsachim (Strasbourg, 
France) and quinoxaline (6,7-dimethyl-2,3-di(2pyridyl)-quinoxaline (QX) was 
obtained from Sigma-Aldrich, UK. Formic acid (minimum 95% pure) and human 
serum albumin (ALB) were also obtained from Sigma-Aldrich, UK. LC-MS grade 
acetonitrile (ACN) was purchased from Fisher Scientific (Loughborough, UK) and 
artificial CSF from Harvard Apparatus, Kent, UK. LC-MS grade methanol was 
purchased from VWR Laboratory Supplies (Poole, UK). De-ionised water (LC-MS 
grade) was produced by an Elga Option-S water purification unit and further purified 
to 18.2 MΩ by a Purelab Ultra (Elga Labwater, High Wycombe, UK). 
 
5.2.2 Equipment 
The HPLC system consisted of a variable loop Accela autosampler (set at a 
temperature of 4
o
C) and an Accela LC pump (Thermo Fisher Scientific, Hemel 
Hempstead, UK). A reverse phase Fortis
TM
 C18 column (3µm: 150 mm x 2.1 mm) set 
at an oven temperature of 30
o
C (Fortis Technologies Ltd, Cheshire, UK) fitted with a 
2 µm C18 Quest column saver (Thermo Fisher Scientific, Hemel Hempstead, UK)  
was used to separate all analytes and internal standards. The HPLC system was 
interfaced with a Thermo Scientific TSQ Quantum Access triple stage quadrupole 
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mass spectrometer fitted with an ion MAX source with a heated-electrospray 
ionization (H-ESI) probe. One E2M30 rotary vacuum pump (Edwards High Vacuum 
International, West Sussex, UK), a Nitro Flow nitrogen generator (Parker, Etten-
Leur, Netherlands) and 99% pure argon gas (10L size V, BOC Gases, Worsely, 
Manchester, UK) were used. Analyte tuning and optimisation parameters were 
gained with the use of TSQ Tune Software (Thermo Fisher Scientific, Hemel 
Hempstead, UK). LC Quan
TM
 software (Version 2.7, Thermo Fisher Scientific, 
Hemel Hempstead, UK) was used to acquire and process the data. 
 
5.2.3 Chromatography and mass spectrometry  
All analytes and internal standards were measured simultaneously. Chromatographic 
separation was achieved by a gradient elution method. Mobile phase A: water with 
0.1% formic acid and mobile phase B: 100% ACN were run as follows: from 0 to 5 
minutes 95% A. At 5 minutes 20% phase A was held for 2 minutes and then 
increased back to the starting conditions for 3 minutes to equilibrate the column, 
giving a total run time of 10 minutes. The flow rate was 400 µL/min. Samples were 
injected (20 µL) on to the column via a partial loop injection. A wash solution 
containing ACN: water (0.1% formic acid), 80:20, v/v, was used to clean the 
injection syringe (2 mL) between each sample. Both the mobile phases and wash 
solution were de-gassed by sonication (20 minutes) prior to use. All analytes were 
scanned for using selective reaction monitoring (SRM) by the TSQ Quantum Access 
operated in positive ionisation mode.  
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5.2.4 Source and liquid chromatography maintenance 
Concentrated constituents of the CSF may build up in the column guard, column and 
LC-tubing if the CSF sample is particularly viscous due to infection. In order to 
circumvent this, the column and column guard were reverse flushed at a flow rate of 
400 µL/ minute, using 95% of mobile phase A and 5% mobile phase B. The MAX 
source housing unit was removed and cleaned after each analytical run with 50% 
methanol and then 100% ultra pure water. The ion MAX source cone and internal 
transfer tube were also removed and cleaned between each assay (50% methanol, 
sonicated for 30 minutes). 
 
5.2.5 Column re-equilibration  
Prior to each assay, the Fortis C18 column was re-equilibrated. This was achieved by 
manually controlling the LC pump conditions to the chromatography starting 
conditions for the assay (95% mobile phase A and 5% mobile phase B, with a flow 
rate of 400 µL/ minute) for 15 minutes. This was also sufficient timing to raise the 
source temperature to optimal conditions prior to an analytical run. 
 
5.2.6 Sample preparation 
5.2.7 Standard curves 
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Stock solutions (1 mg/mL) of each of the analytes (as base) were prepared in 100% 
ultra pure deionised water (with the exception of ETV [50/50 ACN/water]). 
Methanol could not be used as this caused thermal decomposition of the artificial 
CSF and compromised the matrix. The 1 mg/mL stock solutions were further diluted 
and combined to give a master mix stock solution containing all of the analytes.  
To a clean glass tube 250 µL of NVP stock, 25 µL of RAL, APV, ATV, RPV, ETV, 
DRV stock and 10 µL of LPV, MVC and RTV stock were added (total volume 440 
µL). To this, 1560 µL of 50/50 ACN/0.1% formic acid was added to gain the master 
mix stock solution. The master mix stock solution was then further diluted in 
artificial CSF containing 0.2 g/L of human serum albumin (ACSF + ALB) to 
produce the level 9 standard (upper limit of quantification [ULQ]); NVP = 2500 
ng/mL, RAL, APV, ATV, RPV, ETV, DRV = 250 ng/mL, LPV, MVC and RTV = 
100 ng/mL. The level 9 standard was then serially diluted with ACSF + ALB to 
produce a nine point standard calibration curve (including blank containing only 
ACSF + ALB). The lower limits of quantification (LLQ) were as follows; NVP = 
19.53 ng/mL, RAL, APV, ATV, RPV, ETV, DRV = 1.95 ng/mL, LPV, MVC and 
RTV = 0.78 ng/mL. Each of the levels were aliquoted (250 µL) into labelled screw 
cap tubes and stored at -20
o
C until use. 
Fresh stock solution of each analyte was prepared similarly as before to prepare three 
internal quality control levels. The low quality control (LQC) was prepared at a 
concentration within three times that of the lower limit of quantification for each of 
the analytes; NVP = 50 ng/mL, RAL, APV, ATV, RPV, ETV, DRV = 5 ng/mL, 
LPV, MVC and RTV 2 ng/mL. Medium quality control (MQC) samples were 
prepared at; NVP = 250 ng/mL, RAL, APV, ATV, RPV, ETV, DRV = 25 ng/mL, 
LPV, MVC and RTV 10 ng/mL. High quality control (HQC) samples were prepared 
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at; NVP = 1250 ng/mL, RAL, APV, ATV, RPV, ETV, DRV = 125 ng/mL, LPV, 
MVC and RTV 50 ng/mL. Labelled screw cap aliquots (250 µL) of each of the QC 
levels were stored at -20
o
C until use. 
A 1 mg/mL stock solution of the internal standard quinoxaline (QX) was prepared 
(10 mg of QX dissolved in 10 mL of ultra pure deionised water [stable for 6 months 
at 4
o
C]). This was further diluted with ultra pure water to a daily working 
concentration of 1 µg/mL. A 1 mg/mL stock solution of the internal standard 
13
C6-
RPV was also prepared in the same way as QX, however, the daily working 
concentration was diluted to 80 ng/mL and as the compound is light sensitive, the 
glass tube containing the stock solution was wrapped in aluminium foil. 
 
5.2.8 Sample pre-treatment 
Standard calibrators and QC samples were removed from the -20
o
C and allowed to 
thaw at room temperature (18
o
C). After centrifugation (4000 rpm, 5 minutes) 
samples were pipetted in duplicate (100 µL) into labelled clean glass tubes. The 
internal standards QX and 
13
C6-RPV were then added to each sample (20 µL of each 
daily working concentration, 1 µg/mL and 80 ng/mL respectively) prior to protein 
precipitation with 50:50 ACN/0.1% formic acid (200 µL). Samples were then 
vortexed and left to stand at room temperature for 10 minutes. Samples were once 
again vortexed and then centrifuged (4000 rpm, 10 minutes) to pellet any 
precipitated proteins and then aliquoted into autosampler vials. 
 
5.2.9 Validation of the standard calibrators and quality controls 
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Two separate stock solutions were prepared, one for the standard calibrators and the 
other for the QC. Calibration curves consisted of ACSF + ALB spiked with analytes 
as described earlier. The level 1 calibrator which was free of analytes, was extracted 
both with and without external standards. Ten calibration curves were run on 
separate days to assess the linearity of the standard samples. Each standard was run 
in duplicate (two separate extractions). Calibration curves of the standard samples 
were constructed by calculation of the peak area ratio for each analyte to the internal 
standard QX (with the exception of RPV, internal standard used was 
13
C6-RPV). 
These ratios were plotted against the nominal concentration for each standard point, 
from which unknown analyte concentrations could be extrapolated. The equation for 
each standard curve was determined using the best fitted equation model for least 
squares regression analysis. The validation acceptance criteria for the calibration 
curves were calculated using the co-efficient of correlation (r
2
). For a valid assay this 
was equal to or greater than 0.98 and +/- 20% deviation of the nominal standard 
value for the lower limit of quantification (LLQ) and +/- 15% deviation of the other 
standard nominal concentration for each of the analytes. The LLQ was the lowest 
calibration standard level which met the FDA guidelines for industry [21]. The LC-
MS/MS signal response at the LLQ for each analyte was at least five times greater 
than the response obtained for the blank sample. The analyte response 
(chromatographic peak) was also identifiable, discrete and reproducible with a 
precision value within 20% and an accuracy value between 80-120%. To determine 
the LLQ ten samples independent of the standard curve samples were assayed. 
Analyte carryover was also examined at this point to ensure that the LLQ and any 
low concentration sample proceeding a high concentration sample were not 
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compromised. This was assessed by running six extracted level 9 standards, each 
followed by four extracted blank matrix samples. 
Quality control was validated by running ten QC samples (LQC, MQC, and HQC) in 
duplicate (separate extractions) with the ten standard curves run on different days. 
The QC samples were treated as unknown concentrations and compared to their 
target values to determine the inter-assay precision and accuracy for each analyte. 
An additional calibration curve was run which included six QC samples at each level 
to assess the intra-assay precision and accuracy. Inter and intra assay variation for 
the QC samples were expressed by the percentage co-efficient of variation [(CV% = 
standard deviation / mean)*100]. To comply with the FDA guidance for industry, the 
CV% for each QC was within +/- 15% of the nominal QC value for each analyte. 
 
5.2.10 Recovery and matrix effects 
The percentage recovery (extraction efficiency) of each of the analytes and the 
internal standards after extraction via protein precipitation was determined by 
comparing analyte chromatographic peak area extracted from the CSF + ALB matrix 
to those of non-extracted standard solutions spiked in mobile phase (95% mobile 
phase A and 5% mobile phase B). The response data for each analyte in mobile 
phase provided a relative 100% response value and the corresponding response data 
for extracted samples containing the analyte highlighted any loss in signal which was 
attributable to the sample extraction process and the sample matrix (CSF +ALB). 
Recovery experiments were carried out by processing six QC samples (at each level, 
LQC, MQC and HQC) and comparing these with pure solution (spiked mobile 
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phase) at concentrations representing a 100% extraction efficiency of QC sample 
concentrations (non-extracted). The percentage recovery = (peak area extracted from 
CSF + ALB / peak area of directly injected spiked mobile phase)*100. 
The recovery acceptance criteria of an analyte need not be 100 %, but the extent of 
recovery of each analyte and internal standard has to be consistent, precise and 
reproducible (FDA guidance for industry). This was assessed by examining the mean 
% recovery at the LQC, MQC and HQC concentrations and % CV of the mean % 
recovery for all analytes at the LQC, MQC and HQC concentrations. 
Matrix effects (ion suppression or enhancement) can be caused by co-eluting CSF + 
ALB matrix components which can suppress or enhance the ion intensity signal of 
the analytes and therefore compromise the reproducibility and accuracy when 
quantifying analytes from multiple patients or artificial CSF batches. Therefore, an 
absolute matrix effect was determined for each of the analytes by comparison of 
chromatographic peak areas of the analytes spiked into blank extracted CSF + ALB 
to the peak areas obtained from the same concentration of analyte spiked into mobile 
phase. 
The matrix acceptance criteria were calculated using the absolute matrix effect % 
CV equal to or less than 20 %. 
Absolute matrix effect experiments were carried out by processing six QC samples 
(at each level, LQC, MQC and HQC) and comparing these with pure solution 
(spiked mobile phase) at concentrations representing a 100% extraction efficiency of 
QC sample concentrations (non-extracted). The percentage matrix effect = (peak 
area of analyte spiked in blank CSF + ALB extract / peak area of spiked analyte in 
mobile phase)*100. 
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5.2.11 Stability 
Stability experiments were carried out to reflect the conditions likely to be 
encountered during sample transfer, handling and analytical analysis for clinical 
samples. Prior to sample analysis both patient and healthy volunteer CSF samples 
are heat inactivated (58
o
C for 40 minutes in a water bath), stored at -40
o
C and then 
thawed ready for extraction. Thus heat / freeze thaw, short term and long term 
stability was investigated. 
 
5.2.12 Stock solution stability  
Stock solution stability was determined by comparing the freshly prepared stock 
solutions with old stock solutions. A medium concentration (dependant on each 
analyte equal to the MQC) of each of the analytes was prepared from freshly 
prepared stock (1 mg/mL). This was repeated using old (previously prepared under 
the same conditions) analyte stock solutions. Replicates (n=6) of each were injected 
and analysed and the mean response of fresh stock to old stock was compared. The 
percentage difference had to be within +/- 15% (range 85-115%). 
 
5.2.13 Heat / freeze thaw stability 
Blank CSF + ALB was spiked at low, medium and high concentrations: LQC (LPV, 
MVC and RTV = 2 ng/mL, RAL, APV, ATV, RPV, ETV and DRV = 5 ng/mL, 
159 
 
NVP = 50 ng/mL) MQC (LPV, MVC and RTV = 10 ng/mL, RAL, APV, ATV, 
RPV, ETV and DRV = 25 ng/mL, NVP = 250 ng/mL) HQC (LPV, MVC and RTV = 
50 ng/mL, RAL, APV, ATV, RPV, ETV and DRV = 125 ng/mL, NVP = 1250 
ng/mL). These concentrations were chosen to match the predicted therapeutic ranges 
in the published literature. Samples were then analysed in triplicate under the 
following three treatment conditions; i). Freshly prepared (serving as the test 
control). ii). Heat inactivated (58
o
C, 40 minutes). iii). Three freeze/thaw cycles 
(samples were heat inactivated and frozen overnight and allowed to thaw at room 
temperature for 1 hour the following morning and then refrozen). This freeze/thaw 
cycle was repeated and analysed on the third cycle. All samples were then extracted 
under normal assay conditions. The peak areas obtained from samples undergoing 
the heat inactivation process and the freeze/thaw cycles were compared to 
corresponding peak areas (and internal standard adjusted peak area ratios) for each 
individual analyte obtained under the control sample conditions. 
 
5.2.14 Bench top and processed sample stability  
Bench top stability was performed to assess the stability of each of the analytes at 
room temperature over the time period equal to and beyond that of the extraction 
procedure. This was investigated by leaving 6 aliquots of QC samples (at LQC, 
MQC and HQC) on the laboratory bench top for 4-24 hours. These were then 
analysed against a freshly prepared calibration curve. 
Processed sample stability was performed to assess the stability of analytes after 24 
hours and to establish that the reinjection of the samples kept in the autosampler at a 
controlled temperature (4
o
C) would have no effect on the result reproducibility. This 
160 
 
would allow extracted sample to be re-injected in the incidence of unexpected delay 
in the analysis such as mechanical (LC-MS/MS instrument) failure. This was 
investigated by extraction of 6 aliquots of QC samples at LQC, MQC and HQC 
concentrations. The extracted samples were then left in the autosampler (4
o
C) for 24 
hours and analysed against a freshly prepared calibration curve. 
For both the bench top and processed sample stability acceptance, a minimum 
accuracy of 67% of the QC results had to be within +/- 15% of the respective 
nominal value and additional to this 50% of the QC samples at each level (LQC, 
MQC and HQC) also had to be within +/- 15% of the respective nominal value. 
 
5.2.15 Short term stability 
Short term stability (1 month) was assessed by comparing the first calibration curve 
response ratios with later (1 month) calibration curve response ratios. Heat 
inactivation and freeze/ thaw processes were also investigated. 
 
5.2.16 Dilution integrity 
Dilution integrity was investigated by extraction of a calibration curve and QC 
samples. Duplicate LQC samples were extracted as normal with no dilution factor. 
The MQC and HQC samples were also extracted in duplicate as normal with the 
addition of duplicates of each level diluted with CSF + ALB at 1:2 and 1:4. The 
samples were run as normal and the results back calculated with the appropriate 
dilution factor against the calibration curve. Diluted QC samples should have 
precision of <15% and accuracy should be within +/- 15% of the nominal value. 
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5.2.17 Data analysis 
All data analysis for inter and intra- assay variation, carried out at the LQC, MQC 
and HQC levels was expressed as the percentage co-efficient of variation (% CV = 
[standard deviation / mean] x 100). All assays were conducted under good clinical 
laboratory practice (GCLP) conditions and in accordance with the FDA guidelines 
for industry and QC assessed with a modification of the Westgard regulations used 
in the clinical diagnostic setting. All calibration standards and QCs had a mean target 
concentration of +/- 15% of their nominal target concentration with the exception of 
the LLQ which had a mean target concentration of within +/- 20% of its nominal 
concentration for each individual analyte. The % CV concentrations followed the 
same rules. All data was analysed using Microsoft Excel 2007 (Microsoft 
Corporation, USA). 
 
5.3 Results and Discussion 
 
5.3.1 Detection and Chromatography 
Firstly, each of the analytes had to be tuned into the tandem mass spectrometer. This 
was done by direct injection with a T-piece fixture which allowed a continuous flow 
of the mobile phase to enter the source at the same time, simulating the conditions 
which would later be applied in sample analysis. The tuning process allows 
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optimisation of the mass spectrometric performance for the detection of each of the 
analytes. This was achieved by investigating and gaining the best probe position, gas 
flow, lens element and collision energy which detected optimum mass spectral 
performance for each of the analytes. Tuning was carried out on the following 
parameters; the source, a stable spray was obtained by optimising the probe position, 
the flow of the AUX and sheath gas flow rates, and the temperature of the internal 
transfer capillary (ITC) until a variation of <5% was achieved. Ion optics, the 
voltages for the ion optics components were adjusted to optimise the transmission of 
the analyte to the analyser. Finally, the Mass spectrometer collision cell (MS
2
), the 
collision energy and collision pressure were then optimised for each analyte. Each 
parent analyte was scanned for four (daughter) fragment ions, and from these, the 
two with the greatest mass to charge ratio (m/z) and signal to noise ratio were 
selected for quantification analysis, however NVP gave a better response using only 
one fragment ion and RTV, LPV and ETV gave better signal with all four fragments. 
The parameters for each of the analytes are shown in Table 1.
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Table 1. Optimised LC-MS/MS tune parameters for each of the analytes and internal standard.  
Drug Drug class Parent ion 
(m/z) 
Fragment ions 
(m/z) 
Tube lens 
(V) 
Collision energy 
(eV) 
Retention time 
(mins) 
Maraviroc CCR5 antagonist 514.3 280, 389 103 31, 20 3.02 
Nevirapine NNRTI 267.1 226, 96 25 3.61 
13
C6 
Rilpivirine 
IS 372.1 192, 208 124 41, 34 3.71 
Rilpivirine NNRTI 367.1 195, 207 116 34, 33 3.72 
Raltegravir Integrase 
inhibitor 
445.1 109, 361 83 32, 18 4.61 
Quinoxalone IS 313.1 246, 284 105 34, 45 4.83 
Atazanavir PI 705.4 168, 335 129 41, 29 4.94 
Darunavir PI 548.2 156, 392 115 31, 13 5.13 
Amprenavir PI 506.2 156, 245 106 28, 17 5.14 
Ritonavir PI 721.3 140, 171, 197, 268 120 54, 33, 39, 26 5.81 
Lopinavir PI 629.3 155, 183, 429, 447 103 37, 21, 21, 14 5.98 
Etravirine NNRTI 435 144, 162, 273, 303 131 36, 32, 31, 40 6.48 
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All analytes eluted over a ten minute assay run time, which was divided in to three 
segments shown in Table 1. Depending on the retention time of the analyte on the 
column, this was done to enhance the sensitivity of the assay. The mass spectrometer 
was operated in positive ionisation mode though out and acquired the analyte data by 
selected reaction monitoring (SRM) in centroid mode. The scan width and time for 
each analyte was 0.01 m/z and 0.01 sec respectively. As described in our previous 
paper [45], I applied a low pass chromatography filter which is an application in the 
real time data software (LC Quan
TM
 software. Version 2.5.6, Thermo Fisher 
Scientific, Hemel Hempstead, UK). This filter improves peak resolution and 
smoothing by reducing any background noise/ interference at the baseline of each 
analyte chromatographic peak at the point of data acquisition. This is much more 
accurate than using a post-acquisition smoothing approach and reduces the 
likelihood of artificial chromatographic peak tailing [63]. Figure. 1 illustrates a 
typical chromatograph showing the total ion count and each chromatographic peak 
for all ten ARVs plus the two internal standard analytes obtained from extracted 
CSF. 
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Figure.1 CSF LC-MS/MS chromatograph showing the total ion count (TIC) in solid black and each of 
the ARVs and IS retention times, and their respective parent and fragment ions scanned for during the 
10 minute assay run time. 
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5.3.2 Validation of calibrators and quality controls 
To determine the calibration curve upper and lower levels of quantification, the stock 
solutions of the analytes were serially diluted, covering the expected published (if 
any) ranges shown in Table 2, to produce 13 levels including the blank. 
Level 
LPV, MVC, RTV 
(ng/mL) 
RAL, APV, ATV, RPV, 
ETV, DRV (ng/mL) 
NVP 
(ng/mL) 
1 0 0 0 
2 0.049 0.122 1.22 
3 0.098 0.244 2.44 
4 0.195 0.49 4.88 
5 0.39 0.98 9.77 
6* 0.78 1.95 19.5 
7 1.56 3.91 39.1 
8 3.125 7.81 78.1 
9 6.25 15.63 156 
10 12.5 31.25 313 
11 25 62.5 625 
12 50 125 1250 
13 100 250 2500 
 
Table. 2. Serial dilution of the analyte stock solutions to produce calibration curve.   
* Level at which all validation criteria were met. 
The 13 level calibration curve was then run 4 times in duplicate to determine the 
lower limit of quantification (LLQ) for each of the analytes. It was found that at level 
6, all analytes were within +/- 20% of their respective target value. Below this level 
some of the analytes did not meet the criteria. Each analyte response was also 
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compared to the response seen in the blank level 1 samples to ensure that the LLQ 
gave a signal 5 times greater than that of any background noise observed in the blank 
sample. Once this was known 10 standard curves were run with level 6 becoming 
level 2 (level 1 = blank) the LLQ for the assay (which now consisted of 9 levels 
including the blank). Assays were also analysed for their linearity, the calibration 
data was analysed using a 1/ concentration (1/x) weighted quadratic equation which 
achieved co-efficient of correlation (r
2
) values greater than 0.98 for all validation 
assays. This gave the following final calibration ranges for each of the analytes; 
LPV, MVC, and RTV = 0.78-100 ng/mL, RAL, APV, ATV, RPV, ETV and DRV = 
1.95-250 ng/mL and NVP = 19.53-2500 ng/mL. Once the LLQs were identified, the 
quality controls (QC) could be prepared. The low quality control (LQC) 
concentration had to be within 3 times the concentration value of the analytes LLQ. 
The values from the QC concentrations at low, medium and high points of the 
calibration curve were as follows; LPV, MVC, and RTV = 2, 10, 50 ng/mL, RAL, 
APV, ATV, RPV, ETV and DRV = 5, 25, 125 ng/mL and NVP = 50, 250 and 1250 
ng/mL. QC samples at each of the levels were then run ten times against standard 
curves to ensure that all values (both QC and calibrators) achieved a co-efficient of 
variation from the target value within +/- 15% (with exception of the LLQ which 
was within +/- 20%). Carryover was also assessed by running a level 9 (the upper 
limit of quantification ULQ) sample, followed by 5 extracted blank samples 
(repeated X 3) and comparing the mean signal response value for the ULQ to the 
response given for each set of blank samples as a percentage. Carryover range was 
0.000 – 0.1 % (Table. 3) and therefore confirmed that during an analytical run, over 
calculation of analyte concentration due to a high concentration sample preceding a 
low concentration sample would not occur. 
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5.3.3 Accuracy and precision 
The precision of this methodology describes the closeness of each individual analyte 
measured when it is repeatedly applied to multiple samples. The accuracy of this 
method is described by the closeness of the mean test result for each of the 
individual analytes when compared to the target (actual) concentration of the analyte. 
This was carried out at each of the QC levels (low, medium and high) in a total of 10 
replicates. The results for each of the analyte ranges (spread over the QC levels) are 
shown in Table.3. 
Table. 3. Precision, accuracy and carry over results for each of the analytes. 
Precision expressed as the co-efficient of variation [% CV (standard deviation/ 
mean) x 100]. Accuracy expressed as the % bias [((mean concentration – target 
concentration) / mean concentration) x 100]. 
Drug Accuracy (% bias) Precision (% CV) Carry over (%) 
MVC -2.91 to 0.86 5.31 to 12.03 0.000 
NVP -10.5 to 5.96 3.82 to 6.36 0.003 
RPV -3.04 to 1.96 5.06 to 8.84 0.037 
RAL -6.64 to -3.8 3.97 to 7.86 0.007 
ATV 2.54 to -2.17 4.32 to 7.34 0.004 
APV -7.7 to -1.45 8.89 to 15 0.091 
DRV -8.5 to -5.43 4.75 to 7.69 0.017 
RTV 0.04 to 4.48 6.10 to 9.84 0.055 
LPV 1.2 to 4 5.69 to 7.67 0.035 
ETV 4.6 to 6.4 5.83 to 8.46 0.034 
Range -10.5 to 6.4 3.82 to 15 0.000 to 0.091 
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5.3.4 Recovery and matrix effects 
A recovery experiment to assess how much drug is lost during the protein 
precipitation extraction procedure was carried out (n=6). The signal response of six 
extracted QC samples at each level, were compared to the signal response of pure 
drug (spiked into mobile phase) at the same concentration of those extracted 
(representing 100% drug recovery). The % CV of the mean % recovery for each 
analyte was then calculated. In all experiments these values were consistent, precise 
and reproducible. Recovery % CV results are shown in Table. 4. During the assay 
co-elution of CSF components may result in a suppressive or an enhancement effect 
on the ion intensity of the analytes, which may compromise the reproducibility and 
accuracy when analysing patient samples. Therefore the absolute matrix effect of 
CSF was determined for all analytes. This was carried out by comparison of the 
chromatographic peak area of analytes spiked into blank extracted CSF to the peak 
area of mobile phase spiked at the same concentrations (% matrix effect = [peak area 
of analyte spiked in blank CSF extract / peak area of analyte in mobile phase]*100). 
The absolute CSF matrix effect of 100% would be indicative of zero effect of the 
matrix, however, a value below or above 100% would indicate suppression or 
enhancement of any of the analytes, results are show in Table. 4. Although matrix 
suppression and enhancement was shown (range 87% - 120 %), it was within 20 %, 
reproducible and reliable and therefore should not cause a significant effect on the 
quantitation of samples. 
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Table.4. Analyte recovery expressed as % CV and % CSF matrix effects. 
Analyte Recovery (% CV) % Matrix effect 
MVC 14.2 87 
NVP 4.3 115 
RPV 1.7 119 
RAL 1.9 119 
ATV 10.8 114 
APV 12.5 94 
DRV 9.3 101 
RTV 18.5 114 
LPV 18.6 119 
ETV 16.7 120 
 
5.3.5 Stability 
Stability experiments to replicate the conditions which samples are exposed to 
(sample transfer, processing, storage and analysis), were carried out. Clinical 
samples (from both patients and healthy volunteers) which arrive in the laboratory 
are heat inactivated (water bath, 58
o
C for 40 mins), frozen and stored at -40
o
C and 
thawed before they are analysed. Therefore, we replicated these conditions with QC 
samples at each level which had undergone heat inactivation and three freeze/ thaw 
cycles against freshly prepared samples as a control. The results for each analyte are 
shown in Table. 5. 
Short term stability (1 month) was assessed by comparing the first calibration curve 
response ratios with later (1 month) calibration curve response ratios, the results 
showed no significant fluctuations in analyte peak response and drug concentrations 
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did not deviate by +/- 15%, therefore samples were shown to be stable when stored 
at -40
o
C for a 1 month period. Sample stability when stored at 4
o
C overnight and 
stability of samples left in the auto-sampler for 24 hours (in the case of mechanical/ 
equipment failure) were also assessed and again showed no deviation +/- 15% of the 
same samples analysed under normal conditions.  
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Table. 5. Stability analysis for analytes analysed against control samples (freshly 
prepared), after heat inactivation and with three freeze/thaw cycles. 
Drug Low QC Medium QC High QC 
MVC 
   
Control 100 100 100 
Heat inactivated 104 (9) 100 (7) 111 (9) 
Heat -freeze/thaw 99 (10) 99 (5) 111 (4) 
NVP 
   
Control 100 100 100 
Heat inactivated 107(3) 103 (1) 106 (3) 
Heat -freeze/thaw 106 (3) 97 (2) 102 (4) 
RPV 
   
Control 100 100 100 
Heat inactivated 103 (8) 98 (6) 109 (2) 
Heat -freeze/thaw 96 (15) 93 (7) 103 (2) 
RAL 
   
Control 100 100 100 
Heat inactivated 100 (8) 99 (3) 109 (3) 
Heat -freeze/thaw 93 (5) 100 (3) 105 (2) 
ATV 
   
Control 100 100 100 
Heat inactivated 103 (6) 100 (1) 115 (3) 
Heat -freeze/thaw 96 (7) 98 (5) 108 (2) 
APV 
   
Control 100 100 100 
Heat inactivated 101 (10) 101 (2) 114 (2) 
Heat -freeze/thaw 102 (3) 97 (4) 110 (2) 
DRV 
   
Control 100 100 100 
Heat inactivated 104 (9) 100 (5) 111 (3) 
Heat -freeze/thaw 99 (8) 99 (5) 111 (2) 
RTV 
   
Control 100 100 100 
Heat inactivated 114 (6) 110 (7) 127 (2) 
Heat -freeze/thaw 87 (15) 99 (5) 100 (4) 
LPV 
   
Control 100 100 100 
Heat inactivated 118 (3) 113 (2) 124 (1) 
Heat -freeze/thaw 91 (9) 99 (6) 95 (2) 
ETV 
   
Control 100 100 100 
Heat inactivated 81 (10) 115 (10) 95 (4) 
Heat -freeze/thaw 116 (20) 106 (14) 86 (5) 
For each level of QC six samples were analysed. Peak areas of the analytes are 
expressed as a mean percentage (%CV).  
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5.6 Conclusions 
Described here is the development and validation of an LC-MS/MS assay to 
simultaneously quantify 10 antiretroviral agents from different therapeutic classes, in 
cerebral spinal fluid. This assay performance was monitored with the use of known 
concentration quality controls at low, medium and high levels appropriate to each 
analytes concentration range, and showed good accuracy (% bias -10.5 to 6.4) and 
precision (% CV 3.82 to 15) for analyte analysis. All analyte calibration data curves 
illustrated excellent linearity with correlation coefficients (r
2
) greater than 0.998. 
The use of artificial CSF for the matched matrix was selected as the large volumes of 
CSF required to establish a fully validated method were not available to purchase. 
Unlike some research groups who ‘make’ their own artificial CSF in-house, the use 
of artificial CSF bought from Harvard Apparatus, ensured that there was quality and 
batch control and therefore a level of standardisation. The artificial CSF is made up 
of the following; high purity water, sodium 150 mM, potassium 30 mM, calcium 1.4 
mM, magnesium 0.8 mM, phosphorus 1.0 mM and chlorine 155 mM, it did not 
however contain any protein or albumin. During initial development of this assay it 
was quickly observed that there was a rapid loss of analyte signal (some more than 
others) over a short period of time (post two weeks) and we postulate that this drop 
in signal was due to the analytes having nothing to bind to (protein or albumin) in 
the artificial CSF mixture and therefore binding to the plastic microtubes in which 
they were stored. Therefore, the addition of human serum albumin at a concentration 
of 0.2 g/L (which is within the normal clinical range found in CSF) was added to the 
artificial CSF. It was also observed when developing the extraction method that the 
addition of methanol into the artificial CSF caused thermal decomposition of the 
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artificial CSF and therefore methanol was replaced with ACN. The combination of 
the addition of human serum albumin and removal of methanol stabilised the assay. 
The described extraction method uses only 100 µL of patient sample. Given that 
CSF is a sample which requires an invasive lumbar puncture procedure to obtain a 
small amount, this low sample volume required was advantageous. The assay run 
time is only 10 minutes per sample. This rapid time efficiently allows high though 
put sample analysis which is needed when sampling large numbers of samples from 
pharmacokinetic trials, and for therapeutic drug monitoring (TDM). Given that ARV 
therapy consists of a combination of drugs, the ability of this assay to measure ten 
different ARVs, allows multiple drugs from one patient sample to be simultaneously 
quantified, reducing cost of test, analysis time and volume of sample required. 
This method was developed with each ARVs dynamic range in mind. The assay 
shows high sensitivity for all drugs (LLQ; LPV, MVC, RTV = 0.78 ng/mL, RAL, 
APV, ATV, RPV, ETV, DRV = 1.95 ng/mL and NVP = 19.5 ng/mL). This was 
achieved and optimised in the tandem mass spectrometric stage of development, in 
that, for each analyte up to 6 mass transitions were screened for, and from these 
quantification was achieved by careful selection of between one and four fragment 
ions. Selection of these daughter ions was carried out based on their relative signal to 
noise intensity. In doing this, all four fragment ions where scanned and signal 
intensity monitored, then each possible combination of the fragment ions was 
investigated. In some cases it was apparent that even when the signal is at its greatest 
from a particular fragment ion, the background noise was also at its greatest. A high 
level of background noise then affects the sensitivity of the analyte and therefore the 
selection of the fragment ions chosen for detection was a fine balance between which 
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gave the best signal with the least background noise, ultimately giving the greatest 
sensitivity. 
In conclusion, the results of this bio-analytical validation, demonstrate this new 
methodology is reliable and reproducible. It is robust, accurate, selective and highly 
sensitive for the simultaneous quantification of 10 ARVs within CSF, enabling a 
greater insight into ARV concentrations within this sanctuary site. This developed 
assay has successfully been applied to clinical CSF samples collected for 
pharmacokinetic trials [61, 64-68].  
The direct quantification of an ARV in CSF is one important aspect of seeking a 
greater understanding of why some people develop HIV-associated neurocognitive 
disorders despite having optimal ARV plasma levels.  
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Chapter 6 
 
Development and validation for a LC-MS/MS assay to detect 
and quantify the intracellular phosphate metabolites of 
tenofovir and emtricitabine.
177 
 
CHAPTER 6  
 
DEVELOPMENT AND VALIDATION FOR A LC-MS/MS 
ASSAY TO DETECT AND QUANTIFY THE 
INTRACELLULAR PHOSPHATE METABOLITES OF 
TENOFOVIR AND EMTRICITABINE.  
 
6.1 Introduction 
 
6.2 Materials and methods 
6.2.1 Chemicals 
6.2.2 Equipment 
6.2.3 Chromatography and mass spectrometry 
6.2.4 Source and liquid chromatography maintenance 
6.2.5 Column re-equilibration 
6.2.6 Sample preparation 
6.2.7 Isolation and preparation of peripheral blood mononuclear cell (PBMC) for 
lysate matrix 
6.2.8 Standard curves and quality controls 
6.2.9 Sample pre-treatment 
6.2.10 Validation of the standard calibrators and quality controls 
6.2.11 Accuracy and precision 
6.2.12 Lysate matrix effects 
6.2.13 Interpretation and calculation of clinical sample concentrations 
 
178 
 
6.3 Results and Discussion 
6.3.1 Detection and chromatography 
6.3.2 Accuracy and precision  
6.3.3 Signal to noise ratio 
 
6.4 Concluding remarks 
 
 
179 
 
This work was presented as a poster at the 11
th
 International Congress on Drug 
Therapy in HIV infection. 11-15
th
 November 2012, Glasgow, United Kingdom. 
6.1. Introduction 
This chapter describes the development and validation of a LC-MS/MS assay to 
detect and measure the intracellular phosphorylated anabolites of tenofovir (TDF) 
and emtricitabine (FTC). TDF and FTC are first line antiretrovirals which require 
intracellular phosphorylation to their active moieties (Figure 1).  
Tenofovir disoproxil fumarate (TDF) is a prodrug which first requires hydrolization 
into tenofovir (TFV) and then phosphorylation into tenofovir diphosphate (TFV-DP) 
[Figure 1]. It belongs to the ARV drug class known as the nucleotide reverse 
transcriptase inhibitors (NtRTI). NtRTI are analogues of the cellular 
deoxynucleotides. TFV once phosphorylated into its active phosphate anabolite 
TFV-DP is an analogue of adenosine however it does not possess a 3'-hydroxyl 
group on the deoxyribose moiety like its naturally occurring cellular competitor 
deoxyadenosine 5'-triphosphate. TFV-DP competes with the host cellular 
deoxyadenosine 5'-triphosphate during viral DNA replication. When the analogue is 
successfully incorporated into the viral DNA the anabolites lack of the 3'-hydroxyl 
group prevents the formation of the next 5'-3' phosphodiester bond which is essential 
in viral DNA elongation. Therefore DNA chain termination occurs and the 
production of viral DNA is inhibited preventing further viral replication.  
Emtricitabine (2',3'-dideoxy-5-fluoro-3'-thiacytidine; FTC) belongs to the ARV drug 
class known as the nucleoside reverse transcriptase inhibitors (NRTI). NRTI are 
analogues of the naturally occurring cellular deoxynucleosides. FTC once 
phosphorylated into its active phosphate anabolite emtricitabine-triphosphate (FTC-
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TP) [Figure 1] is an analogue of cytidine. Again like TFV-DP its mechanism of 
action is to compete against its naturally occurring intracellular competitor 
deoxycytidine 5′-triphosphate during viral replication to prevent viral DNA 
replication and cause DNA chain termination.  
 
Figure 1. Flow diagram of the intracellular enzymatic phosphorylation steps for TDF 
to TFV-DP and FTC to FTC-TP. 
 
The intracellular concentration of the phosphorylated anabolites is dependant upon 
various factors, including the immune cell type and its activation state (it may be 
latent), the amount of uptake transporters on the cell membrane, and the amount of 
intracellular kinase enzymes available to phosphorylate the parent drug into the 
deoxynucleotide triphosphate (dNTP) active state [7].  
The ability to measure these intracellular phosphorylated anabolites (which show 
very different pharmacokinetic profiles from plasma ‘parent drug’ concentrations) 
will greatly aid understanding of the pharmacology of treatment failure. FTC shows 
a plasma half-life of between 8-10 hours compared to that of its intracellular half-life 
which is 39 hours [69]. TFV in the plasma has a half-life of approximately 14 hours 
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and a far longer intracellular half-life of between 150-180 hours [70]. As for all 
antiretrovirals, high inter-patient variability has been observed [71].  
 
Here I describe the considerable technical challenges in developing a robust assay 
for measuring intracellular TFV and FTC anabolites. Broadly the choice of 
extraction methodology can be divided into two main approaches, i) an indirect 
method which uses solid phase extraction (SPE) utilises fractionation of the 
phosphorylated anabolites, followed by removal of the bonded phosphates 
(dephosphorylation), and finally a desalting step to purify the anabolite back into its 
parent form by conventional LC-MS/MS measurement. During a research 
secondment I observed that this process is extremely labour intensive, introducing 
multiple processing steps with the potential for error. ii) The alternative approach is 
the direct measurement of the phosphorylated anabolites by LC-MS/MS. The major 
drawback with this approach is the difficulty in the adequate separation of the 
phosphorylated anabolites chromatographically. Conventional methods in the direct 
methodological approach rely upon the use of ion pairing agents such as 
dimethylhexylamine (DMHA), but the use of such agents can lead to major mass 
spectrometry instrument contamination issues when not cleared from the system 
adequately. Other direct approaches include the use of weak anion exchange (WAX), 
hydrophilic interaction (HILIC) and porous graphitic carbon (PGC) chromatography. 
Both approaches are illustrated very simplistically in Figure 2. which is adapted from 
Jansen et al. [5].  
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Figure 2. Comparison of direct versus indirect methodological approaches to 
measure phosphorylated nucleotides. Nucleo (N) mono (M) di (D) tri (T) phosphates 
(P). Diagram adapted from Jansen et al. [5] 
 
I selected the direct approach by weak anion exchange chromatography. This 
standard operation procedure of WAX chromatography is a modification of the 
Jansen et al [72] methodology which is based on the findings of Shi et al [73]. Shi et 
al showed that the charge of the basic functional groups (pKa) of a WAX column 
could be changed by applying a pH gradient (6-10.5) via the mobile phases. As a 
consequence the capacity of the column decreased at a higher pH, thereby eluting 
anionic nucleotides. Therefore, as opposed to classical anion-exchange methods, this 
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method does not require high concentrations of involatile competing ions for elution, 
making it directly applicable to MS detection.  
A LC-MS/MS assay has been developed, documented and validated for the specific 
quantitative determination of TFV-DP and FTC-TP in human peripheral blood 
mononuclear cells (PBMC’s). This assay was developed to assist in their 
measurement in a clinical trial outlined in the following chapter. 
 
6.2 Materials and Methods  
6.2.1 Chemicals 
TDF was obtained from Toronto Research Chemicals Inc. Canada. TFV-DP was 
obtained from Gilead, California, USA. FTC was obtained from Toronto Research 
Chemicals Inc. Canada. FTC-TP was obtained from Gilead, California, USA. 2-
chloroadenosine 5′-triphosphate (Cl-ATP), used as the internal standard was 
obtained from Sigma, U.K. Ammonium acetate (1 M), and formic acid (minimum 
95% pure) were obtained from Sigma-Aldrich, UK. LC-MS grade acetonitrile 
(ACN) and acetic acid were purchased from Fisher Scientific (Loughborough, UK). 
LC-MS grade methanol and ammonia were purchased from VWR Laboratory 
Supplies (Poole, UK). De-ionised water (LC-MS grade) was produced by an Elga 
Option-S water purification unit and further purified to 18.2 MΩ by a Purelab Ultra 
(Elga Labwater, High Wycombe, UK). 
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6.2.2 Equipment 
The HPLC system consisted of a variable loop Accela autosampler (set at a 
temperature of 4
o
C, to keep the samples chilled) and an Accela LC pump (Thermo 
Fisher Scientific, Hemel Hempstead, UK). A Thermo BioBasic AX column (5 µm 
50 mm x 1 mm) set at an oven temperature of 40
o
C, fitted with a 2 µm Quest column 
saver (Thermo Fisher Scientific, Hemel Hempstead, UK) was used to separate all 
analytes and the internal standard. The HPLC system was interfaced with a Thermo 
Scientific triple stage quadrupole (TSQ) Quantum Access mass spectrometer, fitted 
with an ion MAX source with a heated-electrospray ionization (H-ESI) probe. One 
E2M30 rotary vacuum pump (Edwards High Vacuum International, West Sussex, 
UK), a Nitro Flow nitrogen generator (Parker, Etten-Leur, Netherlands) and 99% 
pure argon gas (10 L size V, BOC Gases, Worsely, Manchester, UK) were used. 
Analyte tuning and optimisation parameters were gained with the use of TSQ Tune 
Software (Thermo Fisher Scientific, Hemel Hempstead, UK). LC Quan ™ software 
(Version 2.7, Thermo Fisher Scientific, Hemel Hempstead, UK) was used to acquire 
and process all the data.     
 
6.2.3 Chromatography and mass spectrometry  
A mobile phase gradient was used at a flow rate of 250 µL/ min, onto a BioBasic AX 
column, which was maintained at a temperature of 40
o
C. Mobile phase A consisted 
of 10 mM ammonium acetate in ACN/ ultra pure water (30:70, v/v) adjusted to pH 6 
with acetic acid and mobile phase B consisted of 1 mM ammonium acetate in ACN/ 
ultra pure water (30:70, v/v) adjusted to pH 10.5 with ammonia (100%). The 
optimised step-wise gradient is outlined in Table 1.  
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Table 1. Chromatographic conditions during the 12 minute step-wise gradient assay 
run time. 
Time  
(mins) 
Mobile Phase A 
(%) 
Mobile Phase B 
(%) 
Flow rate 
(µL/min) 
0.0 90 10 250 
0.50 90 10 250 
0.51 50 50 250 
1.75 50 50 250 
1.76 0 100 250 
6.50 0 100 250 
6.60 90 10 250 
12.0 90 10 250 
 
The wash solution (2mL) between each sample injection consisted of ultra pure 
water / ACN (80:20, v/v) with 0.1% ammonium hydroxide. A 2 mL flush volume 
was also injected between each injection. Both mobile phases and wash solution was 
sonicated for 20 minutes prior to use.  
The Thermo TSQ tandem mass spectrometer was operated in positive ionisation 
mode and was optimised for the analytes at the following settings: H-ESI spray 
voltage 5000 V, vap temperature 400
o
C, sheath gas pressure 30, AUX gas pressure 5 
and heated capillary temperature 325
o
C. The molecular mass (parent mass), for each 
of the phosphorylated anabolites and the internal standard were scanned for in the 
first quadrupole (Q1) of the instrument. Once detected the tube lens was then 
optimised for each of the drugs. The parent ions then travelled to the second 
quadrupole (Q2) which contains inert gas molecules that fragment the ions into their 
product ions. Collision energy was applied at a range of voltages (V) and the product 
ions for each of the parent masses were scanned for in the selected reaction 
monitoring (SRM) mode in the third quadrupole (Q3). Two product ions for each of 
the parent ions were selected. These were the ions which gave the greatest mass to 
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charge ratio (m/z) for their parent ion, with the least amount of background noise. 
The optimised mass spectrometric parameters are shown in table 2. The method was 
programmed with an acquire time of 12 minutes, during which the divert value was 
used as follows: inject/waste (0 min) > load/detector (1.5 mins) > inject/waste (10 
mins). The scanning width for the analytes was 0.010, with a scan time of 0.025 for 
each. Data was acquired in centroid mode. The collision gas was 1.5 mTorr and the 
chrom filter was applied and used at a setting of 3.0 s.  
Table 2. Mass spectrometry parameters for each of the phosphorylated anabolites 
using the Thermo TSQ in positive ion SRM mode. 
Analyte Precursor ion 
(m/z) 
Product ion 
(m/z) 
Collision 
Energy (V) 
Tube lens 
TFV-DP 447.98 270.0 
350.0 
28 
19 
101 
FTC-TP 487.91 130.0 
229.9 
32 
15 
144 
2-CI ATP 541.92 169.9 31 140 
 
6.2.4 Source and liquid chromatography maintenance 
Due to the highly concentrated samples, constituents of the PBMC lysate matrix can 
build up in the column saver, column frit, column and LC instrument tubing. To 
circumvent and avoid ‘blockages’ the column was ‘back flushed’ daily at a flow rate 
of 250 µL / min, using 90% of mobile phase A and 10% mobile phase B.  
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The source housing unit was also removed daily after each analytical assay and 
cleaned internally with 50% methanol and thoroughly dried. The source cone and the 
internal transfer tube (ITT) were also removed and cleaned by emersion into 50% 
methanol and sonicated for 30 minutes.  
6.2.5 Column re-equilibration  
Prior to each analytical assay the BioBasic AX chromatography column was 
equilibrated with the starting instrument method mobile phase conditions (90% 
mobile phase A and 10% mobile phase B) with the oven temperature set at 40
o
C, for 
a period of 15 mins (approximately 22 column volumes; column volume = 173 µL). 
 
6.2.6 Sample preparation 
6.2.7 Isolation and preparation of peripheral blood mononuclear (PBMC) cells for 
lysate matrix 
This method is adapted from that published by Colombo el al [29]. Sample blood 
was collected in Lithium heparin coated tubes and kept at a temperature of 4
o
C until 
the isolation was carried out. This was done to prevent lysis of the cells. Whole 
blood (10 mL) was carefully layered over 5 mL of Ficoll paque™ in a clean sterile 
universal tube. This was centrifuged at 2000 rpm for 30 minutes at 4
o
C without 
break applied. The isolation of the PBMC fraction (containing the lymphocytes and 
monocytes) was thus achieved on a buoyancy gradient basis as the PBMC’s are of a 
lower buoyancy density than the Ficoll paque™. After centrifugation the central 
band containing the PBMCs was carefully removed using a sterile fine tipped 
Pasteur pipette and transferred into a clean sterile universal container. The volume 
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was adjusted to 25 mL with ice cold Hanks balanced salt solution (HBSS) and 
centrifuged (2000 rpm, 5 minutes, at 4
o
C). This sample wash/spin step was repeated 
X 3. On the final re-suspension only 10 mL (exactly) of HBSS was added and a 50 
µL sample of this was transferred into a clean microtube to which, 50 µL of each 
solution A and solution B was added (solutions supplied and used as per 
manufacture guidelines for Chemometec Nucleocounter cell counting cassettes). 
From this, 50 µL was drawn into a nucleocounter cassette for a cell count 
(Nucleocounter NC-100). Once the cell count was known, the cell suspension was 
centrifuged as before and all the HBSS carefully removed. Methanol (70 %) was 
then added to the cell pellet at a volume calculated to obtain a final PBMC lysed cell 
density of 4 X 10
6
 cells/ mL. This cell lysate was then sonicated for 10 minutes and 
stored at 4
o
C overnight. Finally, the cell lysate was centrifuged (5500 rpm, 5 
minutes, 4
o
C, without brake) and the supernatant / cell lysate (debris free) was then 
carefully transferred into a new tube and the pellet discarded. 
 
6.2.8 Standard curves and quality controls 
FTC-TP and TFV-DP stock solution (1 mg/mL) were prepared in ultra pure water. 
These were then diluted further in ultra pure water to concentrations of 10 µg/ mL, 5 
µg/ mL and 0.1 µg/ mL solutions which were used ‘fresh’ to prepare the standard 
calibrators and quality control samples. Drug-free cell lysate (4 X 10
6
 cells/ mL) was 
spiked with working concentration FTC-TP and TFV-DP solutions (range FTC-TP = 
0.38-103.47 ng/ mL, TFV-DP= 0.35-10.91 ng/ mL). The amount of methanol was 
adjusted at each concentration to keep the cell density the same throughout. Quality 
controls (QCs) were generated similarly at low, medium and high concentrations 
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across the range of the standard curves. Once the standards and QC were prepared 
they were aliquoted into screw top microtubes labelled appropriately and stored in 
the freezer at -80
o
C. 
 
6.2.9 Sample pre-treatment 
Samples were removed from the -80
o
C freezer. 1 mL of LC-MS-grade ACN was 
added to the calibrators, QC and clinical samples. Samples were then microfuged at 
13,000 g for 6 minutes. The supernatant was then transferred into glass tubes and 
internal standard, 2-chloroadenosine 5′-triphosphate (Cl-ATP) [20 μl; 4 μg/ mL] was 
added. The samples were then evaporated to dryness using a rotary evaporator 
(20°C). Once dry, samples were then resuspended in 150 μL of 5 mM ammonium 
formate. From this, 25 µL was transferred to an auto sampler vial and centrifuged at 
2000 rpm for 5 minutes, ready for analysis (20 μL; no waste) by LC-MS/MS. The 
remaining 125 µL of each sample was also placed into glass autosampler vials, 
capped, labelled and stored at -80
o
C.  
 
6.2.10 Validation of the standard calibrators and quality controls 
A total of 20 calibration curves (with each level sampled in duplicate) were run and 
assessed to validate the assay. The assays were also assessed for their linearity, the 
calibration data was analysed using a linear regression of the peak area ratio (drug 
peak area / IS peak area), versus the nominal concentration of the sample with a 
weighting factor of 1 / concentration (1/x), which achieved co-efficient of correlation 
(r
2
) values greater than 0.99 for all validation assays. Once the calibration values 
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were validated the quality control (QC) samples at low, medium and high 
concentrations were prepared. QC samples at each of the levels were run in duplicate 
(n = 10) against the standard curves to ensure that all the values (both QC and 
calibrators) achieved a co-efficient of variation from the target value within +/- 2 
standard deviations of the mean target value.  
6.2.11 Accuracy and precision 
The inter and intra-day precision and accuracy was determined following the FDA 
guidelines. Ten freshly prepared lysate spiked QC samples containing each of the 
analytes and the IS at three concentrations for TDF-DP (low, medium and high) and 
at four QC concentrations for FTC-TP (ultra-low, low, medium and high), were 
analysed in duplicate. Accuracy was determined as the absolute percentage deviation 
from the theoretically determined concentration (% difference), and the precision of 
the assay was expressed as the relative standard deviation of the mean as a 
percentage (% CV) for each of the three concentrations. 
 
6.2.12 Lysate matrix effects 
Lysate matrix effects were assessed by post column infusion of the analytes into the 
LC-MS/MS detector during simultaneous chromatographic analysis of the matrix 
(PBMC) extract. A standard solution of each of the phosphorylated anabolites was 
infused using a T connection mixer, at the same time as the blank PBMC lysate 
matrix and the mobile phase. Unexpected suppression / enhancement, retention time 
drift or shift of the phosphorylated anabolites chromatographic responses due to any 
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co-eluting intracellular endogenous constituents, were examined to ensure there was 
no interference at the retention time of each of the ARVs. 
 
6.2.13 Interpretation and calculation of clinical sample concentrations 
The concentration calculation for the clinical intracellular samples, requires the exact 
number of cells in each patient sample to be known. It is crucial that the cell count is 
accurate and it should be performed and recorded at the point of cell isolation. 
Calculations to normalize the reading from the LC-MS/MS for intracellular samples 
were as follows: 
A = Raw mass spectrometer result 
B = Sample cell count (cells per 1 mL)  
C = 10
6
 (per million cells) 
D = Molecular weight of analyte (TFV-DP = 447, FTC-TP = 487) 
E = ng / 10
6
 cells 
F = pmol / 10
6
 cells 
G = fmol / 10
6
 cells 
Equation 1 
 
 
 
 
 
  = E 
Equation 2     (E / D)*1000 = F 
Equation 3     F*1000 = G 
This allows back calculation to pmol or fmol per million cells. 
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6.3 Results and Discussion 
A successful direct WAX method has been developed for the detection and 
quantification of TFV-DP and FTC-TP in PBMC lysate by LC-MS/MS. 
 
6.3.1. Detection and Chromatography 
Each of the phosphorylated anabolites and the internal standard were tuned and 
optimised on the HPLC-MS/MS system described. Figure 3 shows the 
chromatographic peak and retention time for each of the ARVs, the internal standard 
and the total ion count (TIC). Mass spectrometric parameters were controlled 
through the LC Quan software to provide the optimal conditions which gave way to 
the greatest resolution (sharpest peaks). Each chromatographic peak used at least 16 
individual scanning event points. Confirmation for specificity was achieved using 
the same software, and on highlighting the chromatographic peak product ions, 
showing their mass to charge ratio (m/z), this was observed and checked.  
Figures 4-11 show the individual chromatographic peaks for blank lysate samples, 
LLQ, ULQ samples and clinical patient samples for both FTC-TP and TFV-DP.  
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Figure 3. Chromatograph of a calibration standard showing the peak resolution for 2 
Cl-ATP (internal standard), TFV-DP, FTC-TP and the total ion count (TIC). Also 
shown is the divert valve usage though out the assay run time. 
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Figure 4. Chromatograph of a FTC-TP blank lysate sample. 
 
Figure 5. FTC-TP. Chromatograph of a low level (LLQ) calibrator sample (0.38 
ng/mL).  
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Figure 6. FTC-TP. Chromatograph of a high level (ULQ) calibrator sample (103.17 
ng/mL). 
 
Figure 7. FTC-TP. Chromatograph of a patient sample (2.57 x 10^7 cells). 
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Figure 8. Chromatograph of a TFV-DP blank lysate sample. 
 
Figure 9. TFV-DP. Chromatograph of a low level (LLQ) calibrator sample (0.35 
ng/mL).  
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Figure 10. TFV-DP. Chromatograph of a high level (ULQ) calibrator sample (10.91 
ng/mL). 
 
Figure 11. TFV-DP. Chromatograph of a patient sample (2.57 x 10^7 cells). 
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6.3.2 Accuracy and precision  
The precision of this methodology describes the closeness of each individual analyte 
measured when it is repeatedly applied to multiple samples. The accuracy of this 
methodology is described by the closeness of the mean test result for each of the 
individual analytes when compared to the ARV stock concentration prepared. The 
assay was linear over the concentration ranges for both TFV-DP and FTC-TP in 
PBMC lysate.  
The inter and intra-assay performance testing data is presented in Table 3. Accuracy 
was defined in terms of percentage bias and precision was defined as CV % relative 
to the standard deviation of the mean. All calculations were derived from quality 
control samples with n = 20. Both precision and accuracy was found to be below 
20% for TFV-DP and FTC-TP.  
Table 3. Precision expressed as the co-efficient of variation [% CV; (standard 
deviation / mean) x 100]. Accuracy expressed as the % bias [(mean concentration – 
target concentration) / (mean concentration) x 100]. 
 LLQC LQC MQC HQC 
FTC-TP (ng/mL) 1.39 5.44 26.64 62.01 
% CV (Precision) 10.6 6.3 5.4 8.3 
% Bias (Accuracy) 103 99 100 99 
 LQC MQC HQC 
TFV-DP (ng/mL) 1.17 5.39 10.41 
% CV (Precision) 11 6.3 8.2 
% Bias (Accuracy) 98 98 101 
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Assays were also assessed for their linearity, the calibration data was analysed using 
the linear regression of the peak area ratio (drug peak area / IS peak area), versus the 
nominal concentration of the sample with a weighting factor of 1 / concentration 
(1/x) which achieved a co-efficient of correlation (r
2
) value greater than 0.990 for all 
ARV validation assays. 
 
6.3.3 Signal to noise ratio 
The signal to noise ratio was investigated to determine the lower limit of 
quantification (LLQ) for each of the phosphorylated anabolites. The analyte response 
at the LLQ should be a least five times greater than that of a blank sample response. 
The LLQ represents the lowest point on the standard calibration curve and therefore 
must be measured with accuracy and precision (co-efficient of variation should not 
exceed +/- 20 %). The LLQ (sensitivity) of TFV-DP was 0.35 ng/ mL and FTC-TP 
was 0.38 ng/ mL. Giving standard calibration curve ranges for TFV-DP and FTC-TP 
of 0.35-10.91 ng/ mL and 0.38-103.17 ng/ mL respectively. When using the back 
calculation to determine patient sample results with an accurate individual patient 
cell count, both TFV-DP and FTC-TP LLQ was ~30fmol/10^6 cells. Matrix effect 
analysis was also carried out using a varying concentration of PMBC per mL in 
lysate samples (as this would be representative of patient sample variability) and no 
significant enhancement or suppression of the analytes was shown. 
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6.4 Concluding remarks 
A direct highly sensitive intracellular anabolites, WAX LC-MS/MS assay has been 
developed and validated which elutes analytes and internal standard rapidly (12 
minutes) and has been successfully applied to patient samples from a pivotal trial 
(EudraCT 2009-018055-16), the results of which are presented in the following 
chapter and play a crucial part in our understanding of antiretroviral drug adherence 
and missed dose forgiveness [74]. 
201 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
Tenofovir, emtricitabine intracellular and plasma, and efavirenz 
plasma concentration decay following drug intake cessation: 
Implications for HIV treatment and prevention.
202 
 
CHAPTER 7  
 
TENOFOVIR, EMTRICITABINE INTRACELLULAR AND 
PLASMA, AND EFAVIRENZ PLASMA CONCENTRATION 
DECAY FOLLOWING DRUG INTAKE CESSATION: 
IMPLICATIONS FOR HIV TREATMENT AND 
PREVENTION.  
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My contribution to the publication was as follows; plasma and intracellular 
analytical methods for all drugs, plasma and intracellular pharmacokinetic analysis 
for all drugs, visualisation of data, preparation and corrections of manuscript with the 
other authors. 
 
7.1 Introduction  
The introduction of combination antiretroviral therapy (cART) to patients infected 
with HIV has led to a dramatic reduction in AIDS-related morbidity and mortality 
[59]. The British HIV Association (BHIVA) recommends the administration of two 
nucleoside reverse transcriptase inhibitors (NRTI) in combination with a non-NRTI, 
a ritonavir boosted protease inhibitor (PI), or with the integrase inhibitor raltegravir, 
to therapy naïve patients [75].  
As an initial first line therapy, in patients whom have a high viral load and absence 
of primary ARV resistance, the combination of tenofovir (TDF), emtricitabine (FTC) 
and efavirenz (EFV) has been shown to be highly effective [76, 77]. 
The success of cART is very much dependant on patient adherence to their 
prescribed regime each and every day, to ensure that a drug steady-state is 
maintained at the correct concentration level, which is neither too high causing 
toxicity, and not too low giving way to resistance [78].  
It has been demonstrated that the lower the patient pill burden, the greater the 
adherence [78], therefore the arrival of Atripla® as a combined medication of TDF, 
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FTC and EFV given as a one tablet, once a day dose (245 mg, 200 mg and 600 mg 
respectively), has made adherence for the patient much easier, compared to the 
earlier complicated regimes consisting of many different medications taken at 
different times of the day, some with food, and others without. Importantly, the three 
components of Atripla® each show sustained half-lives, which may allow for a 
reduced dosing frequency and therefore increase patient adherence. The ‘Five-days-
On, Two-days- Off’ (FOTO) study which showed HIV infected patients, taking 
TDF/FTC/EFV five days a week, followed by a two day interruption (or ‘holiday’ 
period), successfully maintained virological suppression in an equal number of 
patients taking the drug for seven days a week [79]. This data suggests that either the 
effects of the drugs or the actual drugs themselves, persist with a sustained efficacy 
for a significant duration following drug intake cessation, and may allow for a 
reduced intake drug regime, greater adherence, a reduced drug toxicity and a lower 
financial cost. However, the persistence time post 48 hours and the inter-individual 
variability of this efficacy for each of the components of Atripla® were not clearly 
defined. 
The ARV drug tenofovir (TDF) is administrated as tenofovir disproxil fumerate 
which requires hydrolization by cellular esterase during the absorption phase to its 
lipophilic and cell permeable pro-drug tenofovir disproxil (TFV). Both TFV and 
FTC require intracellular (IC) phosphorylation to their active IC metabolites. TFV is 
firstly phosphorylated to its monophosphate (TFV-MP) form by adenosine 
monophosphate kinase and then to its active diphosphate form (TFV-DP) by 5’-
nucleoside diphosphate kinase. FTC is phosphorylated firstly to its monophosphate 
(FTC-MP) by deoxycytidine kinase, then to its diphosphate form (FTC-DP) by 
deoxycytidine monophosphate kinase and then to its active triphosphate (FTC-TP) 
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by 5’-nucleoside diphosphate kinase. TFV-DP and FTC-TP are the IC active 
metabolites which inhibit viral reverse transcriptase and ultimately HIV replication. 
The IC metabolites show different pharmacokinetic profiles compared to those of 
their parent drugs within the plasma compartment, with IC concentrations 
characterised by a much longer prolonged half-life (TFV-DP and FTC-TP; 150 [70] 
and 39 [69] hours respectively, compared to TFV 14 hours [80] and FTC 8-10 hours 
[69]). Importantly, plasma concentrations alone may not be enough to interpret the 
intracellular metabolite concentrations, as the patient antiviral response of exposure 
to IC NRTI is not only dependent upon the amount of DP and TP formed, but on the 
concentrations of the endogenous deoxyribonucleotide triphosphates (dNTPs) that 
the metabolites competes against with, for incorporation into to the proviral 
deoxyribonucleic acid (DNA) [76, 81].  
In this study we have assessed the ‘pharmacokinetic forgiveness’ of IC TFV-DP, 
FTC-TP, and plasma EFV over a period of 228 hours (9.5 days) after drug intake 
cessation in HIV-negative healthy volunteers. The pharmacokinetic results should 
help to provide information on how to advise HIV-infected patients on non-
adherence (delayed and missed doses). 
 
7.2 Materials and Methods 
7.2.1 Participants  
Healthy male and non-lactating females were determined as eligible upon medical 
history, physical examination, 12 lead electrocardiogram, and clinical laboratory 
evaluations all being satisfactory. Participants had to provide written informed 
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consent and were all aged between 18 and 65 with a body mass index within 18-35 
kg/m
2
 inclusive.  
Participants were not eligible if they met any of the following exclusion criteria; any 
significant acute or chronic medical illness, evidence of any organ dysfunction, a 
positive blood test for hepatitis B surface antigen and or hepatitis C antibodies, 
positive blood test for HIV 1 or 2 antibodies, any current or recent gastrointestinal 
disease, positive urine drug screen or clinically relevant alcohol use/ or history of 
drug/ alcohol use which the investigator deemed could interfere with trial 
compliance, previous exposure (within 3 months) of investigational trial drugs or 
placebos, use of any co-medications including over the counter and herbal remedies 
unless approved by the trial investigator, and knowledge of any previous allergies to 
any of the trial drug constituents. 
 
7.2.2 Study Design 
This study was conducted at the Pharmacokinetic Unit of the St. Stephen’s Centre, 
Chelsea and Westminster Hospital, London, UK, and was carried out in accordance 
with Good Clinical Practice (GCP), the declaration of Helsinki, and relevant 
regulatory requirements (EudraCT, 2009-018055-16). Ethics and study protocol 
were approved by the Institute of Child Health/Great Ormond Street Hospital 
Research Committee, UK. All participants gave written consent. 
The study was a 24-day (excluding screening and follow up), open label, single 
treatment arm, PK clinical trial. 
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Day -28 to 0 comprised of screening the participants. Eligibility criteria were 
checked and a clinical assessment and laboratory analysis was undertaken. Upon 
successful screening, participants were administered one tablet of Atripla®, once a 
day (taken in the evening) for a total of 14 days. Intensive PK blood sampling (for 
plasma and intracellular analysis) was carried out 10 minutes before the final dose on 
the evening of day 14, and then 2, 4, 8, and 12 hours postdose whilst participants 
were admitted overnight at the unit. Participants were discharged after the 12 hour 
postdose samples were taken and returned to the unit for further sampling over the 
following 10 days (post cessation of Atripla®) at 24, 36, 48, 60, 84, 108, 132, 156, 
180, 204, and 228 hours. 
 
7.2.3 Study Objectives 
The primary object of this trial was to assess the PK  of plasma tenofovir and 
emtricitabine, and their active intracellular metabolites, namely tenofovir- 
diphosphate and emtricitabine-triphosphate, and also efavirenz plasma PK over a ten 
day period following drug intake cessation. To be carried out in healthy HIV 
negative volunteers. 
Secondary objectives of this trial included the assessment of inter-individual 
variability in the concentrations of plasma tenofovir, emtricitabine and efavirenz and 
also TFV and FTC intracellular metabolites after drug intake cessation. 
The safety and tolerability of Atripla® intake in healthy HIV negative volunteers 
over an administration period of 14 days was also assessed. 
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7.2.4 Plasma Collection for Tenofovir, Emtricitabine, and Efavirenz Analysis 
For each scheduled PK time point, approximately, 12 mL of whole blood was 
collected into two Vacutainer® collection tubes (lithium heparin) from each 
participant. Both tubes were immediately inverted several times and then stored on 
ice or refrigerated before centrifugation. Blood samples were centrifuged within a 30 
minutes time window, at 1200 g for 10 minutes at 4
o
C to separate the plasma. 
Plasma was then carefully transferred into three (patient labelled) 2.0 mL screw top 
microtubes (Sarstedt Germany) before being stored at -20
o
C. Samples were then 
transferred on dry ice to the Liverpool Bioanalytical Facility. 
 
7.2.5 Peripheral Blood Mononuclear Cell Isolation for TFV-DP and FTC-TP 
Analysis 
Two 8 mL cell preparation tubes (CPT) (Becton-Dickinson Vacutainer; Oxford, 
United Kingdom) were collected for each time point. The anticoagulant was mixed 
thoroughly by gently inverting the tubes 8-10 times. CPT were then immediately 
(time allowance within 60 minutes to maximize cell yield) centrifuged (horizontal 
rotor) for 20 minutes (1600 relative centrifugal force [rcf]) at room temperature (18-
25°C). Peripheral blood mononuclear cells (PBMCs) were then suspended in the 
plasma by carefully inventing the CPT. The mixed plasma/ cells suspension from 
both cell preparation tubes were then combined into a single graduated 50 mL 
conical tube to which isotonic saline (0.9%) was added to bring the total volume to 
exactly 30 mL. The cell/ plasma sample was then gently mixed by inversion, and a 
40 μL aliquot was taken for initial cell counting (Digital Bio Adam Microchip 
Automatic Cell Counter; NanoEnTek, Inc, Seoul, Korea). The cell count was 
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normalised by multiplying by 30 to calculate the actual total cell count in 30 mL and 
recorded. The plasma/ cell suspension was then centrifuged for 15 minutes, at 400 
relative rcf to pellet the cells. The supernatant was carefully removed to avoid 
disruption of the cell pellet. Ice-cold methanol (precisely 1 mL, 70%) was added to 
the pellet to re-suspend and lyse the cells and ultimately release the intracellular 
drugs. The cell lysate was vortexed (3–5 minutes) and stored at −80°C, before being 
transported on dry ice to the Liverpool Bioanalytical Facility. 
 
7.2.6 Quantification of Tenofovir and Emtricitabine from Plasma 
Plasma samples (300 mL) were prepared in formic acid (300 mL; 0.02%) containing 
an internal standard, 2-chloroadenosine (Cl-A; 5 mg/ mL; 20 mL), and loaded onto a 
100-mg SPE BondElut C18 column (Agilent Technologies, UK Ltd., Berkshire, 
UK). Columns were conditioned with methanol (1 mL) and 0.02% formic acid (1 
mL; pH 3). Samples (400 mL) were loaded onto the column and rinsed with 0.02 % 
formic acid (200 mL). Analytes were eluted with methanol (100 mL), evaporated to 
dryness, reconstituted in 100 µL of mobile phase, and injected (10 µL) onto the high-
performance liquid chromatography (HPLC) column. Chromatography was 
performed on a Synergi polar C18 column (4mm: 150 mm· 2.0 mm; Phenomenex, 
Cheshire, UK). Mobile phase A consisted of 0.1% formic acid in water and mobile 
phase B, 0.1% formic acid in acetonitrile (ACN). Initial conditions consisted of 99% 
mobile phase A, increasing in organic content to 40% B in 0.7 minutes maintained 
over 1.3 minutes and equilibrated back to the initial conditions over a total run time 
of 6 minutes. The ﬂow rate was 400 mL/ minute. The triple quadrupole mass 
spectrometer (TSQ Quantum Access; Thermo Electron Corporation, Hemel 
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Hempstead, UK) was operated in positive ionization mode, and detection and 
quantiﬁcation was performed using multiple reaction monitoring. The assay was 
validated over a calibration range of 0.52–996 ng/mL (TFV) and 0.47–5368 ng/mL 
(FTC). Inter-day precision (coefﬁcient of variation [CV %]) based on quality control 
(QC) samples was between 9 %–12.2 % (TFV) and 4.6 %–6.9 % (FTC), and 
accuracy (% bias) was 97.5 %–100.8 % (TFV) and 107 %–114.2 % (FTC). The 
percentage recovery for both analytes at the low medium and high levels were 
consistent, precise, and reproducible. 
 
7.2.7 Quantification of Efavirenz from Plasma  
Plasma EFV concentrations were quantiﬁed by a validated protein precipitation 
extraction method coupled with reverse phase HPLC–MS/MS, as previously 
described [76]. The assay was validated over a calibration range of 8.58–10,203 
ng/mL. Inter-day precision (CV %) based on quality control (QC) samples was 
between 2.9 % and 5.3 % and accuracy (% bias) was between 93.2 % and 105.1 %. 
The percentage recovery at the low medium and high levels were consistent, precise, 
and reproducible. 
7.2.8 Quantification of IC Tenofovir-Diphosphate (TFV-DP) and Emtricitabine-
Triphosphate (FTC-TP). 
IC TFV-DP and FTC-TP concentrations were quantiﬁed by a validated protein 
precipitation method coupled with weak anion exchange HPLC–MS/MS. ACN (1 
mL) was added to each of the samples of IC lysate (1 mL in 70% methanol). The 
samples were vortexed and centrifuged (13,000 g, 6 minutes). The sample 
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supernatant was transferred into glass tubes and internal standard, 2-chloroadenosine 
5-triphosphate (Cl-ATP; 4 µg/ mL; 20 mL), was added. Samples were evaporated to 
dryness and reconstituted in 150 mL of ammonium formate (5 mM), vortexed, and 
injected (20 mL) onto the HPLC column. Chromatography was performed on a 
BioBasic AX column (5 mm: 50 mm x 1 mm; Thermo Scientiﬁc, Hertfordshire, UK) 
with a pH gradient. Mobile phase A consisted of 10 mM ammonium acetate in 
ACN/water (30:70, v/v), pH 6, and mobile phase B consisted of 1 mM ammonium 
acetate in ANC/water (30:70, v/v), pH 10.5. Initial conditions consisted of 90 % 
mobile phase A, increasing in organic content to 50 % B in 0.51 minutes maintained 
over 1.25 minutes, then increased again to 100 % B, and maintained for 4.75 minutes 
then equilibrated back to the initial conditions over a total run time of 12 minutes. 
The ﬂow rate was 250 mL/ min. The triple quadrupole mass spectrometer (TSQ 
Quantum Access MAX; Thermo Electron Corporation) was operated in positive 
ionization mode, and detection and quantiﬁcation was performed using selective 
reaction monitoring. The assay was validated over a calibration range of 0.35–10.91 
ng/ mL (TFV-DP) and 0.38–103.47 ng/ mL (FTC-TP). Inter-day precision (CV %) 
based on quality control (QC) samples was between 6.3 %–11 % (TFV-DP) and 6 % 
– 18.6 % (FTC-TP) and accuracy (% bias) was 97.5 % – 100.8 % (TFV-DP) and 98 
% – 100.3 % (FTC-TP). The percentage recovery for both analytes at the low 
medium and high levels were consistent, precise, and reproducible. 
 
7.2.9. Pharmacokinetic and Statistical Analysis  
The calculated PK parameters for plasma TFV, FTC, EFV, and IC TFV-DP and 
FTC-TP, were the concentration measured 24 hours after the observed dose (C24h), 
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the maximum observed concentration (Cmax), and the area under the concentration–
time curve (AUC) from 0 to t (in hours). The half-life was determined from the 
elimination phase within the normal dosing interval of 0–24 hours and as a terminal 
elimination half-life to the last measurable concentration. All PK parameters were 
calculated using actual blood sampling times and non-compartmental modelling 
techniques (WinNonlin Phoenix, version 6.1; Pharsight Corp, Mountain View, CA). 
Descriptive statistics, including geometric mean (GM) and 90 % conﬁdence intervals 
(CI) were calculated for plasma TFV, FTC, EFV, and IC TFV-DP and FTC-TP PK 
parameters. Inter-individual variability in drug PK parameters was expressed as a 
coefﬁcient of variation [CV = (SD/mean) x 100]. 
 
7.3 Results 
7.3.1 Demographic and Clinical Characteristics 
A total of 16 (six female in total) participants were recruited and completed the 
study. The median (range) age was 33 (22-58) years, weight was 80 (54–109) kg, 
and body mass index was 25 (20–34) kg/ m2. Ethnicity was as follows; 12 white, 2 
black, 1 of Asian origin, and 1 deﬁned himself as other. All study drugs were well 
tolerated with no grade 3 or 4 adverse events being reported.  
 
7.3.2 Tenofovir and Emtricitabine Plasma Pharmacokinetics 
Plasma TFV and FTC PK parameters are illustrated in Table 1 and concentration–
time curves in Figure 1A, B, respectively. GM and 90% CI plasma terminal 
elimination half-life to 228 hours for TFV was 31 hours (24–45 hours) and longer 
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than the 0–24 hour half-life (14 hours). GM and 90% CI plasma terminal elimination 
half-life to 228 hours of FTC were 37 hours (33–43 hours) and was longer than the 
0–24 hour half-life (6 hours). There was a marked inter-individual variability in both 
plasma TFV and FTC PK parameters (range, 25 %–56 %).  
 
7.3.3 Efavirenz Plasma Pharmacokinetics 
Plasma EFV PK parameters are illustrated in Table 1 and concentration–time curves 
in Figure 1C. GM and 90 % CI plasma terminal elimination half-lives to 24 hours 
was 28 hours (21–47 hours), to 48 hours was 51 hours (43–74 hours), and to 228 
hours was 92 hours (84–108 hours). Five of 16 participants had concentrations below 
the suggested MEC of 1000 ng/mL 48 hours postdose and 50 % maintained 
concentrations greater than the suggested MEC 84 hours postdose. There was high 
inter-individual variability in EFV PK parameters (range, 40 %–77 %). 
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Table 1. Plasma tenofovir (TDF), emtricitabine (FTC), efavirenz (EFV) and 
tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) 
pharmacokinetic parameters 
 
AUC0-24, area under the curve over 24 hours; AUC0-last, area under the curve to the 
last measureable concentration within 228 hours; TE t1/2, terminal elimination half-
life to the last measurable concentration within 228 hours; TFV, tenofovir; FTC, 
emtricitabine; EFV, efavirenz; TFV-DP, tenofovir-diphosphate; FTC-TP, 
emtricitabine-triphosphate. 
 
PK parameter TFV, GM (90% CI) FTC, GM (90% CI) EFV, GM (90% CI)
C24 ng/mL 39 (35-47) 89 (75-121) 1834 (1530-2957)
CMAX ng/mL 181 (157-237) 1538 (1422-1748) 3747 (3345-4661)
AUC0-24 ng/h/mL 1699 (156-2060) 10,768 (9899-12,208) 58,367 (49,856-84,841)
AUC0-last ng/h/mL 2895 (2600-3491) 13,863 (12,709-15,876) 231,569 (187,361-409,449)
TE t 1/2 hours 31 (24-45) 37 (33-43) 92 (84-108)
PK parameter TFV-DP, GM (90% CI) FTC-TP, GM (90% CI)
C24 fmol/10
6 
cells 41 (39-78) pmol/10
6 
cells 4 (3-6)
CMAX fmol/10
6 
cells 62 (57-107) pmol/10
6 
cells 7 (6-12)
AUC0-24 fmol/h/10
6 
cells 925 (853-1712) pmol/h/10
6 
cells 100 (90-63)
AUC0-last fmol/h/10
6 
cells 4717 (4501-8591) pmol/h/10
6 
cells 289 (261-440)
TE t 1/2 hours 164 (152-190) hours 39 (36-45)
Plasma
Intracellular
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Figure 1. Geometric mean (GM) steady-state plasma concentrations 228 hour post 
drug intake cessation for (A) tenofovir, (B) emtricitabine and (C) efavirenz. The 
dashed line on the efavirenz graph illustrates the minimum effective concentration 
(MEC) of efavirenz which is 1000 ng/ mL. 
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7.3.4 Tenofovir-DP and Emtricitabine-TP Intracellular Pharmacokinetics 
IC TFV-DP and FTC-TP PK parameters are illustrated in Table 1 and concentration–
time curves in Figure 2 A, B, respectively. TFV-DP GM and 90 % CI IC terminal 
half-life to 228 or the last measured concentration was 164 hours (152– 190 hours). 
FTC-TP GM and 90 % CI IC terminal half-life to 228 hours of FTC-TP was 39 
hours (36–45 hours). There was marked inter-individual variability in TFV-DP and 
FTC-TP PK parameters (range, 64 %–79 %). 
 
Figure 2. Geometric mean (GM) steady-state intracellular concentrations for 228 
hours post drug intake cessation for (A) tenofovir-diphosphate and (B) emtricitabine-
triphosphate. 
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7.4 Discussion and Conclusions 
Here reports the PK concentrations of the antiretroviral drugs TFV, FTC and EFV in 
a total of 256 plasma samples, and TFV-DP and FTC-TP paired intracellular samples 
after the administration of the co-formulated antiretroviral drug Atripla® 
(TDF/FTC/EFV, 300/200/600 mg once daily, respectively). Both plasma and IC 
sampling from 16 healthy HIV-negative participants (male and female) was carried 
out over a period of 228 hours (9.5 days) after drug intake cessation. This was to 
investigate the decay of each of the individual drugs when given in the co-
formulation Atripla®. No other study has previously looked at the PK decay of these 
ARVs post 10 days drug cessation, therefore this study is the first to fully 
characterise the PK data for missed or late dosing (forgiveness) of TFV/FTC/EFV.  
The IC metabolite concentrations of both TFV and FTC determine their clinical 
therapeutic effect. This trial showed both are characterised by prolonged terminal 
half-lives (164 and 39 hours respectively). Given that EFV is also characterised by a 
long terminal half-life (92 hours), the co-formulated Atripla® tablet, does indeed 
allow for missed or late dosing in non-adhering patients, thus providing a PK 
regimen which is ‘forgiving’. However, the current published data does not 
adequately describe the optimal target concentrations for IC TFV-DP and FTC-TP in 
successful HIV therapy and prevention (TFV and FTC are currently given as a HIV 
chemoprophylaxis; more commonly referred to as pre-exposure prophylaxis [PrEP] 
[82, 83]), and therefore, there is a need for further understanding of their clinical 
pharmacology. 
The results here showed that EFV concentrations had a high level of inter-individual 
variability during the decay phase. This suggests, that in some patients with 
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prolonged EFV terminal half-lives, it is a result of a CYP2B6 polymorphism causing 
slower metabolism of EFV [84].  
Importantly, this data also showed a slightly longer geometric mean EFV terminal 
half-life to that which was previously described during its development (multiple 
dose terminal half-life 40-55 hours) [85], and previously published PK data in HIV-
infected patients stopping EFV intake [83, 86]. Within this area of interest, and 
impact on HIV treatment, the data suggests that this could be beneficial in cases of 
non or sub-optimal adherence, and in particularly when cases are not straight 
forward i.e. initiation of therapy in a patient with a high viral load. These long 
terminal half-lives may also be the reason why the combination shows greater 
superiority to other ARV combinations in published trials [77]. 
In non-adherent patients the concentration of ARVs are reduced. As a result of this, 
the ARV minimal effective concentration (MEC) at which the drug is known to 
suppress the virus can become compromised thus allowing the virus to once again 
replicate. This viral rebound accelerates the rate of viral replication which is HIV-
drug-resistant, therefore, non-adherence can be directly related to ARV drug 
resistance [83, 87]. The level of non-adherence is crucial in knowing how many 
doses can be missed before this occurs. As we are aware, multiple missed doses can 
cause serious pharmacological effects, but we are still unaware of the impact of 
delayed / missed doses or controlled reduced drug doses can have on the long term 
effect of ARV therapy. Therefore the data presented here, indicates the level of drug 
persistence post drug cessation, for EFV and the IC phosphorylated metabolites of 
TFV and FTC, increasing our understanding of their PK forgiveness. A greater 
knowledge of PK forgiveness plays an important part in HIV prevention when we 
begin to look at the use of ARVs in PrEP. This is because for an ARV drug to be an 
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idea candidate for PrEP use, it must show a PK profile which is forgiving and allows 
for reducing dosing whilst sustaining a virological efficacy.  
The study data shows a wide level of inter-individual variability in the 
concentrations of the IC phosphorylated metabolites TFV-DP and FTC-TP. This 
may be due to individual variation in the level of cell transporters which are required 
to uptake the drugs into the cells where they are then phosphorylated to their active 
form, it may also be due to lack or response of the kinases within the cell which are 
ultimately responsible for the steps in the phosphorylation of the TFV and FTC into 
their active forms [82, 88]. At present, this variability cannot be assessed in the terms 
of efficacy because one of the limitations of this study highlights the lack of PK 
knowledge known. We are aware of EFV decay, which allows us to establish an 
MEC (1000 ng/ mL), and this enables us to understand clinical therapeutic drug 
monitoring (TDM) for patients taking EFV. However, it is still unclear as to what the 
target concentrations of the IC diphosphate and triphosphates should be, and 
therefore, no MEC has been established. In order to play a key role in PrEP, further 
PK research is required to investigate IC accumulation and persistence of these drugs 
in vaginal and rectal tissue.  
This study enrolled HIV-negative participants to investigate Atripla® cessation. 
Rather than enrolling HIV-infected patients, HIV-negative participants avoided 
withholding established ARV therapy whilst we examined the effect that this would 
have. The involvement of HIV-negative patients may be seen as a limitation of the 
study as the data may or may not be influenced by absence of the virus [69, 77, 81, 
89]. A final limitation of this study was the amount of time participants were given 
Atripla® for (14 days). It may be that a period of greater length is needed to reach a 
PK steady-state. However published data demonstrates that after only a few doses, 
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concentrations of IC TFV-DP and FTC-TP achieve a steady accumulation of level 
which plateaus [89, 90].  
In conclusion, this study looked at the cessation of the co-formulated drug Atripla®, 
and highlighted high concentration and prolonged terminal half-lives of the study 
drugs. Although further investigations are required to determine exactly how many 
reduced doses may result in therapeutic failure, this data increases our understanding 
of PK forgiveness for Atripla® when non-adherence occurs. This information also 
helps us to better understand the role of Atripla® in HIV prevention. 
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Chapter 8 
 
Concluding Comments 
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The work conducted in this thesis shows the feasibility to pharmacologically 
characterise ARV drugs and their metabolites exposure within plasma, PBMCs and 
anatomical sanctuary sites through the use of the newly developed LC-MS/MS 
assays. The data presented yields an important insight into the effectiveness of 
current HIV antiretroviral therapy, a greater understanding of drug sanctuary sites 
and guidance for missed or late dosing. 
The LC-MS/MS assays developed and validated facilitate the pharmacology of ARV 
drugs in proposed sanctuary sites, namely PBMCs and CSF, shown in the numerous 
collaborative clinical trials. The interpretation of the clinical relevance of this 
analysis and the results obtained here rely upon the production of the standard 
operating procedures produced in the validation of each LC-MS/MS assay 
methodology. The simultaneous detection and quantification of ARVs within the 
produced assays also allow the investigation of whole drug regimes in combination 
therapy instead of single drug analysis. Benefits are expected to accrue in design of 
more forgiving ARV therapy regimes for HIV patients, and better drug selection to 
specifically target HIV replicating within sanctuary sites. 
Whilst developing and validating the IC metabolite assay, I further incorporated the 
dNTPs to enhance the assay. However, time boundaries did not allow for the full 
vigorous validation procedures to be completed and therefore were not presented 
here. This is an area which should be researched and conducted in the future.  
Further future work from this thesis would also include looking at the transfer of the 
described LC-MS/MS assays to other antiretroviral agents used in the therapy for 
viral diseases such as hepatitis C (HCV) and cytomegalovirus (CMV). The design of 
the LC-MS/MS assays could also be applied and modified to other matrices, mainly 
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genital tract (vaginal tissue) and seminal fluid in order to investigate ARVs in the use 
of pre-exposure prophylaxis (PrEP) and further our knowledge of HIV prevention 
measures and transmission studies.  
Future use of the CSF LC-MS/MS could also be applied to more clinical studies 
investigating cognitive impairment. The ability to measure the concentration of each 
ARV gaining access to cerebral fluid and the brain may allow more informed clinical 
prescribing in prevention of HIV associated neurological disorders.  
In conclusion, the methodologies developed in this thesis will play an essential role 
in future studies of HIV ARV therapy as well as the treatment of other chronic 
diseases.  
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